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Summary 
Activating mutations in RAS are often found in different human cancers. The expression 
of an oncogene is called a driver mutation because it provides the bases for tumour 
initiation, but it still requires additional mutations to achieve tumour progression. 90% of 
invasive pancreatic ductal adenocarcinoma (PDAC) present activating KRAS mutation, in 
conjunction with inactivation of various tumour suppressor genes such as BRCA1, TP53, 
SMAD4 and CDKN2A. The most important effectors of RAS are PI3K and its 
downstream kinases. These function as mediators of RAS-induced cell survival and 
proliferation. Interestingly, concurrent mutations of RAS and PI3K/PTEN/Akt pathway 
have been described in the same human tumour types. Endometrial cancer, thyroid cancer 
and acute lymphoblastic leukemia have all been shown to harbor the simultaneous 
mutation of RAS gene and those encoding various members of the PI3K signalling 
pathway. Published data suggest that 25% of human colon cancers contain mutations in 
both K-­‐RAS and PI3K-associated genes. Moreover, 60% of human PDAC show PTEN 
loss, due to deletions, mutations or epigenetic silencing. Despite this prevalence, the 
molecular mechanism for the cooperation between RAS and PI3K pathway in 
tumourigenesis is poorly understood.  
A fundamental barrier for tumourigenesis is senescence. The activation of an oncogene 
such as RAS in a primary cell line drives cells into unscheduled DNA synthesis, resulting 
in a high frequency of stalled replication forks and DNA double strand breaks (DSBs). A 
DSB is one of the most deleterious lesions if unrepaired, and it is the primary trigger of 
oncogene-induced senescence (OIS).  DSBs activate the ATM/ATR signalling pathway 
and senescence-associated cell cycle arrest. However, various oncogenes differ in their 
ability to induce senescence, for example activated Akt is a weak inducer of senescence 
compared to RAS. Previous work from our lab and others has suggested that the co-
activation of these two oncogenes may serve to bypass certain aspects of the senescence 
program, but the precise mechanism by which this is achieved remains unclear. 
Surprisingly, detailed cell cycle analyses in this study demonstrate that the simultaneous 
activation of Akt in primary fibroblasts expressing oncogenic RAS reinforces RAS-
induced senescence. This correlates with an increased accumulation of unrepaired damage, 
which is known to directly contribute to establishment of senescence. Interestingly, the 
expression of activated Akt in these cells correlates with reduced expression of MRN 
   II 
complex components, which in presence of RAS-induced damage impairs the activation of 
the checkpoint kinases. The inhibition of Mre11, the nuclease component of the MRN 
complex, in RAS expressing cells recapitulates the phenotype of RAS/Akt cells. Thus, Akt 
downregulates Mre11 to exacerbate RAS-induced DNA damage and induce a qualitatively 
stronger senescence. 
Multiple studies have previously reported the negative regulation of DDR by Akt, however 
a mechanism for this has not been described. Experiments on two colon cancer lines, 
HCT116 and DLD1, have revealed that inactivation of PTEN/activation of Akt suppresses 
DDR via a reduction in MRN complex expression and activity. In these cells, the 
components of the MRN complex display low protein stability and are rapidly degraded by 
an unknown mechanism. MRN complex is central in the DNA damage response to DSBs. 
Its suppression impairs the activation of the two checkpoint kinases Chk1 and Chk2, which 
mediates the G2/M arrest, and also impairs HR repair. The inhibition of these two events 
severely affects cell survival in presence of DSBs, and the surviving fraction present high 
levels of genome instability. The use of specific inhibitors targeting S6K1 activity rescues 
the levels of MRN complex in these cells, suggesting a role of this kinase in DDR 
suppression. 
Thus, the enhanced RAS-induced senescence in cells caused by Akt can be ascribed to the 
high levels of unrepaired damage due to the suppression of MRN complex. Despite 
compounding senescence, the simultaneous mutation of RAS and Akt allow the cells to 
acquire genome instability, which in vivo significantly contributes to bypassing senescence 
and promotes tumour progression.  
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1.1 Cell cycle and checkpoints  
1.1.1 The cell cycle 
The cell cycle is an orderly sequence of events by which a cell grows, replicates its DNA 
and then segregates it equally into two daughter cells (Tessema et al. (2004). This process 
is divided into four sequential phases: the synthesis phase (S phase) when DNA replication 
occurs, and the mitosis phase (M phase), during which the replicated DNA is divided 
between two genetically identical daughter cells (Figure 1.1). Interspersed between these 
two phases lie the two gap phases: gap 1 (G1), during which the cell is sensitive to the 
growth signals and prepares for DNA synthesis, and gap 2 (G2), when the cell prepares for 
entry into mitosis (Garrett et al., 2001; Norbury and Nurse, 1992). However, the majority 
of cells of the human body are not actively proliferating, but exist in a quiescent state 
called G0 or resting phase. This happens when the cells have not reached their homeostatic 
size or are in absence of mitogenic signals (Tessema et al., 2004).  
Different classes of cellular proteins coordinate cell progression through the four phases of 
the cell cycle. Key components of this regulatory network are the cyclin-dependent kinase 
(CDK) family of Serine/Threonine kinases, which are activated at specific points of the 
cell cycle, in part, by the cyclins (Tessema et al., 2004; Vermeulen et al., 2003). Cyclin 
levels are regulated by their synthesis and degradation in a “cyclic” pattern during the cell 
cycle, thus periodically activating CDKs. Different cyclin-CDK combinations form 
catalytically active hetero-dimeric complexes that phosphorylate downstream targets and 
regulate their activity (Johnson and Walker, 1999; Sherr, 1996). In addition to this, a 
network of proteins negatively regulates cyclin-CDKs. These complexes can be bound by 
p16 and CIP/KIP (CKI proteins) forming inactive trimers (CKI/cyclin/CDK), or can be 
inhibited due to phosphorylation by Wee1-type kinases (Lee et al., 2001; Tyson et al., 
1995).  
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Cyclin D (1-3)-CDK4/6 and cyclin E-CDK2 complexes drive cells into G1 phase through 
the restriction point to commit cells to cell cycle. Once cyclin D synthesis is stimulated by 
growth factors, it associates with CDK4/6 mediating the phosphorylation of the 
retinoblastoma (Rb) protein (Norbury and Nurse, 1992). Hyper-phosphorylation of pRb 
releases Rb-bound E2F factors, thus enabling the transcription of E2F target genes that are 
required for S phase, such as cyclins (A and E) and DNA polymerase (Winston and 
Pledger, 1993). These cells are now pushed by cyclin E-CDK2 complexes to transit from 
G1 to S phase (Blomen and Boonstra, 2007). Cyclin A-CDK2 phosphorylates different 
protein complexes responsible for the tight regulation of replication origins during S phase. 
This event ensures that the genome is correctly replicated only once (Blow and Gillespie, 
2008). The progression to mitosis and its activation is then driven by the formation of 
cyclin B-CDK1.  
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Figure 1.1: The cell cycle. A model depicting the progression of a cell through the cell cycle and the proteins that 
regulate the transition through each stage [Figure adapted from Zafonte et al., 2000]. 
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1.1.2 Cell cycle checkpoints, senescence and apoptosis 
Cells are continuously exposed to a variety of endogenous and exogenous insults such as 
replication stress, reactive oxygen species, radiation and activated oncogenes. These insults 
can directly damage DNA and/or cause faults in DNA replication during the cell cycle 
(Nurse et al., 1998; Nyberg et al., 2002). To preserve the integrity and stability of the 
genome, the progression from one phase to the next one of the cell cycle is tightly 
monitored by sensor mechanisms called checkpoints (Tyson et al., 1995). These regulatory 
points have the ability to transiently arrest the cell cycle and activate DNA damage 
response (DDR) pathways to ensure the fidelity of DNA replication and minimize the 
possibility of genetic damage (Yu, 2007).  Key players in this process are the ATM/Chk2 
and ATR/Chk1 pathways (Reinhardt and Yaffe, 2009). Their activation is crucial for the 
proper coordination of checkpoint activation and the DNA repair mechanisms (Smith et 
al., 2010). Another important factor activated in response to ATM/Chk2 and ATR/Chk1 is 
p53, which is pivotal in shaping the appropriate cellular outcome in response to damage 
(Figure 1.2). There are several cellular outcomes, most of which are severely influenced by 
cell type, cellular environment and the severity of the DNA damage. If the damage is not 
severe, the outcome will be transient cell cycle arrest due to activation of the checkpoint 
and appropriate repair. When the damage is unrepairable, the cell may undergo senescence, 
a naturally irreversible cell cycle arrest, or even programmed cell death (apoptosis). In the 
worst-case scenario the repair attempt fails, however the cell still survives and does not 
arrest permanently, which may results in accumulation of mutations or/and chromosomal 
aberrations, promoting the development of cancer. Thus p53 is called the “guardian of the 
genome”, because it prevents the passage of genetic alterations to the next generation 
suppressing tumourigenesis (Sancar et al., 2004; Yu, 2007).  
 
 
 
 
 
 
 
 
 
 
Chapter 1  6 
 
 
 
 
 
 
 
 
Figure 1.2: Cell cycle arrest, senescence or apoptosis? A model depicting the decision flow determining cell fate 
following DNA damage [Figure adapted from Rodier et al., 2007]. 
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1.1.2.1 DNA damage and checkpoints: transient cell cycle arrest 
The progression of cells from G1 to S phase is controlled by the G1/S checkpoint (Figure 
1.3). Its function is to prevent cells with damaged DNA from initiating DNA replication. 
DNA damage activates ATM/Chk2 (in presence of DNA Double-Strand Breaks (DSBs)) 
and ATR/Chk1 (in presence of Single-Stranded DNA (ssDNA)), triggering a cascade of 
inhibitory events to block the activation of cyclin E-CDK2, thus inducing a rapid and 
sustained activation of G1/S checkpoint. Activated Chk1/Chk2 phosphorylates and inhibits 
the phosphatase CDC25A, marking it for ubiquitination and rapid degradation by 
proteasome (Falck et al., 2002). The lack of CDC25A locks cyclin E-CDK2 complex in a 
hyper-phosphorylated and inactive form, which is unable to promote the loading of CDC45 
into chromatin and formation of the pre-replication complex, thereby inhibiting the 
initiation of DNA replication (Mimura and Takisawa, 1998). This is considered the early 
response, which has the role to quickly block the cell cycle for the repair of the damage. As 
previously mentioned, ATM/Chk2 and ATR/Chk1 proteins are also pivotal for the 
phosphorylation and stabilization of p53, preventing its binding with MDM2, a p53 
specific ubiquitin-ligase that triggers p53 degradation (Shieh et al., 2000). p53 has a 
number of transcriptional targets that contribute to checkpoint activation, including the 
CK1A (p21). In turn p21 binds and inhibits cyclin E-CDK2 securing the maintenance of 
the G1/S checkpoint arrest (Mirza et al., 2003). This is considered the later response, 
which has the role to maintain the arrest if the damage is still not repaired. 
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Figure 1.3: DNA damage and checkpoints. A schematic showing the checkpoints that control the progression of a cell 
through the cell cycle and the proteins involved [Figure adapted from Lopez-Contreras, 2012]. 
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Stalled replication forks, latent replication origins or UV-light can cause the formation of 
long tracks of ssDNA during S phase. This, in turn can activate the ATR/Chk1 pathway, 
the major regulator of the intra-S checkpoint (Choi et al., 2010). This checkpoint has the 
ability to delay the onset of mitosis until DNA replication is correctly completed (Bartek 
and Lukas, 2003). In this case, Chk1 inhibits the S/M transition through inhibition of 
CDC25A, which otherwise activates cyclin B-CDK1 and entry into mitosis. However, 
Chk1 can also activate this checkpoint through a CDC25A/CDK1 independent pathway. 
The main target of this pathway is CDC45, a key protein in the regulation of DNA 
replication. Chk1 inhibits both CDC45 loading on the replication origins and its interaction 
with MCM7, affecting DNA replication initiation and elongation (Broderick and Nasheuer, 
2009).  
Cyclin B-CDK1 is crucial for the G2/M transition of the cell cycle. It is specifically 
required for mitosis as it is responsible for the disruption of the nuclear envelope and 
initiation of prophase. During the G2 phase, this complex is maintained in a hyper-
phosphorylated inactive form by Wee1 and Myt1 kinases. Approaching M phase 
CDC25A/C are activated, which leads to the de-phosphorylation and activation of cyclin 
B-CDK1, promoting the transition to mitosis. If DNA damage occurs during G2, 
ATM/ATR kinases and Chk1/Chk2 kinases activate the G2/M checkpoint to prevent 
damaged cells from propagating. Chk1/Chk2, once activated, target the phosphorylation of 
CDC25A and CDC25C phosphatases. CDC25A phosphorylation on serine 123 mediates 
its ubiquitination and degradation (Falck et al., 2001). Instead CDC25C phosphorylation 
on serine 216 promotes its binding with 14-3-3 protein, causing its export from the nucleus 
(Peng et al., 1997). Hence, Chk1 and Chk2 cause cell cycle arrest in both G1 and G2 
phases by shifting the balance of the cyclin-CDK complexes towards phosphorylated and 
inactive forms (Tyson et al., 1995). At the same time p53 stabilization, driven by 
ATM/ATR activation, stimulates the transcription of genes that contribute directly to the 
maintenance of the G2/M arrest. These genes include: 14-3-3 itself, GADD45 that binds 
and dissociates cyclin B-CDK1, and p21 inhibitor of CDKs (Falck et al., 2001). 
Collectively these mechanisms prevent the activation of cyclin B-CDK1 causing the arrest 
of the cell cycle in G2-phase.  
Chapter 1  10 
1.1.2.2 Senescence: permanent cell cycle arrest 
A checkpoint is a transient and reversible cell cycle arrest, from which cells can exit if the 
damage is repaired. On the contrary, senescence is described as permanent and irreversible 
cell cycle arrest due to unrepaired damaged DNA.  
Senescence was first observed by L. Hayflick in a culture of human primary cell lines. It 
was described as growth arrest due to exhausted capacity of the cells to divide in vitro and 
called replicative senescence (Hayflick, 1965; Hayflick and Moorhead, 1961). However, 
the DSBs caused by the erosion of the telomeres, which progressively shorten every time 
the cell divides, was later identified as the determinant for this irreversible block of these 
cells in G1 phase of the cell cycle (d'Adda di Fagagna et al., 2003; Harley et al., 1990; 
Herbig et al., 2004). The activation of an oncogene leads to the production of high level of 
reactive species, more active replicons, anomalies in DNA replication forks progression 
and then the formation of single and double strand breaks that initiates DDR response (Di 
Micco et al., 2007; Moiseeva et al., 2006; Passos et al., 2010). This can lead to non-
replicative, i.e. premature senescence (Di Micco et al., 2006; Mallette et al., 2007; 
Michaloglou et al., 2005; Serrano et al., 1997; Zhu et al., 1998). Collectively, regardless of 
the stimulus, the response is the activation of ATM/Chk2 and ATR/Chk1 pathways that 
mediate the activation of the cell cycle checkpoints associated with cellular senescence. 
This occurs via p53 and with the participation of p21, p16 and pRb (Schmitt, 2007). Thus, 
senescence is a physiological barrier against tumourigenesis that could provide a potential 
avenue for targeting DDR in new cancer therapies (Halazonetis et al., 2008).  
1.1.2.3 Apoptosis: cell death 
Cells with intolerable amount of DNA damage are eliminated by apoptosis, a form of 
programmed cell death. It is one of the most dramatic p53-mediated responses that has a 
pivotal role in various physiological processes. Not only is it important for normal 
development, but also for removing damaged cells in aging and is often the mechanism of 
action for genotoxic cancer therapies.  
The induction of apoptosis by p53 includes the transcriptional upregulation of pro-
apoptotic factors of BH3-only family of proteins (PUMA and NOXA), and downregulation 
of anti-apoptotic factors such as BCL-2 and SURVIVIN (Oren, 2003). BH3-only proteins 
translocate to the mitochondrial membrane where they stimulate an apoptotic-cascade 
(Oda et al., 2000). This cascade is further amplified by the translocation of p53 to the 
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mitochondria and inhibition of BCL-2 family members (Murphy et al., 2004). These events 
lead to the permeabilization of the mitochondrial membrane, release of cytochrome C into 
the cytosol, formation of the apoptosome, and ultimately causing the activation of effector 
caspases (Ferri and Kroemer, 2001).  
1.2 DNA damage response pathways  
Different type of DNA lesions can activate DDR pathway, which involves the activation of 
various kinases that constitute a complex network of signalling cascade (Figure 1.4). The 
aim is to coordinate checkpoint activation, proper repair mechanism, senescence and 
apoptosis, thereby preventing the transmission of any genetic lesions to daughter cells 
(Ciccia and Elledge, 2010). Defects in any of the DDR pathway components contributes to 
aging, various disorders such as development defects, and therefore, cancer (Jackson and 
Bartek, 2009). The two main signalling pathways activated by DDR are ATM/Chk2 and 
ATR/Chk1 protein kinase pathways, which respond to different DNA lesions.  
1.2.1 ATM/Chk2 pathway  
The ATM/Chk2 pathway is primarily activated by DSBs caused by radiation and 
genotoxins. ATM is a Ser/Thr protein kinase that belongs to phosphoinositide-3-kinase-
related protein kinase (PIKK) family. Its importance is documented by the fact that ATM 
deficiency causes the genetic disorder ataxia-telangiectasia (A-T), characterized by 
immunodeficiency, cerebellar degeneration, radiation sensitivity, chromosomal instability 
and cancer predisposition (Uziel et al., 2003). 
In undamaged cells, ATM exists as inactive homodimers. Following DSBs, these 
homodimers auto-phosphorylates in trans, resulting in partially active monomers. Three 
auto-phosphorylation sites have been documented for ATM. Serine 1981 was the first to be 
discovered and its phosphorylation is tightly associated with ATM activation in most of the 
circumstances (Bakkenist and Kastan, 2003). Serine 367 and 1893 are considered 
additional phosphorylations that may contribute to its activation (Kozlov et al., 2006). 
However, the precise mechanism for ATM auto-phosphorylation and activation is still 
unclear. Alterations in the chromatin structure surrounding a DSB have been proposed to 
drive the association of ATM with DNA and initiate its activation (Bakkenist and Kastan, 
2003). Following ATM activation, the first event is ATM-dependent phosphorylation of 
the histone variant H2AX, forming the DNA damage histone mark γ-H2AX (Fernandez-
Capetillo et al., 2004). This is a crucial event because it functions as signal for the 
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subsequent accumulation of DNA damage-response proteins (Bassing et al., 2003). The 
second component of the pathway is the mediator of DNA-damage checkpoint protein 1 
(MDC1) that binds H2AX and acts as platform for the retention of other DNA-damage 
recognition/repair proteins on the chromatin (Kastan and Lim, 2000). MDC1 also 
contributes to the long-range phosphorylation of H2AX and the maintenance of the 
response (Huen and Chen, 2008). The RING-finger ubiquitin ligase RFN8 then associates 
to phosphorylated MDC1, and ubiquitinates H2AX inducing the accumulation of p53-
binding protein (53BP1) and BRCA1 at the sites of the damage.  
However, the full activation of ATM is achieved by the association of the Mre11-Rad50-
Nbs1 (MRN) sensor complex, through its interaction with MDC1-Nbs1 (Berkovich et al., 
2007). ATM phosphorylates a series of downstream targets, which include a multitude of 
proteins involved in DNA repair, cell cycle checkpoint activation and transcription 
(Matsuoka et al., 2007). The phosphorylation of Nbs1, BRCA1 and CTIP are crucial for 
the initiation of the homologous recombination (HR) repair. ATM also targets 53BP1 
(Ward et al., 2003), the cohesin SMC1 (Kitagawa et al., 2004) and its kinase effector Chk2 
(Bartek and Lukas, 2003). In addition to this, ATM also targets proteins localized in the 
nucleoplasm. ATM is important for the activation p53-mediated response to DNA damage. 
ATM stabilizes p53 through its phosphorylation and the stability of its regulators, MDMX 
and MDM2 (Chen et al., 2005a; Lavin, 2008).  
Chk2 is the main kinase effector of ATM in the DDR pathway. ATM activates Chk2 via 
phosphorylation at Threonine 68, which is located in N-terminal serine/threonine-
glutamine (SQ/TQ)-rich motif (Ahn et al., 2000). Phosphorylated Chk2 proteins can 
associate to each other through their fork-head associated domains, forming transient 
homodimers, which leads to intermolecular activation loop auto-phosphorylation and then 
its full activation (Ahn et al., 2002; Cai et al., 2009). Once activated, Chk2 dissociates 
from the DSBs and rapidly disperses as a monomer into the nucleoplasm, where it 
regulates the activation of substrates involved in various cellular processes (Bartek and 
Lukas, 2003). As previously mentioned, Chk2 not only regulates the stability of p53 and its 
regulator MDMX, but also inhibits CDC25 phosphatase family, thus controlling the cell 
cycle progression and apoptosis (Chehab et al., 2000; Chen et al., 2005a). It also regulates 
FOXM1 and E2F1, thereby regulating gene transcription (Stevens et al., 2003; Tan et al., 
2007), and BRCA1, thus contributing to HR regulation (Zhang et al., 2004).  
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1.2.2 ATR/Chk1 pathway  
ATR, as ATM, is a Ser/Thr kinase that belongs to PIKK family. It is activated in response 
to a broad spectrum of DNA damage that induces the formation of ssDNA (Ciccia and 
Elledge, 2010; Flynn and Zou, 2011). The formation of these ssDNA regions can occur by 
multiple mechanisms. For example, chemical agents can directly or indirectly affect active 
replication forks causing them to stall or collapse forming ssDNA. Moreover, single-
stranded DNA can also be formed as DNA repair intermediate of DSBs activating ATR 
(Hurley and Bunz, 2007). Its unusual versatility makes ATR essential for cell survival, 
even in absence of genomic insults. Indeed, ATR knockout in mice results in embryonic 
lethality at day 7.5 (Brown and Baltimore, 2000).  
Following ssDNA formation, ATR is rapidly recruited in association with its binding 
partner ATRIP. Tracts of ssDNA are rapidly covered with the trimeric ssDNA binding 
protein complex, which recruits ATRIP through its 70KD RPA1 subunit (Zou and Elledge, 
2003). Like ATM, ATR activation requires an auto-phosphorylation event on Thr 1989, 
which occurs amongst ATR-ATRIP complexes in trans on RPA-ssDNA (Liu et al., 2011).  
However, its full activation is achieved by ATR interaction with two mediator proteins: 
TOBP1 and Claspin. TOBP1 is recruited on ssDNA via PCNA-like Rad9:Rad1:Hus1 
“checkpoint clamp” (Delacroix et al., 2007). It recognizes and binds ATR at its 
phosphorylated Thr 1989, stimulating its kinase activity. Claspin, instead, is normally 
associated with the replication forks and is phosphorylated in an ATR-dependent manner 
within a short repeated motif (Lee et al., 2003). Its phosphorylation induces a structural 
modification that stimulates its binding to Chk1 (Jeong et al., 2003). Both these mediators 
work as a platform for ATR substrates activation.   
Once Chk1 is recruited at ssDNA by Claspin and brought in proximity of ATR, it is 
phosphorylated at multiple S/T-Q sites within its C-terminal regulatory domain by ATR 
(Jeong et al., 2003). The first phosphorylation event is on Ser 317, and is specifically DNA 
damage induced (Niida et al., 2007). This modification is required for the subsequent 
phosphorylation on other sites including Ser 345, achieving its full activation. S345 is 
normally found phosphorylated even during an unperturbed cell cycle. A pool of activated 
Chk1 is normally associated to the chromatin, stimulating the transcription of growth 
promoting genes (Niida et al., 2007; Wilsker et al., 2008). When Chk1 is phosphorylated at 
both S317 and S345, it dissociates from chromatin and diffuses into the nucleus and the 
cytosol targeting proteins for phosphorylation (Smits, 2006).  
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Active Chk1 targets include multiple proteins involved in cell cycle progression, repair and 
gene transcription. As already mentioned, activated Chk1 regulates CDC25 family 
phosphatase (CDC25A and C) and Wee1 activity, controlling cell cycle transition. Chk1 
mediates the inhibition of both CDC25 phosphatases, whereas Chk1-directed 
phosphorylation of Wee1 stimulates its activity (Lee et al., 2001). Chk1 also targets 
BRCA2 and RAD51 for phosphorylation to govern HR repair (Sorensen et al., 2005), and 
mediates H3 phosphorylation to repress gene transcription of factors that promote cell 
cycle progression (Shimada et al., 2008).  
In conclusion, ATM/Chk2 and ATR/Chk1 pathways are activated in response to different 
stimuli. The ATM/Chk2 pathway is specifically activated in presence of DNA damage. On 
the contrary, ATR/Chk1 pathway is also found activated at low levels also during S phase 
of the cell cycle, ensuring the correct DNA replication (Syljuasen et al., 2005). These 
pathways together coordinate the cell cycle checkpoints and the DNA repair process.  
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Figure 1.4: The activation of ATM/Chk2 and ATR/Chk1 pathways. A model showing the pathway involved in 
triggering the G1/S, intra-S or G2/M checkpoints [Figure adapted from Smith et al., 2010]. 
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1.3 MRN complex and DNA repair mechanisms 
1.3.1 MRN complex, the DSB sensor and activator 
MRN complex is amongst the first proteins to be rapidly recruited on DNA-double strand 
breaks. It is a DSB sensor and directly binds the broken DNA independently without 
sequence specificity (de Jager et al., 2001b). It is a global player in DDR response, because 
it functions as co-activator of DSB-induced cell cycle checkpoint signalling, and an 
effector of both HR and non-homologous end-joining (NHEJ) repair mechanisms 
(D'Amours and Jackson, 2002; Zha et al., 2009). MRN complex is also responsible for the 
telomeres maintenance, thus contributing to genome integrity (Assenmacher and Hopfner, 
2004). Moreover, MRN complex has also been found associated with the chromatin during 
unperturbed cell cycle, preventing the accumulation of DSBs during replication (Mirzoeva 
and Petrini, 2003). 
The MRN complex is formed of three proteins: Mre11, Rad50 and Nbs1. Mre11 and 
Rad50 are well conserved in all taxonomic kingdoms, instead Nbs1 is specific to 
eukaryotes (Stracker et al., 2004). Mre11 is the key component of the complex, because it 
contains numerous biochemical activities (de Jager et al., 2001a; Usui et al., 1998). It has 
DNA nuclease, strand dissociation and strand annealing activities, which are all crucial for 
HR and NHEJ repair (Milman et al., 2009; Zhuang et al., 2009). The DNA nuclease 
activity is 3'!5' endo and exonuclease that works in association with both DSBs and 
ssDNA (Trujillo and Sung, 2001; Trujillo et al., 1998). However, in order to repair DSBs 
by HR, the 5’-terminated DNA strand must be resected to produce the 3' ssDNA overhang. 
Mre11 lacks of the 5'!3' nuclease activity to catalyse this, suggesting the involvement of 
other DSB processing factors (Farah et al., 2009). Mre11 is able to form dimers and large 
multimers with itself (Desai-Mehta et al., 2001), and can interact independently with both 
Rad50 and Nbs1 (Johzuka and Ogawa, 1995). It also has an intrinsic capacity to bind DNA 
that is stimulated by Rad50 on its own or in combination with Nbs1 (Paull and Gellert, 
1999).  
Rad50 belongs to a group of proteins known as the structural maintenance of chromosome 
(SMC) proteins, because they regulate chromosome condensation and sister-chromatid 
cohesion (Hirano, 2002). This protein contains Walker A and B nucleotide (NTP)-binding 
motifs (ATPase domains) at the N and C terminus respectively (Alani et al., 1989). Rad50 
proteins associate to form homodimers, which in turn bind Mre11 dimers forming 
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heterotetramers called the “core” complex (Figure 1.5). The function of the core complex 
is to mediate the spatial juxtaposition of DNA molecules to achieve spatial proximity more 
conducive for homology-mediated repair (Hopfner et al., 2002).  Mre11 dimers mediate 
short-range DNA end interactions, whereas Rad50 dimers, with the two large coiled arms, 
mediate long-range interactions. Rad50 association with Mre11 also stimulates its endo 
and exonuclease activity (Paull and Gellert, 1998).  
The last component to associate to the core complex is Nbs1. It contributes to checkpoint 
activation and DSB repair functioning as an adaptor for various protein-protein 
interactions. Indeed, Nbs1 consists of an FHA and two BRCT domains essential for 
recognising phosphorylated proteins involved in DDR response, most importantly ATM 
(Lloyd et al., 2009). However, Nbs1 is itself phosphorylated by ATM at these breakage 
sites as part of the DDR response (You et al., 2005). Nbs1 retains also an Mre11-binding 
domain. Its association with the Mre112-Rard502 core complex not only is fundamental for 
MRN complex translocation from the cytosol to the nuclei, but also for stimulating its 
DNA binding capacity and endonuclease activity (Desai-Mehta et al., 2001; Paull and 
Gellert, 1999).  
The role of MRN complex in DDR signalling is to activate it, however, the master 
regulator of cellular response to DSBs is ATM (Shiloh, 2003b). MRN leads to the 
activation of ATM in a two-step process. MRN binds DSBs and this leads to an increase in 
the local concentration of DNA ends to such a level that induces dimeric ATM to 
dissociate into monomers. These monomers are then recruited at the DSBs by Nbs1-
mediated interaction, which at the same time stimulates ATM enzymatic activity leading to 
its auto-phosphorylation (Dupre et al., 2006). 
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Figure 1.5: MRN complex assembly at a double strand break. A model depicting the assembly of the core subunits of 
the MRN complex and its associated proteins at a DSB [Figure adapted from Nakamura et al., 2010]. 
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1.3.2 DSB repair mechanisms 
DSBs are the most toxic and deleterious form of DNA damage, as both of the DNA strands 
are broken simultaneously. They are really dangerous lesions because they leave cells 
without an intact template to use for the repair. Moreover, these broken DNA ends can also 
subjected to further physical and chemical assault, which can cause the loss or the damage 
of bases or formation of abnormal DNA structure, all them concurring in loss of genetic 
information (Hiom, 2010). Various types of insults can cause DSBs. Among those, 
radiation or radiomimetic drugs cause DSBs by generating free radicals that attack the 
deoxyribose, whereas DSBs can also arise from the inhibition or failed DNA end ligation 
by topoisomerase II (Jackson and Bartek, 2009).  Any errors during DNA replication or 
replication during the repair of single stranded DNA breaks is another source of DSBs in 
cells. DSBs can also originate due to free-oxygen radicals formed by normal aerobic 
metabolism (Chance et al., 1979).   
Two major pathways are used by the cells to repair these DNA lesions, which differ in 
template and fidelity requirements: HR and NHEJ (Figure 1.6) (Pardo et al., 2009). The 
NHEJ is the most used pathway in mammalian cells for repairing DSBs, as it can operate 
quickly and through all cell cycle phases (Rothkamm et al., 2003). However it is an error-
prone mechanism, since it mediates the ligation of broken DNA ends together without 
considering their homology, often generating deletions or insertions (Lieber, 2010). An 
alternative repair mechanism called microhomology mediated end-joining (MMEJ) is used 
when NHEJ cannot occur, but this is also prone to errors (McVey and Lee, 2008). Contrary 
to these, HR is a more accurate repair mechanism because it uses a homologous template 
for repairing the damage. Since a sister chromatid is usually used as template, this pathway 
acts on post-replicative DNA in S and G2 phase of the cell cycle (Moynahan and Jasin, 
2010; San Filippo et al., 2008).  
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1.3.2.1 HR repair mechanism 
The MRN complex has a pivotal role in the initial processing of a DSB, although its 
nuclease activity works in the opposite polarity of that required for HR. Thus, additional 
factors are required to work in conjunction with MRN complex for the 5'-end nucleolytic 
resection (Rupnik et al., 2010). A recent study in yeast has proposed a bidirectional model, 
by which MRN complex could overcome this problem.  In the first step, the endonuclease 
Sae2 (orthologl of the mammalian Ctip) stimulates the endonuclease activity of Mre11 to 
mediate a cleavage of double-stranded DNA downstream of the DSB to form an 
intermediate. In the second step, MRN complex then proceeds back to dsDNA using its 3´ 
to 5´ exonuclease activity (Cannavo and Cejka, 2014). Following this, nucleases ExoI and 
RECQ1, in conjunction with Dna2 are recruited to carry out the long-range resection in the 
5´ to 3´ direction to facilitate the generation of the 3´-single stranded DNA (Bernstein and 
Rothstein, 2009; Mimitou and Symington, 2009; Sartori et al., 2007). The resultant ssDNA 
is then rapidly coated by the ssDNA-binding protein RPA, in order to avoid the formation 
of secondary structures (Starczynowski et al., 2010). BRCA2 then mediates the 
displacement of RPA from the ssDNA, allowing the binding of RAD51 recombinase, 
which associates in multimers to form a nucleoprotein filament.  BRCA2 is essential for 
this step, since RPA has higher affinity than RAD51 in binding ssDNA. RAD51 together 
with various HR factors mediates the search for the homologous sister chromatid, followed 
by DNA strand invasion and finally extension of the DNA end using intact homologous 
sequence as a template. Lastly, the second end of the broken DNA is captured and the 
junctions are solved by the activities of DNA polymerases δ/η, DNA ligase I, DNA 
helicase and resolvase enzymes (Mazon et al., 2010; Pardo et al., 2009).  
The strand resection step is regulated in a cell cycle dependent manner. Since HR is mainly 
used to repair DSBs in S and G2 phases, resection is indeed tightly regulated by S/G2 
phase CDKs, ensuring maximal resection activity. For example, it has been shown that 
Ctip becomes more abundant in S phase and its enzymatic activity is directly regulated by 
CDK-mediated phosphorylation. Ctip upregulates DNA-ends resection, which in-turn 
increases the number of DSBs repaired by HR (Huertas and Jackson, 2009; Sartori et al., 
2007; Yun and Hiom, 2009). Nbs1 is also phosphorylated by cyclin B-CDK1 in S/G2/M 
phase, potentiating HR-mediated resection (Falck et al., 2012). However, the cell cycle 
regulation of the resection mechanism is insufficient to ensure the safe use of HR. In 
addition to this, SMC proteins help to restrain HR repair to the sister chromatids, thus 
avoiding its use on other sequences (Cortes-Ledesma et al., 2007; Covo et al., 2010). The 
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mutation of most proteins involved HR repair predispose to cancer, suggesting the critical 
role of HR in the maintenance of genome stability. 
1.3.2.2 NHEJ repair mechanism  
MRN complex is also required in the NHEJ pathway and functions within the first step of 
this pathway. The ring hook domain of RAD50 is thought to assist Ku70/80 and DNA-PK 
in tethering DNA ends and bringing them in proximity to each other (Hopfner et al., 2002). 
NHEJ is a relatively simpler DSB repair pathway than HR and it is mediated by a different 
set of proteins. Ku70 and Ku80 combine to form a heterodimer that binds with high 
affinity to the two-ended DSBs promoting the alignment of the two DNA ends (Cary et al., 
1997; Walker et al., 2001). The complex then recruits the catalytic subunit of the DNA 
dependent protein kinase stimulating its kinase activity (DNA-PKcs) (Ciccia and Elledge, 
2010; Yaneva et al., 1997). DNA-PK once active together with the nuclease Artemis can 
trim the DNA ends, or with DNA polymerases (Polµ or Polλ) can fill in to create 
compatible ends. Finally, the XRCC4, Xrcc4 like factor, and DNA ligase IV form the 
ligation complex that, through its interaction with Ku-DNA, ligates the DNA ends 
completing the repair process (Grawunder et al., 1997; Hentges et al., 2006). 
Altogether, the activation of repair pathways following DNA damage is critical for genome 
stability and tumour prevention. This event is influenced by different factors, such as cell 
cycle phase, complexity of the breaks, genetic factors or even genome complexity. In 
higher eukaryotes, the genome is characterized by a large number of highly repetitive 
sequences making HR prone to misalignment (Karanam et al., 2012). Indeed, mammals 
tend to use NHEJ as a preferred mechanism to repair DSBs, whereas HR is more often 
used in organisms where the genome has low amount of repetitive sequences. However, 
HR is mainly used if the damage occurs in S and G2 phases of the cell cycle (Brandsma 
and Gent, 2012; Karanam et al., 2012). In conclusion, the choice of the correct pathway for 
repairing that type of damage is crucial and can be irreversible, and wrong decisions may 
lead to dramatic consequences.  
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1.3.2.3 MMEJ repair mechanism 
MMEJ is used as an alternative repair mechanism to NHEJ, when polypeptides bound to 
the broken DNA ends hamper Ku proteins from binding them. It is a poorly defined 
mechanism, which requires the nucleolytic excision of the blocked DNA followed by the 
resection of one of the strand until a 5-20 nucleotide long complimentary sequence is 
found. This event is called a microhomology search and is necessary to achieve the base-
pairing required to stabilize the DNA ends. The displaced DNA ends are then removed and 
ligation occurs (McVey and Lee, 2008). Both MRN complex and Ctip have been reported 
to play a pivotal role in this repair mechanism, but their exact functions are still not clear 
(Yun and Hiom, 2009). However, like NHEJ, MMEJ is error-prone and implies the loss of 
genetic information.  
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Figure 1.6: DSB repair mechanisms. A model showing the mechanism and proteins involved in HR, NHEJ  and MMEJ 
repair pathways [Figure adapted from Brandsma and Gent, 2012]. 
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1.4 Alterations in DDR and cancer 
DDR plays a crucial role in the maintenance of genome stability. In response to DNA 
damage, cells normally arrest or die. However, mutations in apoptosis, DDR-response 
pathway or mitotic-checkpoint genes allow the survival and even the proliferation of cells 
with genomic abnormalities, promoting oncogenic transformation. Therefore, loss of 
function mutations in DDR response genes, involved in both checkpoint and repair 
regulation, results in human cancer predisposition syndromes and cancer (Kastan and 
Bartek, 2004). Thus, DDR pathway is a powerful anti-cancer barrier that blocks oncogenic 
progression (Halazonetis et al., 2008).  
1.4.1 DDR component mutations predispose to cancer 
ATM is the master regulator of all the cellular responses to DSBs. Therefore, germline 
mutations in ATM with loss of function cause the genetic disorder ataxia-telangiectasia 
(A-T). As in humans, ATM-null mice are predisposed to develop T-cell lymphoma, 
whereas loss of ATM in APC mutant mice increases the incidence of intestinal tumours 
(Barlow et al., 1996; Liao and Van Dyke, 1999; Xu et al., 1996). Interestingly even though 
A-T is a recessive disease, heterozygous mutations for ATM make the cells more sensitive 
to DSB-inducing agents. These cells are characterized by high chromosomal instability and 
radioresistance to DNA synthesis, suggesting an inability to fully activated intra-S 
checkpoint (Shiloh, 2003a; Swift et al., 1991). However, ATM is not the only protein in 
which mutations cause syndromes and predisposition to cancer.  
It has been shown that the inactivation of components of the MRN complex not only 
severely affect DSB processing (HR and NHEJ repair) and checkpoint regulation, but also 
DNA metabolic processes, telomere maintenance and the formation of meiotic DSBs (van 
den Bosch et al., 2002). This suggests that MRN complex is fundamental for several 
processes in cells. Germline knockout of Mre11 or Rad50 or Nbs1 genes in mice is 
embryonically lethal (Luo et al., 1999; Xiao and Weaver, 1997; Zhu et al., 2001). 
Hypomorphic mutations of Nbs1 cause the Nijmegen Breakage Syndrome (NBS), whereas 
hypomorphic mutations of Mre11 cause a milder form of A-T disease, called Ataxia-
Telangiectasia-like disorder (AT-LD). Both these syndromes show similar cellular and 
animal phenotypes to A-T disease, such as hypersensitivity to radiation, immunodeficiency 
and predisposition to cancer (Shiloh, 1997). NBS patients are also found to have mutations 
in Rad50. Altogether, these observations suggest how important the MRN complex is in 
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orchestrating the right response to DNA damage, and in particular for DSB-specific ATM 
activation (Shiloh, 2003a). In sum, all three components of the MRN complex are linked to 
cancer, presumably due to the central role of this complex in ensuring genome stability.  
Mutations in other components of DDR signalling downstream of ATM and MRN 
complex can also lead to cancer predisposition. Chk2 knockout mice don’t develop 
tumours spontaneously, however exposure to carcinogens increases the risk of skin 
tumours (Hirao et al., 2002). Surprisingly, tumours originated from these individuals don’t 
tend to lose the other Chk2 allele, suggesting a non-canonical role of Chk2 as tumour 
suppressor (Antoni et al., 2007). Chk1 is also considered to be a tumour suppressor gene. 
Chk1 knockout mice are not viable and it has been hypothesized that a haploinsufficiency 
of Chk1 contributes to tumourigenesis. This mechanism was studied by the conditional 
knockout of Chk1 in mammary epithelial cells. The disruption of Chk1 gene was found to 
cause inappropriate entry of cells into S phase, accumulation of damage during DNA 
replication and abnormal progression to mitosis (Lam et al., 2004). These observations 
indicate that defects in checkpoint activation caused by Chk1 or Chk2 haploinsufficiency 
predispose cells to cancer (Tho et al., 2012). 
Inheritance of one or both mutated alleles of BRCA1 or BRCA2 is associated with high 
risk of developing breast and ovarian cancers (O'Donovan and Livingston, 2010). 
Differently from Chk1 and Chk2, BRCA1/2 is a canonical tumour suppressor, whereby 
loss of both alleles is observed in tumours. BRCA proteins are activated in response to 
DSBs by ATM, Chk2 and ATR, thus contributing to intra-S and G2/M checkpoint 
regulation. Specifically, BRCA proteins are necessary for HR repair during those phases of 
the cell cycle. Therefore, BRCA deficient tumours are characterized by HR deficiency, 
whereas tissue surrounding it is HR proficient (Turner et al., 2005). 
However, an altered DDR response pathway is not sufficient for cancer development, 
implying that additional mutations are critical for promoting viability or growth and 
proliferation of pre-cancer cells. Hypomorphic mice for Mre11 show high level of genomic 
instability, but are not prone to tumourigenesis (Liu et al., 2004). However, the additional 
mutation of p53 helps tumour development, suggesting that the combination of genomic 
instability and checkpoint defects contribute significantly to tumour progression.  
In conclusion, defects in DDR pathway as a result of genetic mutations of its components 
cause predisposition to cancer. In addition to this, alterations in proteins that regulate the 
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DDR pathway can also lead to a similar predisposition. Mounting evidences have shown 
that the PI3kinase pathway is involved in the modulation of DNA damage response and 
genome instability in many complex ways.  
1.5 PI3K/Akt/mTOR signalling, DDR and cancer 
Phosphoinositide 3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR) 
signalling network has a central role in several cellular processes critical for cancer 
progression, such as survival, growth, metabolism, differentiation, motility and genomic 
instability (Hanahan and Weinberg, 2011). It is recognised to be one of the most mutated 
pathways in cancer (Engelman et al., 2006; Samuels et al., 2004).  
1.5.1 The PI3K/Akt/mTOR signalling network 
PI3K belongs to the PI3K family of protein kinases, which includes ATM and ATR. There 
are three classes of PI3K grouped according their structure and function, of which class IA 
is the most mutated one (Yuan and Cantley, 2008). PI3K is characterized by a catalytic 
subunit called p100 (or also PIK3CA) and a regulatory domain called p85 (or also PIK3R). 
PI3K is activated by numerous factors such as cytokines and growth factors that bind 
receptor tyrosine kinases (RTKs), G-protein coupled receptor or integrins (Kang et al., 
2006; Zhao and Vogt, 2008). Following stimuli, the regulatory p85 subunit recognizes and 
binds the phosphotyrosine residues on RTK relieving its intermolecular inhibition of p110 
the catalytic subunit (Carpenter et al., 1993). PI3K can be also activated in a receptor-
independent mechanism, for example by direct binding of RAS to p110 (Shaw and 
Cantley, 2006). PIK3CA is the second most often mutated oncogene in human cancer, 
resulting in its increased enzymatic activity. However, oncogenic lesions upstream in the 
tyrosine kinase and/or RAS can also cause the constitutive activation of PI3K signalling 
(Engelman, 2009).  
Activated PI3K at the plasma membrane initiates a multi-step PI3K-mediated signalling 
process (Figure 1.7). PI3K phosphorylates PIP2 (phosphotidylinositol 4,5-bisphosphate) 
converting it to PIP3 (phosphotidylinositol 3,4,5-trisphosphate). This reaction is 
antagonized by the phosphatase and tensin homolog deleted on chromosome 10 (PTEN), 
blocking PI3K-mediated signalling. PIP3 acts by forming a docking site for pleckstrin 
homology (PH)-containing proteins, such as Akt and 3-phosphoinositide dependent protein 
kinase-1 (PDPK1) (Ericson et al., 2010). Akt, once translocated to the plasma membrane, 
is phosphorylated by PDPK1 at Threonine 308. However, additional phosphorylation at a 
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secondary site Serine 473 is required for its full activation. This can be catalysed by target 
of rapamycin complex 2 (mTORC2), however other molecules like Integrin kinase (ILK) 
and Mitogen-Activated protein Kinase Activated protein kinase-2 (MAPKAPK2) are also 
able to phosphorylate this residue of Akt.  Akt is the central protein kinase in mediating 
PI3K-signalling and active Akt modulates the function of numerous substrates to regulate 
multiple cellular events.  
1.5.1.1 Akt, a multifunction protein kinase 
Akt (also known as PKB) belongs to a family of Serine/Threonine protein kinases. Three 
members characterize this family, which are tissue-specific: Akt1 (PKBα), Akt2 (PKBβ) 
and Akt3 (PKBγ) (Brodbeck et al., 1999; Cheng et al., 1992). Despite being produced by 
three different genes, they share 80% homology of amino acid sequence, suggesting 
similar substrates specificities (Vanhaesebroeck and Alessi, 2000). All three isoforms have 
the same protein structure that contains a pleckstrin homology domain (PH) domain, which 
mediates Akt binding to the plasma membrane, a central kinase domain, and a regulatory 
domain typical of the cAMP-dependent protein kinase A/G superfamily of protein kinases 
(Song et al., 2005). 
Activated Akt regulates many cellular events controlling many targets by either direct 
phosphorylation, or indirectly by regulating their expression levels. For example, Akt 
promotes cell survival through the phosphorylation-mediated inhibition of pro-apoptotic 
Bcl2-family proteins BAD and BAX (Engelman et al., 2006). This pro-survival effect is 
reinforced by Akt-mediated MDM2 activation and then p53 inhibition. In addition to this, 
Akt also negatively regulates the pro-apoptotic forkhead box O (FOXO) transcription 
factors (Majumder and Sellers, 2005).   
mTORC1 is one of the most important Akt targets and its activity relies on the nutrient 
status of the cells. Under nutrient sufficiency, it regulates cell growth by promoting 
metabolic processes such as anabolism and biosynthesis, whereas it suppress catabolic 
processes such as autophagy (Laplante and Sabatini, 2012). Akt inhibits tuberous sclerosis 
complex (TSC1/2) by phosphorylation of TSC2, thus relieving the inhibition of Rheb 
GTPase, which is then free to activate mTORC1. Akt can also inhibit the glycogen 
synthase kinase 3 (GSK3), which phosphorylates TSC2, reinforcing its inhibitory effect on 
TSC complex. Moreover, mTORC1 activation can also be fine tuned by other inputs such 
as growth factors, energy sensors and cellular stresses (Laplante and Sabatini, 2012). 
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mTORC1 activates p70-S6 kinase that then phosphorylates S6 protein and 4E-BP1, thus 
inducing protein synthesis (Engelman et al., 2006). It also inhibits autophagy by preventing 
the formation of the autophagosome by inhibiting phosphorylation of its components 
ULK1 and ATG13 (Chan, 2009).  
Lastly, Akt signalling pathway also contributes to regulating cellular progression through 
an unperturbed cell cycle. Akt controls G1/S transition by positive regulation of cyclin-
CDK complexes by phosphorylation and inactivation of CKIs such as p21 and p27 (Xia et 
al., 2011). Akt also protects cells from apoptosis during G2/M transition by 
phosphorylation of CDK1 activators and inhibitors, promoting entry into mitosis (Baldin et 
al., 2003; Karlsson et al., 1999). In summary, Akt is a fundamental protein for promoting 
survival and cell cycle progression, thus its overexpression or overactivation may play a 
central role in cancer. 
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Figure 1.7: PI3K activation and its signalling pathway. A schematic showing the PI3K signalling pathway, the 
proteins involved and achieved cellular outcome [Figure adapted from Yap et al., 2008]. 
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1.5.1.2 Akt, DDR and cancer 
It has been shown that several components of PI3K/Akt/mTOR pathway can also be 
phosphorylated in response to DNA damage (Matsuoka et al., 2007). PIKK family 
members can mediate the phosphorylation and activation of Akt, thus providing a pro-
survival signal by triggering cell cycle arrest or inhibiting apoptosis (Bozulic et al., 2008; 
Caporali et al., 2008; Lu et al., 2006; Viniegra et al., 2005). For example, following γ-
irradiation DNA-PK phosphorylates Akt at Serine 473, which then forms nuclear foci 
together with DNA-PK at DNA double-strand breaks. Following this, Akt induces a 
transcriptional program that promotes survival in response to DNA damage (Bozulic et al., 
2008). Other data have shown that ATM also interacts with Akt targeting it for 
phosphorylation at S473 in response to stimuli such as γ-irradiation or insulin (Viniegra et 
al., 2005). Interestingly, it has also been reported that following treatment with 
temozolomide (TMZ), a therapeutic methylating agent, ATR is required for 
phosphorylation of Akt at S473 (Caporali et al., 2008).  
Thus, Akt promotes cell survival in presence of damage induced by various genotoxic 
stresses through inhibition of apoptosis. Accordingly, positive regulators of Akt activity 
are often found upregulated and PTEN lost or inactivated by mutations in cancer. 
Increased Akt activity is associated with cellular resistance to radiotherapy in a broad 
variety of cancers such as glioblastoma, prostate, colon, breast and cervix (Brognard et al., 
2001; Kim et al., 2006). However, the role of Akt in radiation resistance is not only 
dependent on its anti-apoptotic activity. Akt has indeed been reported to modulate DNA 
repair, hence affecting the efficacy of radiation therapy by several possible mechanisms 
(Kao et al., 2007; Toulany et al., 2008; Tran et al., 2002). Several studies have shown that 
activated Akt could contribute to resistance to radiotherapy by stimulating error-prone 
NHEJ repair and promoting cell survival by interaction with DNA-PK. This seems to be a 
reciprocal interaction, where they phosphorylate each other in a positive feedback loop, 
stimulating high repair efficiency (Bozulic et al., 2008; Toulany et al., 2008). In breast 
cancer cell lines, high levels of Akt affect BRCA1 nuclear localization at DNA foci 
inducing its cytoplasmatic retention (Plo et al., 2008; Tonic et al., 2010). Thus, Akt can 
affect DNA processing by the promotion of error-prone NHEJ and inhibition of the 
initiation of HR repair following DNA damage.  
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Akt can also promote genome instability by other mechanisms. Evidences show that hyper-
activated Akt is able to abrogate DNA damage induced G2/M checkpoint upon exposure to 
genotoxic stresses. It has been shown that Akt can phosphorylate Chk1 at Serine 280 
inhibiting its activation and its execution of the checkpoint (Kandel et al., 2002). In 
addition, Akt is able to reduce Chk2 recruitment at sites of DNA lesions and its activation 
in glioblastoma cells (Hirose et al., 2005).  
In summary, alterations in PI3K pathway usually result in production of constitutively 
active Akt, which enhance its oncogenic activity. This seems to be strongly linked to cell 
transformation, as demonstrated by high frequency of hyper-activated Akt in tumours. 
Numerous evidences have shown that Akt may have a crucial role in negatively regulating 
checkpoint activation and fidelity of DNA repair, thus directly affecting genome stability. 
Therefore, an activated Akt signalling pathway may contribute to tumourigenesis and 
tumour survival by several mechanisms. However, further work clarifying the exact 
mechanism by which Akt exerts these functions will be particularly important for cancer 
therapy.  
1.5.1.3 mTOR, DDR and cancer 
mTOR is a Serine/Threonine kinase related to PI3K family and it exists in two complexes: 
mTORC1 and mTORC2 (Hara et al., 2002). Both these are large multisubunit complexes 
that have distinct binding partners and specific substrates. Moreover, they are differently 
sensitive to rapamycin and are differently regulated (Sarbassov et al., 2004; Zoncu et al., 
2011).  
mTORC2 is composed of the rapamycin-insensitive partner (Rictor), Sin1, GβL and 
Deptor. The functions of this complex are less understood compared to mTORC1. It’s 
thought to modulate the signalling of growth factors by phosphorylation of the C-terminus 
of several members of the AGC subfamily of kinases such as Akt, glucocorticoid-induced 
protein kinase 1 (SGK1) and protein kinase C-α (PKC-α) controlling cell survival, 
metabolism and cytoskeletal organization (Jacinto et al., 2004; Sarbassov et al., 2004; 
Sarbassov et al., 2005).  
The rapamycin-sensitive mTORC1 is formed by a regulatory protein Raptor, an associated 
protein LST8, and an mTOR-interacting protein Deptor (Efeyan et al., 2012). mTORC1 
functions as integrator of signals from five different major intracellular and extracellular 
cues, such as nutrients, growth factors, energy levels, stress and oxygen, to regulate major 
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processes such as autophagy and lipid/protein synthesis. mTORC1 promotes protein 
synthesis by phosphorylation of the translation initiation factor 4E-BP1 (eIF4E-binding 
protein) and S6K1/2. 4E-BP1 phosphorylation prevents its binding to cap-binding protein 
eIF4E, which binds and forms the eIF4F complex stimulating the initiation of the 
translation. Instead through S6K activation, mTORC1 controls the biogenesis of a variety 
of mRNAs, as well as the initiation and elongation of the translation (Ma and Blenis, 2009; 
Ruggero et al., 2004).  
Mounting evidences have shown that mTOR is a critical mediator of the cellular responses 
to many stresses including DNA damage. In normal conditions p53 is the central regulator 
of DNA damage response (Riley et al., 2008; Vousden and Ryan, 2009). It has been 
reported that p53 in these conditions mediates mTORC1 repression by different 
mechanisms (Feng et al., 2005). p53 induces transcription of PTEN, TSCs and Redd1, all 
of which inhibit mTORC1 activity (Ellisen et al., 2002; Feng et al., 2005; Stambolic et al., 
2001). It also transactivates Sestrin1 and Sestrin2 that inhibit mTORC1 by AMPK-
dependent regulation of TSC1/TSC2 complex (Budanov and Karin, 2008). In addition to 
this, p53 also decreases mTORC1-mediated translation initiation by affecting the 
phosphorylation and activation of the 4E-BP1 along with the activity of the p70-S6k 
(Horton et al., 2002). Contrary to this, it has also been reported that mTOR/S6K1 regulates 
the p53-mediated DNA damage response. S6K1 is able to phosphorylate and inhibit 
MDM2, thus inducing p53 activation and response to DNA damage. S6K1/MDM2 forms a 
complex that adjusts DNA damage response to the growth conditions (Lai et al., 2010). 
Several evidences have shown that mTOR has a role in S phase of the cell cycle, 
suggesting the requirement of TORC1 function in response to DNA replication stress. 
Therefore, treatment of several p53 null cell lines with rapamycin induces apoptosis that 
coincides with the entry into S phase (Huang et al., 2001). Moreover, the use of rapamycin 
enhances the DNA-damaging agent cisplatin (Shi et al., 1995). These observations suggest 
that mTOR has an important role in cell survival in response to aberrations in DNA 
replication (Shen et al., 2007a).   
In summary, mTOR is important for many cellular processes that are crucial for cancer cell 
growth, survival and proliferation. Therefore, many components upstream and downstream 
of mTOR are found mutated in cancer. mTOR activity is altered in nearly 100% of 
advanced human prostate cancer (Taylor et al., 2010). Constitutive activation of mTOR by 
deficiency of TSC1 and TSC2 causes the rare genetic disease tuberous sclerosis, in which 
patients develop benign tumours in many organs including the brain (Guertin and Sabatini, 
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2007). Therefore, diverse cancer therapies use rapamycin and its analogues targeting the 
activated mTOR pathway. Interestingly, it has been reported that the inhibition of mTOR 
signalling by rapamycin or S6K deficiency significantly extends lifespan in mice 
suggesting the crucial role of mTOR/S6K signalling in ageing (Harrison et al., 2009; 
Selman et al., 2009). In conclusion, the correct regulation of mTOR pathway is pivotal for 
protecting cells from both tumourigenesis and ageing-associated disease.  
1.6 Senescence  
Senescence is an irreversible growth arrest that is associated with morphological and gene 
expression changes which cause resistance to apoptosis (Beausejour et al., 2003; Cristofalo 
et al., 2004; Seluanov et al., 2001). It is a potent natural barrier to tumourigenesis in 
response to not just DNA damage, but also to many insults like oncogene activation, 
telomere dysfunctions, oxidative stress and to drug treatments. However, depending on the 
cellular or extracellular context, cellular senescence can have detrimental effects (Campisi, 
1997; Ohtani et al., 2012). Senescent cells seem to recapitulate ageing or loss of 
regenerative capacity of cells in vivo. In this case, senescence is considered to be 
deleterious, because it affects tissue renewal and function. Thus, senescence is a “double 
edged-sword” that prevent tomourigenesis, however contributes to ageing (Campisi, 1997). 
1.6.1 Senescence triggers 
A variety of stimuli can trigger differential senescence responses (Figure 1.8). These 
responses can be categorized as replicative senescence and premature senescence, the latter 
of which is induced by oncogene-activation or the loss of tumour suppressor genes such as 
PTEN (PICS) (Chen et al., 2005b; Di Micco et al., 2007; Gewinner et al., 2009; Moiseeva 
et al., 2006; Shamma et al., 2009).  
Replicative senescence is the result of a combination of events, the first of which is 
telomere erosion. Telomeres are constituted by G-rich sequence repeats and associated 
proteins that cap the ends of linear chromosomes to protect them from degradation or end 
to end fusion by DNA repair processes (Allshire et al., 1989; Moyzis et al., 1988). Cell 
cycle after cell cycle, cells undergo a progressive shortening of these repeats, because 
DNA polymerase can’t completely replicate DNA ends in S phase (the end-replication 
problem), resulting in “critically short” or “uncapped telomeres” (Campisi and d'Adda di 
Fagagna, 2007; Olovnikov, 1973). These eroded telomeres are sensed by the cells as 
persistent DSBs, resulting in the formation of γ-H2Ax-positive associated DNA damage 
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foci (SDF), which trigger ATM/ATR-mediated DDR. The unrestrained DDR signalling 
activates p53 in manner to execute senescence, mediating cell cycle progression arrest and 
DNA repair if it is possible (d'Adda di Fagagna et al., 2003). In addition to this, the 
increase in CDKIs such as p16 and Rb tumour suppressor also contribute to the replicative 
senescence functioning as second barrier to growth arrest of those cells with severely 
damaged DNA (Campisi and d'Adda di Fagagna, 2007; Kiyono et al., 1998; Kuilman et 
al., 2010). Several mouse models have addressed the importance of healthy telomeres in 
tumour development (Artandi et al., 2000; Deng et al., 2008). Mice deficient for the RNA 
component of telomerase (Terc) (the enzyme required for the maintenance of telomere 
length) develop significantly less tumours by activating a p53-dependent cellular 
senescence. Thus, the loss of p53 in these mice significantly increases tumour formation 
(Cosme-Blanco et al., 2007; Feldser and Greider, 2007).  
The mutation of certain genes in certain circumstances can potentially induce the 
transformation of normal cells into cancerous tumour cells. These are called oncogenes, 
and normal cells respond to it by undergoing senescence, thus preventing oncogenic 
transformation (Campisi and d'Adda di Fagagna, 2007; Serrano et al., 1997). This is called 
oncogene-induced senescence. In human fibroblasts, overexpression of the oncogenic form 
of RAS (HRASG12V), a cytoplasmic transducer of mitogenic signals, induces OIS due to 
DNA hyper-replication and hyperproliferation (Bartkova et al., 2006; Di Micco et al., 
2006; Moiseeva et al., 2006). Moreover, the overexpression of other proteins in the RAS 
pathway (such as RAF, MEK and BRAF) has also been shown to induce OIS (Lin et al., 
1998; Michaloglou et al., 2005; Zhu et al., 1998). OIS causes the activation of a S-phase 
specific DDR pathway. Although, in this case DDR is initiated by a different pathway 
from that one of replicative senescence, it still forms SDF and shares the activation of the 
same pathways and effectors downstream culminating in the activation of p53 (d'Adda di 
Fagagna, 2008). Moreover, OIS-induced DNA damage leads to ROS-mediated p16 
expression, which significantly contributes to the maintenance of OIS (Yamakoshi et al., 
2009). OIS is entirely dependent on p53 and p16 functions, and therefore their inactivation 
by E1A protein (viral oncoprotein) bypasses senescence (Serrano et al., 1997). Numerous 
mouse models support the physiological role of OIS in vivo and its relevance to cancer 
progression. Activated oncogenes or loss of tumour suppressor genes cause the formation 
of benign lesions in mice, which contain senescent like-cells. An example of it is the 
benign naevi in human skin, which shows the presence of cells expressing oncogenic 
BRAF and are senescent at the same time (Michaloglou et al., 2005). However, DDR can 
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be also triggered directly by γ-irradiation or UV-light or chemotheraupetic drugs inducing 
a p53/p21 and p16-dependent senescent phenotype (Borodkina et al., 2014).  
Senescence can also occur in a DDR-independent way. PTEN-induced cellular senescence 
(PICS) is a form of senescence caused by PTEN deletion. In this case, senescence doesn’t 
involve OIS-like hyper-replication or DDR. It manifests when cells are treated with 
aphidicolin, arresting them before entry into S phase and then preventing DNA replication 
(Alimonti et al., 2010). Also in this case, the main effector of PICS is p53, whose 
activation is mediated by mTOR translation (Alimonti et al., 2010; Nardella et al., 2009). 
PTEN deletion also induces p16, resulting in disruption of the anaphase-promoting 
complex APC/C-CDH1 and high levels of ETS2, interrupting the completion of mitosis 
(Song et al., 2011). The inactivation of p53 with PTEN loss in mice prostate demonstrated 
the relevance of PICS for preventing the progression to aggressive form of cancers (Chen 
et al., 2005b).  
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Figure 1.8: Cellular senescence and the associated pathways. A schematic representation of the various causes and 
effectors leading to cellular senescence [Figure adapted from Nardella et al., 2011]. 
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1.6.2 Effectors of senescence 
As mentioned previously, the most important pathways that mediate senescence growth 
arrest are the p53-p21 and p16-pRb pathways. They affect the cell cycle independently and 
by different mechanisms. The activation of one or the other or both pathways, and their 
ability to induce senescence depends on various conditions that are cell-type and species-
specific. However, it appears that there are also cases of senescence driven by pathways 
other than p53 and pRb (Michaloglou et al., 2005; Olsen et al., 2002).  
1.6.2.1 The p53 pathway 
p53 is a key tumour suppressor protein, integrating many signals and mediating many 
physiological processes, such as cell cycle arrest, differentiation and also senescence 
following DDR. p53 activity is regulated at different levels by several mechanisms. As 
previously mentioned, the ATM/Chk1 and ATR/Chk2 pathways induce p53 activation by 
enhancing its stabilization through its direct phosphorylation or phosphorylation and 
inhibition of its negative regulator MDM2 (Ou et al., 2005; Sancar et al., 2004).  MDM2 is 
also negatively regulated by p19ARF resulting in p53 activation (Sherr and McCormick, 
2002). In addition to this, many other proteins or modification can also regulate p53 
activity. p53 activation results in transcriptional regulation of many genes, most 
importantly, that of p21, which is responsible for both transient and permanent DNA 
damage-induced arrest. The choice between transient arrest of the cell cycle or permanent 
arrest leading to senescence, depends on the severity of the DNA damage. It has been 
shown that senescent cells present irreparable DNA damage, which is caused by the 
accumulation of DNA lesions at telomeric regions, causing a persistent DDR activation 
p53-mediated (Fumagalli et al., 2012; Hewitt et al., 2012; Suram et al., 2012).  
Experimental reduction in p53, p21 or any of the DDR proteins (such as ATM and Chk2) 
in mice and human cells, restrains the induction of DNA damaged-induced senescence. 
Moreover, in some cells that don’t express p16 or RAS, this can even reverse senescence 
growth arrest (Baus et al., 2003; Beausejour et al., 2003; Brown et al., 1997; d'Adda di 
Fagagna et al., 2003; Di Micco et al., 2006). Overall, p53 and the DDR pathway function 
as quick and powerful barriers for arresting cells with severely damaged DNA, thus 
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preventing the accumulation and propagation of oncogenic mutations (Bartkova et al., 
2005; Gorgoulis et al., 2005). 
1.6.2.2 The p16-pRb pathway 
Several stimuli can induce the activation of pRB pathway. As mentioned, p16 can activate 
pRb by the inhibition of cyclin/CDK complexes, inducing inhibition of the E2F-mediated 
regulation of the cell proliferation and control genes (Sherr, 1996). p16-pRb pathway 
contributes to induce senescence, sometimes as a secondary effect after the activation of 
p53 (Jacobs and de Lange, 2004; Stein et al., 1999). However, senescence can also be 
directly induced via p16-pRb pathway in a cell type dependent and species-specific 
manner. For example, epithelial cells, contrary to fibroblast, engage senescence by a p16-
mediated proliferation arrest (Overhoff et al., 2014). The decision to engage one or both 
pathways not only depends on the cell type, but also on the species. For example, telomere 
disruption in human cells induces senescence by both p53 and p16-pRb pathways, whereas 
in mice it induces senescence just by p53 activation (Nalapareddy et al., 2010; 
Smogorzewska and de Lange, 2002).  
p16 expression can be regulated by different factors. p16 expression is induced by the 
oncogenic RAS through the activation of the transcriptional factor ET2 (E26 
transformation-specific). The ID family of helix-loop-helix (HLH) proteins generally 
counteract ET2 activity, however they are downregulated upon induction of senescence 
(Ohtani et al., 2001). Another class of proteins called Polycomb repressor complexes 1 and 
2 (PRC1/PRC2) regulate growth arrest by regulating transcription from the INK4A-ARF 
locus, which encodes for p16 and p14 (Bracken et al., 2007). In normal proliferating cells, 
p16 and p14 expression is repressed by promoter hypermethylation mediated by Ezh2 
factor of the PRC2 complex. This repression is maintained by the factors of the PRC1 
complex, such as Bmi-1, CBX8 and CBX7. In senescent cells, the reduction in the level of 
Ezh2 decrease the trimethylation of the promoter, causing the dissociation of PRC1 
proteins from chromatin and the transcription of the INK4A-ARF genes (Bracken et al., 
2007; Maertens et al., 2009). Moreover, p16 expression can be also regulated in a ROS-
dependent manner (Yamakoshi et al., 2009). As previously mentioned, the expression of 
oncogenic RAS induces E2F mediated transcription of DNMT1, a methyl-transferase 
involved in the methylation-mediated repression of the p16 promoter. However, RAS-
induced hyperproliferation causes DNA damage and production of ROS, which in-turn 
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inhibits E2F activity, thereby supressing DNMT1 expression and allowing p16 
transcription. 
Despite p21 and p16 both being CDK inhibitors involved in keeping pRb in the active 
form, they are not equivalent and the senescence caused by them seems qualitatively 
different. In case of p53-p21 mediated senescence, growth arrest can be resumed after 
deletion of p53 (Beausejour et al., 2003; d'Adda di Fagagna et al., 2003; Gire et al., 2004; 
Won et al., 2006). Instead, once the cells completely engage p16-pRB pathway for several 
days, growth cannot be resumed even after deletion of p53, pRb or p16 (Beausejour et al., 
2003). In addition to this, the loss of pRb-p16 pathway causes upregulation of p53 and 
p21, because E2F induces ARF expression (Bates et al., 1998; Zhang et al., 2006). In 
conclusion, p53 and pRb are the master regulators of senescence and they reciprocally 
regulate each other. However, the outcome of the activation of one or the other, and nature 
of senescence achieved are different.  
1.6.3 Features of senescent cells 
Senescent cells can be identified by several characteristic features, which all together 
define the state of senescence. These features are discussed below.  
1.6.3.1 Growth arrest  
Senescent cells are characterised by their inability to progress through the cell cycle. The 
genetic background and the species of a cell define the severity and the features associated 
with the senescence growth arrest (Di Micco et al., 2006; Olsen et al., 2002; Zhu et al., 
1998). In most cases, senescence induces a G1 arrest, thus preventing cells from entering 
the S phase and replicating their DNA. In this case the cell remains metabolically active 
(Di Leonardo et al., 1994; Herbig et al., 2004; Ogryzko et al., 1996; Serrano et al., 1997). 
High levels of cell cycle inhibitors such as p21 and p16 mediate this permanent arrest, 
which is different from quiescence and cannot be reversed by any physiological stimulus. 
It has been shown that oncogene activation can also induce a fraction of cells to arrest in 
the G2 phase of the cell cycle (Di Micco et al., 2006; Olsen et al., 2002; Zhu et al., 1998).  
1.6.3.2 Senescence-Associated Secretory phenotype 
Various transcriptional profiling experiments have revealed that senescent cells compared 
to proliferating cells demonstrate a pronounced change in gene expression (Shelton et al., 
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1999; Yoon et al., 2004; Zhang et al., 2003). As expected, many genes associated with 
proliferation and cell cycle progression are significantly downregulated. However, a 
surprising number of gene expression alterations involve genes not correlated with growth 
arrest. Many of them encode for secreted factors, such as pro-inflammatory cytokines and 
chemokines, or proteases and various growth factors, upregulation in which affect the 
surrounding cells and the tissue microenvironment (Chang et al., 2002; Mason et al., 2004; 
Rodier and Campisi, 2011; Shelton et al., 1999; Zhang et al., 2003). This feature of 
senescent cells is called senescence-associated secretory phenotype (SASP). SASP is a key 
feature of senescent cells that distinguishes them from other non-proliferative cells (Coppe 
et al., 2008). SASP-produced factors and their composition vary depending on the cell 
context and senescence trigger, suggesting that SASP is plastic and versatile. Pro-
inflammatory cytokines and chemokines are the most conserved SASP-secreted factors, 
indicating that most senescent cells share the characteristic to attract immune cells to 
induce local inflammation (Coppe et al., 2008). However, there are exceptions such as the 
human nevi where the accumulation of senescent cells doesn’t involve any immune 
response or inflammation (Benz et al., 1991).  
Although it is considered a typical hallmark of senescent cells, SASP is also important 
effector mechanism involved in the establishment of senescence. Some of its components 
have indeed been shown to reinforce the senescence-mediated proliferation arrest by an 
autocrine feedback mechanism. For example, the expression of oncogenic RAS in human 
ovarian fibroblasts has been reported to induce the expression and secretion of the factor 
GRO-1. Pre-conditioned medium with GRO-1 was found to be able to induce senescence 
in wild-type fibroblasts. (Yang et al., 2006).  Similarly, the expression of BRAF in human 
cells causes senescence through the expression and secretion of the IGFB7, which inhibits 
the RAF-MEK-ERK pathway (Wajapeyee et al., 2008). Moreover, other works have 
shown that the cytokine IL6 and the chemokine IL8 significantly contributes to establish 
and maintain senescence by expression of a C/EBPβ- and NF-κB-dependent network of 
inflammatory factors (Acosta et al., 2008; Kuilman et al., 2008). These two transcription 
factors C/EBPβ- and NF-κB in particular are crucial for the regulation of the secretion of 
several SAPS factors to reinforce senescence. The depletion of C/EBPβ- in BRAFV600E 
expressing cells has shown indeed to abolish the expression of IL6 and IL8 bypassing 
senescence (Kuilman et al., 2008). Another factor that contributes in regulating SASP-
secreted factors is DDR. The silencing of several components of DDR decreases the 
expression of diverse SASP factors (Rodier et al., 2009). Altogether, these evidences 
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demonstrate that SASP factors can reinforce senescence, but its complexity warrants 
additional investigations.  
1.6.3.3 Apoptosis resistance 
Many senescent cells acquire resistance to certain apoptotic signals. Senescent human 
fibroblasts are much more resistant to ceramide-induced apoptosis, compared to 
endothelial senescent cells (Hampel et al., 2004). Senescent human fibroblasts are also 
resistant to apoptosis induced by growth factor deprivation and oxidative stress, but they 
are not resistant to apoptosis induced by Fas death receptors (Chen et al., 2000; Tepper et 
al., 2000). The capacity of these cells to be stable in culture and resist apoptosis could 
explain why the number of senescent cells increases with age. However, how a cell 
acquires resistance to apoptosis is still not fully understood, but it is clear that p53 plays a 
crucial role in this process. In some cells, resistance is associated by p53-mediated 
regulation of expression of proteins that inhibit, promote or implement apoptotic cell death 
(Marcotte et al., 2004; Murata et al., 2006). In some others, p53 can specifically activate 
genes to mediate cell proliferation arrest, instead of activating pro-apoptotic factors 
(Jackson and Pereira-Smith, 2006).  
1.6.4 Senescence markers  
Several biomarkers can be used to identify senescent cells in culture and in vivo. However, 
it must be noted that none of these markers is present exclusively in the state of 
senescence, and they require several days to develop. Amongst these, the most striking 
marker is the lack of DNA replication due to cell cycle arrest. This phenotype can be easily 
identified by incorporation of 5-bromo-2’-deoxyuridine (BrdU) or [3H]-thymidine, or by 
immunostaining for proteins like PCNA or Ki-67. However, this marker can’t discern a 
senescent cell from one that may share the features of the terminal arrest but it still retains 
the ability to re-enter the cell cycle, i.e. quiescent or differentiated post-mitotic cells 
(Campisi and d'Adda di Fagagna, 2007; Schmitt, 2007).  
Another marker that can help recognize senescent cells is the presence of senescence-
associated β-galactosidase (SA-βgal). It is known that SA-βgal derives from the lysosomal 
β-galactosidase due to an increase of lysosomes biogenesis in senescent cells (Lee et al., 
2006), and it can be detected by the use of the chromogenic substrate X-Gal (5-bromo-4-
chloro-3-indolyl β-D-galactopyranoside). Organs from aged animals show accumulation of 
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senescent cells and high level of SA-βgal activity (Kurz et al., 2000). However, this marker 
can also present in cells in a condition of stresses such as prolonged confluence in culture.  
Senescent cells can also be directly identified by their characteristic morphological 
changes. They appear to have a flattened and enlarged cell shape with a vacuole-rich 
cytoplasm. However, this phenotype doesn’t present in all senescent cells. For example, 
BRAF induced senescence or p400 silencing-induced senescence result in a spindle-shaped 
morphology of the cells (Chan et al., 2005; Michaloglou et al., 2005). Thus, morphological 
features of senescence can be different according to cell type and context.  
Senescent cells undergo a profound change in chromatin structure, and one the most 
characteristic one is the appearance of senescence-associated heterochromatin foci 
(SAHF). SAHFs are described as structures of facultative heterochromatin that can be 
detected by the use of dyes such as 4',6-diamidino-2-phenylindole (DAPI) as a distinct 
punctuate foci (Narita et al., 2003). Studies on SAHF composition have shown that these 
heterochromatic foci are enriched in HP1 (Heterochromatin protein 1), histone marks 
associated with gene repression, such as H3K9me3, and the histone variant macro-H2A 
(Narita et al., 2003). Therefore, the function of these SAHF was thought to facilitate the 
silencing of genes involved in cell-cycle control to reinforce the growth arrest during 
senescence (Kosar et al., 2011). Consistent with this concept, the expression of cyclin A2 
gene in senescent cells is inhibited by H3K9 methylation histone and co-localization with 
SAHF foci (Funayama et al., 2006; Narita et al., 2003). However, a recent study has 
described the presence of two distinct forms of heterochromatin in senescent cells. ATM or 
p53-dependent heterochromatin that is required for the repression of gene expression and 
DNA replication/ATR-dependent SAHF heterochromatin, which dampens DDR following 
OIS-induced replication stress (Di Micco et al., 2011). Interestingly, loss of p53 or ATM in 
cells expressing oncogenic RAS was found to allow cell proliferation, even in presence of 
SAHF, suggesting that SAHFs are not associated with cell cycle arrest. 
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1.7 Physiological consequences of senescence 
The concept of senescence was historically restricted to a cellular context. However, 
during the past decade the role of senescence in a number of physiological processes such 
as embryogenesis, development, tissue repair, wound healing and tumour suppression has 
been highlighted.  
1.7.1 Role of senescence in wound healing 
Several evidences have shown that senescence contributes to wound healing. Wound 
healing is a coordinated process involved in restoring tissue integrity following damage or 
injury. Many cellular components and pathways are involved in this process, which can be 
broken down into three different stages: inflammation, re-epithelialization, and tissue 
remodeling (Gurtner et al., 2008). Wound repair in adults causes the formation of scars, 
which are constituted by regions of non-functional fibrotic tissue. It has been shown that 
senescent cells accumulate in these regions restricting the formation of this fibrotic tissue 
by secretion of extracellular matrix enzymes. Experiments on a mouse model of chemical-
induced liver fibrosis have shown that the treatment of hepatic stellate cells (HSCs) with 
carbon tetrachloride (CCl4) induced their initial proliferation and production of 
extracellular matrix components (ECM) (Krizhanovsky et al., 2008). These HSCs then 
senesce, downregulate the production of ECM and upregulate the expression of ECM 
degrading enzymes and immune modulators, thus reducing the fibrotic scarring. However, 
when the treatment with CCl4 was stopped, the hepatic fibrosis was reversed and HSCs 
eliminated by immune clearance. Conversely, in p53-/- and INK4a/ARF-senescence 
deficient mice, hepatic fibrosis and activated HSCs were present even after withdrawal of 
CCl4. Therefore, senescent cells are able to limit the extent of chemical-induced hepatic 
fibrosis by secretion of ECM degrading enzymes and by regulating the immune clearance 
of activated HSCs.  
Another study, performed in mouse model of cutaneous wound healing has showed that 
senescent fibroblasts accumulate in granulating tissue during the proliferating phase of the 
wound repair process. The expression of CCN1, a matricellular protein expressed in 
granulating tissue of transgenic mice, induces senescence in fibroblasts by p53 and ROS-
mediated activation of p16 (Jun and Lau, 2010). The accumulation of these senescent 
fibroblasts causes a reduction in type I collagen by secretion of ECM degrading enzymes 
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MMP1 and MMP3. Therefore, senescent cells are able to restrict the formation of fibrotic 
tissue during cutaneous wound healing.  
A recent work from the Campisi lab has used mice models where the precocious 
appearance of senescent cells in the wound was found to be beneficial for the wound 
repair. This study showed that by the secretion of platelet-derived growth factor (PDGF-
AA), senescent cells induce the differentiation of myofibroblasts to accelerate the closure 
of the wound (Demaria et al., 2014). In conclusion, all these evidences highlight that 
crucial role of senescent cells, in particular of SASP, in tissue repair.  
1.7.2 Role of senescence in tumour suppression  
For years, senescence has been considered a powerful tumour suppression mechanism that 
limits proliferation of pre-malignant cells, thus severely hindering the development of 
cancer (Mathon and Lloyd, 2001). Numerous evidences have shown the presence of 
senescent cells in premalignant neoplastic lesions such as benign melanocytic nevi, dermal 
neurofibroma, prostate and pancreatic intraepithelial neoplasia, colon adenoma and early-
stage of thyrods tumours (Braig et al., 2005; Caldwell et al., 2012; Chen et al., 2005b; 
Collado et al., 2005; Courtois-Cox et al., 2006; Michaloglou et al., 2005; Morton et al., 
2010). In addition to this, the loss of function of key senescence pathway proteins has been 
shown to enable the progression of early stage pre-malignant lesions to more advanced 
tumour stages. Several studies in various mice models have shown that loss of p53 or 
INK4/ARF accelerates tumourigenesis (Braig et al., 2005; Chen et al., 2005b). All these 
evidences suggest that senescence functions a barrier to tumourigenesis by its anti-
proliferative property. However, other studies have shown that senescence restrains tumour 
formation also by promoting immune-clearance of damaged cells.  
An elegant study by Scott Lowe and colleagues has shown that the reactivation of p53 in 
HRAS-induced hepatocarcinomas in mice induces senescence, tumour regression and 
immune-mediated tumour clearance (Xue et al., 2007). Interestingly, the tumour regression 
was facilitated by the active clearance of senescent cells by natural killer (NK) cells. 
Following studies have confirmed that NK cells preferentially eliminate senescent cells in 
vitro (Krizhanovsky et al., 2008). Moreover, RAS-induced senescent hepatocytes secrete a 
wide array of chemokines and cytokines, which attract the innate and adaptive immune 
response elements such as monocyte/macrophage and CD4+ T cells (Kang et al., 2011). 
Thus, SASP secreted factors are important for the immune clearance of senescent cells in 
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vivo and fulfil a crucial role in tumour suppressive potential of senescence (Acosta et al., 
2013). In conclusion, senescence is a potent barrier to tumourigenesis due to the permanent 
proliferation arrest and SASP.  
1.8 Pathological consequences of senescence 
Senescence has also been associated with multiple pathological processes, such as ageing 
and tumour promotion (Munoz-Espin and Serrano, 2014). However, the kinetics of 
senescence induction and functionality differ amongst these different processes, regarding 
acute or chronic senescence (Figure 1.9). For example, acute senescence occurs during 
tissue repair and embryogenesis, where specific cell-extrinsic stimuli target a specific 
population of cells to senesce in a strictly programmed manner. Those senescent cells are 
then eliminated efficiently by the immune system that targets the secreted SASP 
components. Conversely, ageing and age-related diseases are caused by chronic 
senescence. In this case, senescence is a stochastic and unscheduled event that can affect 
any cell and occurs after a period of accumulation of macromolecular damage and cellular 
stress, resulting a permanent arrest of the cell cycle (Munoz-Espin et al., 2013; Storer et 
al., 2013; van Deursen, 2014). This type of senescence is more persistent probably due to 
the age-related decline in the efficiency of immune system or reduced production of SASP 
factors (Nikolich-Zugich, 2008; Wang et al., 2011). Cancer therapies, for example, can 
induce acute and then chronic senescence affecting the integrity of tissues and organs in 
cancer survivors (Allan and Travis, 2005).  
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Figure 1.9: Acute and chronic senescence. A model depicting the differences between acute and chronic senescence 
along with related senescence triggers and the associated physiological processes [Figure adapted from Van Deursen, 
2014]. 
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1.8.1 Role of senescence in ageing 
The correlation between ageing and senescence is demonstrated by the increase in the 
number of senescent cells in the tissue of a number of different species such as rodents, 
monkeys and humans. This increase is most marked in the liver, spleen, skin and lung 
(Dimri et al., 1995; Herbig et al., 2006; Wang et al., 2009). The number of senescent cells 
is also found elevated in tissue associated with age-related diseases such as atherosclerosis, 
osteoarthritis, degenerating intervertebral discs, renal tubuleinterstitial fibrosis, 
glomerulosclerosis and slow healing venous ulcers (Ding et al., 2001; Erusalimsky and 
Kurz, 2005; Stanley and Osler, 2001). Therefore, it is important to address why ageing 
leads to accumulation of senescent cells. Various different factors are found to influence 
this phenomenon. It has been shown that the number of stimuli inducing senescence 
increases with age (Baker et al., 2004; Faggioli et al., 2012; Garinis et al., 2008), which is 
further helped by the reduced efficiency in the immune clearance of senescent cells. In 
both rodents and humans, the immune system goes through a series of changes in innate 
and adaptive immunity leading to age-associated immunodeficiency (Nikolich-Zugich, 
2008).  
It has been shown that senescence contributes to all these age-related diseases and 
organs/tissues dysfunction through different mechanisms (Munoz-Espin and Serrano, 
2014). A clear example is provided by studies in mice showing the relevance of p16-
dependent senescence in haematopoiesis, neurogenesis and pancreatic functions (Janzen et 
al., 2006; Krishnamurthy et al., 2006; Molofsky et al., 2006). In middle-age mice, the 
expression of p16 in stem and progenitor cells of brain, bone marrow and pancreas is high. 
This rise in p16 levels is associated with the suppression of stem-cell proliferation and 
tissue regeneration. Thus, as expected, p16-knockout mice present a retarded decline in 
stem-cell growth and tissue regeneration, however they die prematurely of cancer (Janzen 
et al., 2006; Krishnamurthy et al., 2006; Molofsky et al., 2006). This suggests that p16 pro-
ageing effect is strictly linked to its tumour suppressive function. Thus, senescence 
contributes to the decline of tissue homeostasis and regeneration in a cell-autonomous 
manner by depleting the organism of cycling cells, including progenitor and stem cells, and 
in a cell-non-autonomous manner by disrupting the local stem-cell niche. 
Moreover, ageing is also severely influenced by the senescence-associated alterations in 
gene expression that may not only affect the function of cell itself, but also of 
neighbouring cells, and in some cases the morphological structure of distal tissues. For 
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example, the altered expression and secretion of proteases in the extracellular matrix can 
induce the cleavage of extracellular proteins, membrane-bound receptors, signalling 
ligands and other components, thus affecting the tissue structure and organization (Coppe 
et al., 2008; Parrinello et al., 2005). SASP components such as IL-6 and IL-8 can induce 
fibrosis in epithelial tissues by inducing epithelial-mesenchymal transition (EMT) 
(Laberge et al., 2012; Parrinello et al., 2005). Therefore, SASP is thought to drastically 
affect the tissue architecture amplifying the age-related tissue deterioration. Furthermore, it 
has been shown that senescent cells can spread their phenotype to nearby cells by secretion 
of IL-1β, TGFβ and other chemokine ligands (Acosta et al., 2013; Nelson et al., 2012), so 
called paracrine or secondary senescence. 
In addition to this, the accumulation of senescent cells induces chronic tissue inflammation 
by infiltration of lymphocytes, macrophages, cell death and fibrosis, which are the causes 
of further ageing-related diseases. This inflammation is caused by secretion of pro-
inflammatory SASP factors such as GM-CSF, GROα and macrophage inflammatory 
proteins (MIPs), that altogether with matrix metalloproteinases to create a tissue 
microenvironment that stimulates survival, proliferation, dissemination and angiogenesis 
of nearby premalignant cells (Bavik et al., 2006; Campisi, 2013; Coppe et al., 2006; Dilley 
et al., 2003; Krtolica et al., 2001; Martens et al., 2003).  This may in part explain why the 
risk of cancer increases with age (Campisi, 2011, 2013; Urassa et al., 2006). Therefore, 
senescent cells protect themselves from transformation, however, ironically can promote 
cancer progression in nearby premalignant cells in ageing organisms.  
Some post-mitotic cells show key features of senescent cells. Post-mitotic cells constitute 
most of the cells in mammalian organisms. It has been shown that post-mitotic neurons in 
human and mice brains have a typical p21-dependent senescence phenotype caused by 
accumulation of high amounts of DNA damage. This phenotype is characterized by 
heterochromatinization, synthesis of pro-inflammatory cytokines and β-galactosidase 
activity, directly linking them with senescence (Jurk et al., 2012; Sedelnikova et al., 2004). 
Further investigations have shown that adipocytes in mice under high-fat diet also present 
senescence-like features, suggesting that this could be a broader phenomenon (Minamino 
et al., 2009; van Deursen, 2014). Thus, also terminally differentiated cells can undergo 
senescence contributing to the deterioration of the tissues that characterizes ageing.  
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1.8.2 Role of senescence in tumour promotion 
Contrary to the tumour suppressive role of senescence, mounting evidences have now 
shown that senescence may also contribute to hyperplastic pathologies. Numerous 
xenograft studies have demonstrated that the injection of senescent fibroblasts into 
immune-deficient mice stimulates the proliferation of mouse and human epithelial tumour 
cells, but has no effect on normal epithelial cells (Coppe et al., 2006; Krtolica et al., 2001; 
Liu and Hornsby, 2007). This tumour promoting effect of senescent cells is partly due to 
the secretion of SASP factors. Several SASP components have been shown to promote 
tumourigenesis: MMP3 (stromelysin) promotes tumour cell invasion, VEGF is involved in 
tumour-driven angiogenesis, GROs and amphiregulin stimulate tumour growth (Bavik et 
al., 2006; Coppe et al., 2006; Coppe et al., 2010; Liu and Hornsby, 2007; Yang et al., 
2006). Furthermore, other SASP factors can also fuel the malignant phenotypes. SASP 
secreted IL-6 and IL-8 can facilitate the EMT of pre-malignant epithelial cells and 
nonaggressive cancer epithelial cells (Coppe et al., 2008; Laberge et al., 2012; Parrinello et 
al., 2005). A reduction in secretion of IL-6 and IL-8 by depletion of IL-1α, an upstream 
regulator, drastically reduces the pro-malignant properties of the SASP (Orjalo et al., 
2009). Moreover, senescent cells, in particular ones that engage senescence due to DNA-
damaging radiation or chemotherapeutic agents, can produce SASP factors (IL-6, WNT6B, 
TIMP-1) that have been shown to protect neighbouring tumour cells from being killed by 
the chemotherapeutic agents (Lujambio et al., 2013). 
In conclusion, depending on the physiological context, senescent cells play an important 
role in creating a tissue microenvironment that is permissive for the development or 
progression of cancer. Therefore, it will be important to consider combination therapies 
that not only kill tumour cells, but also prevent the formation of a malignant 
chemoresistant senescent niche. 
1.9 General Aims 
The aims of this study were to investigate the effect of activated Akt on the DNA damage 
response and DNA repair. In addition to this, the impact of Akt signalling on the 
establishment of oncogene-induced senescence was evaluated.  
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2.1 Tissue Culture 
2.1.1 Cell culture of human cell lines 
Human colorectal carcinoma cells line DLD1WT, DLD1 PTEN-/-, HCT116 WT and 
HCT116 PTEN-/- were kindly provided by Todd Waldman’s lab. They were all cultured in 
DMEM (Dulbecco’s modified Eagle medium) supplemented with 10% Foetal Bovine 
Serum (FBS), 2mM L-Glutamine, 50U/ml Penicillin G and 50µg/ml Streptomycin. The 
cells were grown in a humidified incubator at 37°C and 5% CO2. 
Phoenix-AMPHO embryonic kidney cells (SD-3443) were used for the generation of 
helper-free ecotropic and amphotropic retroviruses. This cell line was obtained from the 
American Type Culture Collection. They were cultured in DMEM supplemented with 10% 
FBS, 2mM L-Glutamine, 50U/ml Penicillin and 50µg/ml Streptomycin at 37°C in a 
humidified atmosphere containing 5% CO2. 
Human foetal lung primary fibroblasts IMR90 were obtained from Coriell Cell 
Repositories. They were cultured in DMEM supplemented with 20% FBS, 2mM L-
Glutamine, 50U/ml penicillin G and 50µg/ml Streptomycin. The cells were grown in a 
humidified incubator at 37°C with 5% of CO2 and 3% O2. 
ER-RAS cells containing the conditional inducible system with the estrogen receptor ER 
fused to the RAS protein were cultured in DMEM supplemented with 20% FBS, 2mM L-
Glutamine, 50U/ml penicillin G and 50µg/ml Streptomycin. The cells were grown in a 
humidified incubator at 37°C with 5% of CO2 and 3% O2. RAS induction was achieved by 
the addition of 4-hydroxytamoxifen (4-OHT) to the growth medium. 
Cells were passaged at 70-80% confluency in order to allow continued growth of the 
culture. The media was aspirated and the adherents cells were washed twice with 5 ml of 
buffered 0.05% EDTA. After the wash, 1ml of buffered trypsin-EDTA (0.05% trypsin, 
0.02% EDTA) was added and the plate was left at 37°C for 3mins. Following 
trypsinisation, fresh medium containing FBS was immediately added to the dissociated 
cells in order to neutralise the trypsin, and a proportion of this cell suspension was 
transferred to a new plate containing fresh media. The cells were then returned to the 
incubator. 
Chapter 2  52 
2.1.2 Cryo-freezing and recovery 
Cryo-freezing was used for long-term storage of all cell lines. Healthy cells in log phase of 
growth were trypsinised as described, pelleted by centrifugation at 1000 rpm for 5mins, 
resuspended in 90% FBS and 10% of dymethil sulphoxide (DMSO, sigma) and divided 
into 1ml aliquots in 1.5 ml cyovials. Initial freezing was carried out in a Mr Frosty 
container (containing isopropanol) at -80°C to give a cooling rate of 1°C/minute. The cells 
were then transferred to liquid nitrogen storage at -180°C. For cell recovery after liquid 
nitrogen storage, the cryovials were quickly thawed at 37°C by placing in a container of 
warm water and washed in media at 37°C to remove DMSO. The following day the cells 
were passaged or media was changed depending on the confluence of the cells. 
2.1.3 Cell counting  
The automated Casy® cell counter and analyser system was used to count cells. Following 
trypsinisation, cells were resuspended with media at 37°C, and 400µl of cell suspension 
was added to 20ml PBS and counted using cell size cut-off settings that exclude debris 
from the calculation. For growth curve analysis measurements were taken in triplicate.  
2.2 Transfection/Transduction 
2.2.1 Transient transfection  
Transient transfection was performed using the reagent Lipofectamine® 2000 (Invitrogen) 
following the manufacturer’s instruction. This method was used to introduce plasmid DNA 
and siRNA into cells (Table 2.1). The cells were seeded in antibiotic free medium the day 
before transfection in order to be 60-70% confluent. The transfection reaction was 
prepared with Lipofectamine® 2000 and plasmid were diluted separately in Opti-MEM® 
(Eagle's Minimum Essential Media) in a ratio of 6µl:1µg per plate of HCT116 cell line and 
a ratio of 5µl:3µg per phoenix cells. 10ul Lipofectamine® 2000 was used with siRNAs to 
give 200nM final concentration of siRNA per plate. Following incubation of 5mins, 
Lipofectamine® 2000 containing Opti-MEM® and plasmid containing Opti-MEM® were 
mixed and incubated at room temperature for 20mins. The resulting lipid-plasmid 
complexes were added to the cells and the dish rocked gently to ensure an even coverage 
of the plate. Cells were returned to the incubator and harvested at the appropriate time 
point to check expression. 
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Table 2.1: Plasmids or siRNA used. 
Plasmid/siRNA Details Source 
pBabe-neo Empty vector Peter Adams Lab 
pBabe-puro Empty vector Peter Adams Lab 
pBabe-neo-H-RASG12V Activated RAS Peter Adams Lab 
pBabe-puro-Myr-Akt Activated Akt Peter Adams Lab 
pCMV6 Empty vector Origene PS100001 
pCMV6-Mre11A Mre11A  Origene 
RC209414 
pcDNA5/FRT/TO Empty vector Dave Gillespie 
Lab 
pcDNA5/FRT/TO/GAG-
Akt 
Activated Akt Cloning 
ON-TARGET plus 
Non-targeting pool 
Negative control Dharmacon 
D001810 
ON-TARGET plus 
SMARTpool 
Mre11A Dharmacon  
L009271 
 
 
2.2.2 Viral transduction 
Phoenix-AMPHO cells was used to package retroviruses for transduction.  The cells were 
transfected with the appropriate plasmid as described above. The day after transfection, the 
cells were replenished with 6ml of fresh media and incubated at 32°C for 24 hours 
allowing the production of the recombinant viruses. The target cells IMR90 were seeded in 
order to reach 50% of confluency the day after. Two hours prior infection, IMR90 cells 
were incubated with 3ml of fresh media containing 8µg/ml of Polybrene. Media from the 
Phoenix cells was collected 2 days after transfection and passed through a 0.45µM filter in 
order to remove cellular material from the retroviral supernatant. 3ml of the retroviral 
supernatant was added to IMR90 cells. The plate of Phoenix cells was replenished with 
6ml of fresh media for second viral harvest and incubated at 32°C overnight. A second 
round of infection was performed as outlined 24 hours later. Infected IMR-90 cells were 
then selected for Puromycin (1mg/ml) or Neomycin (0.5mg/ml) resistance.  
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2.3 Irradiation 
In order to induce DNA-Double Strand Breaks (DSBs) the cells were exposed to Ionising 
Irradiation (IR). Cells were treated with x-ray using the Xstrahl RS225 unit. Radiation 
doses used were between 1-10 Gy min-1. Cells were irradiated directly in the culture plates. 
Control cells were left outside the incubator for the same period time as the treated ones.   
2.4 Drug treatments 
HCT116 cells were treated for varying times with different doses of Mirin (Sigma), an 
inhibitor of the nuclease activity of Mre11 disrupting its ability to repair DNA double 
strand breaks. HCT116 cells were treated with 2µM of AKT1/2 kinase inhibitor (Sigma), 
500nM of Everolimus (Sigma) and 10µM of S6K inhibitor (Tocris Bioscence) for 72 hours 
to inhibit Akt/mTOR pathway. Protein translation in HCT116 cells was inhibited with 20 
µM  Cycloheximide (CHX) (Sigma) treatment for varying lengths of time. 
2.5 Clonogenic cell survival  
Clonogenic cell survival was performed to determine the ability of cells to proliferate 
indefinitely after exposure to an insult. Cells were trypsinised and 600 cells were seeded 
per well of a six well plate or 5000 cells per 10cm plate. The cells were left in incubator 
for 12 days until colony formation was visible. The plates were washed twice with PBS 
and stained for 5mins with diluted (1:30 in PBS) Crystal Violet (Sigma). Once the colonies 
were stained, the plates were washed abundantly until the water is clear. The plates were 
left to air dry. Colony number was counted with GelCountTM. 
2.6 Protein analysis 
2.6.1 Preparation of whole cell extracts 
Cells were harvested at 70-80% confluency.  The media was aspirated and the cells were 
washed twice with PBS. Cells were then scraped into 1X sample buffer (62.5mM Tris-HCl 
pH 6.8, 2% SDS, 10% glycerol, 0.1M DTT, 0.01% bromophenol blue) and transferred to 
eppendorfs. The amount of buffer used depends on the cell type and plate size. The lysates 
were then vortexed for 1 min, boiled for 5 mins at 95°C, snap-frozen on dry ice and stored 
at -80°C until analysis.  
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2.6.2 Protein quantification 
The protein concentration of the lysates was determined by Bradford assay. The Bradford 
Assay relies on the blue colour generated when Coomassie Brilliant Blue reagent binds to 
protein side chains. 1µl of protein sample was added to 700µl of 1X Bradford reagent was  
in a cuvette. Standard measurements were generated for each experiment using 5µg and 
10µg of Bovine Serum Albumin (BSA). The absorbance of the protein samples and 
standards were then read at 595nm using a Biophotometer. The protein concentration of 
the samples was determined by comparing the reading to the standard readings. 
2.6.3 SDS-PAGE electrophoresis 
SDS-PAGE is the most widely gel system used to separate a broad range of protein. It 
comprises a stacking gel component to allow the proteins to focus into sharp bands at the 
beginning of the electrophoresis, and a resolving gel component where varying acrylamide 
gel percentage separates proteins according to their mass weight. The following tables 
were used as guide for casting the gel.  
Table 2.2: Resolving and stacking gel recipes.  
 Resolving Gel Stacking Gel 
Acrylamide %  5% 7.5% 8.75% 10% 15% 5% 
Distilled H2O 21.21ml 19.35ml 17.68ml 16.12ml 9.42ml 6.34ml 
Acrylamide/Bis-
acrylamide  
(30%/0.8% w/v) 
8.35ml 10ml 11.7ml 13.3ml 20ml 1.3ml 
4x TRIS buffer 
(pH=8.8 / 6.8) 
10ml 10ml 10ml 10ml 10ml 2.5ml 
10% w/v Ammonium 
Persulfate (APS) 
400µl 400µl 400µl 400µl 400µl 100µl 
Temed 40µl 40µl 40µl 40µl 40µl 10µl 
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The resolving gel mix was placed in the gel casting apparatus and over-laid with water-
satured Butanol to avoid drying. Once the gel was polymerised, the stacking gel was 
layered on top and a comb was inserted to form the wells for loading the protein samples 
into the gel. SDS-PAGE running buffer (25mM Tris pH8.3, 192mM Glycine, 0.1% SDS) 
was added to the lower and upper chambers of the electrophoresis tank. Protein samples 
were prepared to have equal concentration. They were boiled for 5 mins, briefly 
centrifuged and loaded into the wells. A protein ladder such as the Spectra multicolor 
broad range (Themo Scientific) was also loaded to aid the identification of proteins by 
molecular weight. Depending on the percentage of the gel, the samples were resolved 
using 80 – 160 volts and the gel was run until the dye front had just entered the running 
buffer.  
2.6.4 Western blot analysis 
Once the SDS-PAGE electrophoresis was completed, the protein samples were from the 
gel transferred into a PVDF membrane in order to identify proteins using with specific 
antibodies. The PVDF membrane was activated with 100% methanol prior to use, 
following which it was washed thoroughly with dH2O to remove all greasiness and then 
equilibrated in transfer buffer (25mM Tris, 192mM Glycine, 0.01% SDS, 20% methanol). 
The method involves in making a sandwich comprising of sponge/3MM 
paper/gel/membrane/3MM paper/sponge in that order. The entire sandwich is then placed 
into the transfer apparatus in a way that the gel is towards the negative electrode and the 
membrane towards the positive. The transfer was performed at 80V for 1 hour and 20mins. 
Following transfer, the membrane was air dry and re-hydrated with 100% methanol. This 
allows the proteins to be fixed onto the membrane. The membrane was then stained with 
Ponceau S (Sigma-Aldrich) to ensure even transfer of the proteins onto the membrane. It 
was then washed and incubated in blocking buffer (5% Marvel (non-fat dried milk powder) 
solution in 1X TBS-Tween) for 1 hour at RT with gentle agitation. Following blocking, the 
membrane was incubated with the appropriate dilution of the primary antibody (Table 2.3) 
in blocking buffer either for 1 hour at RT or overnight at 4°C. The membrane was then 
washed three times in 1 x TBS-Tween for 10mins with gentle agitation, and then incubated 
with the appropriate HRP conjugated secondary antibody diluted 1:5000 in blocking for 1 
hour. The membrane was again washed three times in 1X TSB-Tween and the bound 
secondary antibody was detected using Enhanced Chemiluminescence by autoradiography. 
The film was developed in a Kodak X-Omat 3000RA automatic film processor. 
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Table 2.3: List of antibodies and the appropriate dilutions used for Western blotting. 
Antigen Host Dilution Source 
Anti-Flag® M2 Mouse 1:10000 Sigma F1804 
Akt (pan)(40D4) Mouse 1:1000 Cell signalling 2920 
Phospho-Akt 
(Ser473)(D9E) XP® 
Rabbit 1:1000 Cell signalling 4060 
Beta-actin  Mouse 1:5000 Sigma A1978 
Chk1 (2G1D5) Mouse 1:1000 Cell signalling 2360 
Phospho-Chk1 (Ser345) Rabbit 1:1000 Cell signalling 2341 
Chk2 (1C12) Mouse 1:1000 Cell signalling 3440 
Phospho-Chk2 (Thr68) Rabbit 1:1000 Cell signalling 2661 
Cyclin A  Rabbit 1:1000 Santa Cruz SC-751 
Phospho-GSK-3α/β (Ser21/9) Rabbit 1:1000 Cell signalling 9331 
MYC tag Mouse 1:1000 Proteintech 60002-2-Ig 
Mre11 (C16) Goat 1:1000 Santa-Cruz 5859 
Nibrin (Nbs1)(H300) Rabbit 1:1000 Santa Cruz 11431 
PTEN (D4.3) XP® Rabbit 1:1000 Cell signalling 9188 
Rb (4H1) Mouse 1:1000 Cell signalling 9309 
Phospho-Rb (Ser807/811) Rabbit 1:1000 Cell signalling 9308 
p21 Mouse 1:1000 Santa Cruz SC-817 
p53 (1C12) Mouse 1:1000 Cell signalling 2524 
p53 (Ser15) Rabbit 1:1000 Cell signalling 9284 
p16 (G175-405) Mouse 1:1000 BD 51-1325GR 
Rad50 (13B3/2C6) Mouse 1:1000 Abcam 89 
RAS Mouse 1:1000 BD 610001 
p70-S6K (49D7) Rabbit 1:1000 Cell signalling 2708 
p70-S6K (Thr389)(1A5) Mouse 1:1000 Cell signalling 9206 
S6 Ribosomal protein  
(54D2) 
Mouse 1:1000 Cell signalling 2317 
S6 Ribosomal protein 
 (Ser240/244)(D68F8) XP® 
Rabbit 1:1000 Cell signalling 5364 
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2.7 Gene expression analysis 
2.7.1 RNA extraction  
RNeasy mini kit was used according manufacturer’s (QIAGEN) specifications to extract 
total RNA. The medium was aspirated and the cells were washed twice with PBS. Cells 
were lysed in 600µl of RLT buffer per 10cm plate and samples were harvested with a cell 
scraper. The lysate was vortex for few minutes to remove any clumps and then 
homogenized by blunt 20-gauge needle. One volume of 70% ethanol was added to each 
homogenized lysate, mixed and transferred to an RNeasy spin column. The samples were 
centrifuged at 8000g for 15 sec at 4°C to allow the RNA to bind the spin column resin. The 
resin was then washed few times with RW1 and RPE buffers. The RNA eluted from the 
column using 30-50µl of RNase-free water. The RNA concentration was determined by 
reading the absorbance at 260nm with a NanoVue spectrophotometer (GE Healthcare). 
2.7.2 cDNA synthesis 
The SuperScriptIII® reverse transcriptase (Invitrogen) was used to synthesise cDNA. 0.4µg 
of RNA was mixed with 2µl of 1X hexanucleotide mix (Roche) and made up to a final 
volume of 25µl with RNase-free water. The mix was then incubated at 80°C for 10mins 
and cooled down quickly to allow primer annealing. 14µl of reaction mixture with 8µl First 
Strand Buffer (Invitrogen), 4µl 0.1M DTT, 2µl 10mM dNTP mix and 1µl of SuperScriptIII 
was added to the random primed RNA mix. The mix was then incubated at 42°C for 
10mins to allow the cDNA synthesis and the reactions stopped by boiling the samples at 
70°C for 15mins. cDNA was stored at -20°C. A duplicate reaction without SuperScriptIII 
was also performed in order to rule out any DNA contamination.  
2.7.3 Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR was performed using the C1000TM Thermal Cycler (BIO-RAD). The RT-PCR 
mix consisted of 0.5µg of cDNA, 2X PerfeCTaTM  SYBR® Green FastMixTM  and 0.25µM 
of appropriate primers (Table 2.4) in a final volume of 10µl was prepared in white walled 
96 well qPCR plates. Each reaction mix was performed in duplicate to account for 
pipetting errors. An appropriate standard curve encompassing the samples was constructed 
for each RT-PCR to ensure that the samples were within the linear range of detection. The 
cycling protocol consisted of initial denaturation at 95°C for 15mins, 40 cycles of 95°C for 
20sec, annealing at 60°C for 20sec and 72°C for 20sec. A final extension of 5mins at 72°C 
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was carried out followed by melt curve analysis, whereby the reaction is heated from 65°C 
to 95°C in 0.5°C increments for 5sec each. The melt curves were analysed to ensure that a 
unique product was obtained from each primer set. The average of the ΔΔC(t) of duplicate 
samples was calculated using Actin as a lading control. Overall average and standard 
deviation values were calculated from multiple experiments.  
Table 2.4: Sequences for the primers used in the qRT-PCR analysis.  
Gene name [Species]  Primers 
Mre11 F 
R 
GCCTTCCCGAAATGTCACTA 
TTCAAAATCAACCCCTTTCG 
Rad50 F 
R 
CTTGGATATGCGAGGACGAT 
CCAGAAGCTGGAAGTTACGC 
Nsb1 F 
R 
TTGGTTGCATGCTCTTCTTG 
GGCTGCTTCTTGGACTCAAC 
PTEN F 
R 
GCAGAAAGACTTGAAGGCGTA 
AGCTGTGGTGGGTTATGGTC 
 
2.8 Flow Cytometry 
2.8.1 Fixing cells 
Cells were resuspended in warm media after trypsinisation and pelleted at 1000 rpm for 5 
mins. The resulting pellet was resuspended in 200µl of phosphate buffered saline (PBS) 
and 2ml of ice cold 70% Ethanol was added slowly while vortexing the cells in order to 
ensure uniform fixation. The samples were stored at 4°C or at -20°C before further 
analysis. 
2.8.2 DNA content 
Cells were fixed as described and kept at 4°C for at least 30 mins. Cells were washed with 
PBS for a few times by centrifugation at 1000rpm in order to remove the Ethanol and the 
pellet resuspended with 400µl of PBS containing 10µg/ml Propidium Iodide (PI) and 
250µg/ml RNAse A. The cells were stored in the darkness for 30 mins prior to analysis 
using Fluorescence-Activated Cell Sorting (FACS).  
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2.8.3 S-phase analysis 
To analyse the proliferation status of a culture, cells were incubated with 25µM of 5-
Bromo-2’-Deoxyuridine (BrdU) for 4 to 24 hours, then fixed as described and kept at 4°C 
for at least 30 mins. BrdU is a Uridine derivative and a structural Thymidine analog, thus it 
is selectively incorporated into the newly synthesized DNA of replicating cells (during the 
S phase of the cell cycle) by substituting Thymidine. BrdU incorporation thereby serves as 
a marker for proliferation.  
Fixed cells were resuspended in 1ml of PBS and then 1ml of 4N HCl was added while 
vortexing. The samples were incubated at room temperature (RT) for 15 minutes. The HCl 
treatment denatures the DNA and exposes the BrdU epitopes that can then be recognized 
by the anti-BrdU antibody. The cells were then washed once with PBS and once with PBS 
containing 0.5% BSA, 0.1% Tween 20 (PBT). The pellet was then resuspended in 200μl	  of	   PBT	   containing	   a	   1:40	   dilution	   of	   the	   anti-BrdU antibody (BD Bioscience) and 
incubated at RT for one hour. The cells were then washed with 1ml of PBT and 
resuspended	   in	  200μl of PBT containing a 1:40 dilution of the Alexa Fluor® 488 Goat 
anti-mouse antibody (Life technologies). The cells were incubated for 30 minutes in the 
dark and then washed with 1ml of PBT. The cell pellet was then resuspended in 400μl of PBS	  containing	  10μg/ml	  PI	  and	  250μg/ml	  RNase	  A.	  The	  cells	  were stored in the dark 
and after 30 minutes were analyzed by FACS. The data analyzed using WinMDI software. 
2.8.4 M-phase analysis 
To estimate the number of cells undergoing mitosis in a culture, cells were analysed for the 
phosphorylation of Histone H3 on Serine 10 (pS10 H3) by Flow Cytometry. This 
modification is tightly correlated with the chromatin condensation during mitosis, thereby 
is specific mitotic marker.  
Cells were fixed as above and stored at. The cells were permeabilised by incubation in 1ml 
PBS containing 0.25% Triton X100 for 15 minutes on ice. The cells were then incubated in	  200μl	  of	  PBT containing a 1:50 dilution of the anti-pS10 H3 antibody for one hour at RT. 
The cells were washed once with PBT and then resuspended	  in	  100μl	  of	  PBT	  containing 
1:100 dilution of the Alexa Fluor® 488 Goat anti-rabbit antibody (Life technologies). 
Following incubation for 30 minutes in the dark, the cells were washed with 1ml of PBS. 
The cell pellet was then resuspended	   in	   1ml	   of	   PBS	   containing	   10μg/ml	   PI and 
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250μg/ml	  RNase	  A	  and	  stored	  in	  the	  dark	  for	  30 minutes before FACSCalibur analysis. 
The data analyzed using WinMDI software. 
2.8.5 Reporter assay of NHEJ and HR repair 
The NHEJ and HR reporter vectors were obtained from Vera Gorbunova’s lab (Seluanov 
A., 2010). The constructs were digested with I-SceI enzyme in vitro to induce DSBs, and 
then transfected as linear DNA into cells. In the extrachromosomal assay 0.5µg of NHEJ 
and 2µg of HR construct were co-trasfected with 0.1µg of pDs-Red2-N1 as transfection 
control. Cells transfected with 1µg of GFP-expressing plasmid, 1µg of pDs-Red2-N1 and 
1µg of a control plasmid that does not express a fluorescent protein were used as 
calibration controls for the FACS. Cells were trypsinised and resuspended in ice-cold PBS 
for FACS analysis. Prior to the analysis the FACS machine was calibrated by the 
acquisition of GFP, DsRed and control samples. The voltage and color compensation was 
adjusted in order to include all the fluorescent cells. The samples were acquired counting 
100.000 events. The efficiency of DNA DSB repair was calculated as the ratio of GFP+ to 
DsRed+ cells. 
Table 2.5: Primary and secondary antibodies used for FACS analysis.  
Antigen Host Dilution Source 
Alexafluor 488 goat 
(secondary) 
Mouse 1:40 Life Technologies 
A11011 
Alexafluor 488 goat 
(secondary) 
Rabbit 1:40 Life Technologies 
A11008 
BrdU (CloneBu20a) Mouse 1:40 Dako  
M0744 
Phospho-Histone H3 (Ser10) Rabbit 1:50 Santa Cruz 
sc-8656-R 
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2.9 Immunofluorescence 
Cells were seeded on glass coverslip and treated as required before being harvested. For 
RPA staining, coverslips were pre-treated with an extraction buffer (25mM HEPES pH 
7.4, 50mM NaCl, 1mM EDTA, 3mM MgCl2, 300mM Sucrose, 0.5% Triton x-100 in 
ddH2O) on ice for 5mins to extract soluble RPA, so that the retained RPA fraction is 
primarily chromatin-bound. The cells were then fixed with 4% of Paraformaldehyde for 
15mins at RT, washed three times with PBS and blocked with 3% of BSA in PBS for 
30mins. The cells were then incubated with the appropriate dilution of the primary 
antibody (Table 2.6) in 3% BSA in PBS for 1hour at RT or overnight at 4°C. The 
coverslips were washed few times with PBS and incubated with the appropriate dilution of 
secondary antibody (Table 2.6) for 40mins at RT in the dark. Following few washes in 
PBS, the cells were stained with a solution of DAPI (Sigma) diluted in PBS for 10mins. 
The coverslips were then mounted on glass slides and stored in the dark at 4°C. 
Fluorescent microscopic images were acquired with a 60x oil immersion lens on a Nikon 
A1R laser scanning confocal microscope. 
Table 2.6: Primary and secondary antibodies used for immunofluorescence analysis. 
Antigen Host Dilution Source 
Alexafluor 594 goat 
(secondary) 
Mouse 1:300 Life Technologies 
A11005 
Alexafluor 488 
donkey (secondary) 
Rat 1:200 Life Technologies 
A21208 
Phospho-Histone 
H2A.X (Ser139) 
Mouse 1:300 Millipore 05-636 
RPA32/RPA2 (4E4) Rat 1:200 Cell signalling 
 2208 
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2.10 β-Galactosidase staining  
Prior to the onset of senescence, 3x105 cells were seeded onto sterile glass coverslips, 
allowed to adhere and transferred to 6-well tissue culture dishes. When the cells were 
senescent, the coverslips were rinsed twice with 1X PBS, and incubated with 2ml of 
freshly prepared fixing solution (1X PBS containing 2% formaldehyde, 0.2% 
glutaraldehyde) for 5 mins at room temperature. After two washes in 1X PBS, the cells 
were incubated with 2ml of freshly prepared staining solution (40mM Na2HPO4 pH 6, 
150mM NaCl, 2mM MgCl2, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 1mg/mL X-gal (in 
DMSO)) and incubated for 12-16 hours at 37° C in a non-CO2 incubator. The coverslips 
were then washed twice with 1X PBS and twice with dH2O to remove any residual salt. 
The coverslips were air dried at room temperature, mounted on glass slides and visualized 
using conventional bright field microscopy. 
2.11 CometAssay®, single cell gel electrophoresis 
Alkaline CometAssay® was used to quantify single and double DNA strand breaks in 
single cells after exposure to DNA damage agents. 2.5x105 cells were resuspended with 
1ml of 1X Ca2+ Mg2+ free PBS (to inhibit endonuclease activity). 50µl of this cell 
suspension was then mixed with 500µl of molten low melting Agarose (at 37°C) and 
spread in a CometSlideTM (Trevigen). The slides were then placed in the fridge for 10mins 
to allow the agarose to solidify. Once the cells were immobilized on the slides, they were 
covered in lysis buffer (Trevigen) and incubated overnight at 4°C. The slides were 
immerged in Alkaline unwinding solution (200mM NaOH, 1mM EDTA pH 13) for 
20mins at RT.  The cells were then placed in the slide tray on the CometAssay® ES unit, 
covered in Alkaline Electrophoresis solution (200mM NaOH, 1mM EDTA pH 13) and run 
at 21Volts for 40mins. After washing the slides twice with ddH2O, the cells were fixed 
with 70% ethanol for 5mins and then dried at 37°C for 15-30mins. DNA was stained using 
diluted SYBR® Gold and visualized by fluorescent microscopy.  
2.12 Quantification of CometAssay® with ImageJ 
In healthy cells the fluorescence is confined to the nucleoid (comet head), which is 
constituted of undamaged DNA. Undamaged DNA is supercoiled and thus, does not 
migrate far out of the nucleoid under the influence of an electric current. Whereas in cells 
with accrued DNA damage, the presence of DNA fragments migrating from the nucleoid is 
observed forming the comet tail. The negatively charged DNA migrates toward the anode, 
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and the extraction length reflects increasing relaxation of supercoiling, which is indicative 
of damage. OpenComet, a plug-in for ImageJ, was used to identify comets and quantify 
their parameters. The head-finding function identifies the head of the comet and quantifies 
the intensity of fluorescence. Another function is used to identify the tail and quantify its 
fluorescence. The measurement results are saved in an excel spreadsheet, which includes 
measurement obtained for each individual comet, as well as the statistics for the population 
of comets extracted from all input images. The extent of DNA damage is a normalized 
measure of the DNA found in the tail as a percentage of total DNA in the cell (i.e. head + 
tail). 
2.13 In vitro kinase assay 
A kinase assay is used to verify if a specific protein is substrate of a protein kinase by 
measuring the incorporation of radiolabeled phosphate from [γ-32P]-ATP. Each reaction 
contained 500ng of Mre11A (Origene) and a range of 2-400 ng of S6k1 (Abnova). The 
kinase and the substrate were incubated at 30°C for 30mins along with 2mM DTT, 20mM 
Tris, 1mM EGTA, 1mM MgCl2 and 1µl of  [γ-32P]-ATP (2µCi/µl) made up to a final 
volume of 20µl with ddH2O. The reaction was terminated by adding 6µl of 4x NuPAGE® 
LDS Sample Buffer at 95°C for 5mins. The samples were resolved on a SDS-PAGE gel, 
which were coomassie stained. The gel was then incubated with 10% Glycerol for 30mins, 
placed on two-sheet wet paper and covered with cling film. The gel was then dried in a 
GelAir dryer for 1hour at 80°C.  
 The gel was exposed to x-ray film for 1-24hrs in an autoradiography cassette and 
developed in a Kodak X-Omat 3000RA automatic film processor. The proteins bands of 
interest were then excised, transferred to microcentrifuge tubes and 32P incorporation was 
quantified by Cerenkov counting in a scintillation counter. 
2.14 Cell viability assay 
The CellTiter-Glo®. Luminescent Cell Viability Assay is a method to determine the number 
of viable cells in culture based on quantitation of the ATP present, which signals the 
presence of metabolically active cells. The cells were seeded in an opaque-walled 96-well 
plate. They were then incubated with a concentration range 0-100µM of drug Mirin for one 
day. The following day, the cells were replenished with 100µl of fresh medium. An empty 
well just containing medium was also filled with fresh medium. This was used obtain a 
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value for the background luminescence. 100µl of CellTiter-Glo® Reagent was added to 
each well, and the plate was placed in an orbital shaker for 2mins to mix the content in the 
wells and cause cell lysis. The plate was then incubated for 10mins at RT to stabilize the 
luminescence signal, which was then recorded with a Luminometer.  
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3.1 Introduction 
The DNA damage response is a crucial and complex mechanism aimed at safeguarding 
cells from accumulating damage during cell divisions that can affect the stability and 
integrity of the genome. DSBs are one of the most deleterious of form of DNA damage, 
which arise from the exposure to various genotoxic stresses as IR, some chemicals, and 
also from cellular processes as replication, meiosis and V(D)J recombination (Bierne et al., 
1997; Michel et al., 1997; Sun et al., 1989; Ward, 1988). Failure to properly process such 
damage can result in a series of chromosomal rearrangements causing various 
immunological, developmental and neurological disorders, and even cancer (Hoeijmakers, 
2001; Khanna and Jackson, 2001). Therefore, it is essential to protect from these diseases 
by activating the cell cycle checkpoints and coordinating the appropriate repair pathways 
in response to DSBs.  
MRN complex is a multifaceted molecular machine critical for DNA repair and checkpoint 
responses, as well as for the appropriate induction of apoptosis (Bakkenist and Kastan, 
2003; D'Amours and Jackson, 2002; Stracker et al., 2004). Mre11 is a sensor for damage 
and one of the first to be recruited to DSBs in the S and G2 phases of the cell cycle. It then 
recruits the ATM machinery, which in turns phosphorylates Nbs1 for the full activation of 
MRN complex (Dupre et al., 2006; You et al., 2005), and triggers the activation of DDR 
pathway, by phosphorylating Chk2. Mre11 also activates the other two components of the 
MRN complex, Rad50 and Nbs1, whose binding in turn stimulates its nuclease activity that 
is crucial for the repair process. Ultimately, the combined actions of Mre11 and Ctip 
proteins resect the DNA near the DSB to generate a 3’ ssDNA tail, which is critical for 
repair by HR (Paull and Gellert, 1998). The ssDNA is then covered by the high affinity 
ssDNA binding protein, replication protein A (RPA) (Biankin et al.), which mediates the 
recruitment and activation of ATR/Chk1 pathway components.  
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The initial step in processing a DSB is important in determining the choice of DNA repair 
mechanism that is used to accomplish the repair. This choice in turn is crucial for the 
maintenance of genome stability (Grabarz et al., 2012). This choice is strongly influenced 
by the cell cycle phase in which the cells are at the moment of the damage. Cells in S and 
G2 phase are likely to be arrested by the G2/M checkpoint. The G2/M checkpoint prevents 
cells from entering mitosis, providing them an opportunity to stop proliferating and repair 
the damage, thus avoiding the transmission of the damage to daughter cells (Stark and 
Taylor, 2004). The proteins responsible for mediating the G2/M checkpoint activation are 
the two checkpoint kinases Chk1 and Chk2. Chk2 is been found mutated in many cancers, 
however Chk1 expression and function are found to be quite conserved in cancer cells 
(Feijoo et al., 2001; Hangaishi et al., 2002; Ingvarsson et al., 2002; Papp et al., 2007). 
These two kinases cooperate in the phosphorylation and inhibition of phosphatase 
CDC25C, stimulating its binding to 14-3-3 proteins. 14-3-3/CDC25C complexes sequester 
CDC25C in the cytosol, blocking its ability to dephosphorylate and activate CDK1 in the 
nuclei. The CDK1-cyclin B complex is therefore kept phosphorylated and inhibited by 
Myt1 and Wee1 kinase, thus inhibiting cellular progression into mitosis (Furnari et al., 
1997; Peng et al., 1997; Sanchez et al., 1997).  
Another important protein involved in DDR signalling is Akt. PIKK family members such 
ATM, ATR and DNA-­‐PK are able to activate Akt in response to genotoxic stress, thus 
providing a pro-­‐survival signal by triggering cell cycle arrest and inhibiting apoptosis 
(Bozulic et al., 2008; Caporali et al., 2008; Lu et al., 2006; Viniegra et al., 2005). 
However, the permanent activation of Akt enhances its oncogenic activity and has been 
shown to have detrimental effect on cells. Hyperactivation, overexpression or 
amplification of Akt is commonly found in human cancers (Calvo et al., 2009; Hennessy et 
al., 2005). Activation of Akt signalling also results from mutation in upstream regulators 
such as PI3K and PTEN. Loss of PTEN expression or function is frequently observed in 
primary and metastatic cancer (Carnero, 2010; Parsons et al., 2005; Vivanco and Sawyers, 
2002). PIK3CA encodes for one of the p110α subunit of the PI3K, and many activating 
mutations in this gene are found in human colon, breast, glioblastoma and lung cancers 
(Knobbe and Reifenberger, 2003; Samuels et al., 2004; Woenckhaus et al., 2002). 
Therefore, Akt activity is crucial for cancer development and progression, because it 
regulates many cellular processes such as survival, proliferation and metabolism that are 
crucial for tumourigenesis.  
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However, mounting evidences have shown that both hyperactivation of Akt and PTEN 
deletion can affect DDR signalling in presence of genotoxic stresses (Henry et al., 2001; 
Kandel et al., 2002; King et al., 2004; Puc and Parsons, 2005; Tonic et al., 2010). 
Therefore, one could hypothesise that Akt promotes tomourigenesis by allowing cells to 
escape the deleterious consequences of DNA damage. Early stage neoplasia often present 
high levels of DNA damage, which leads to tumour suppressive responses such as 
senescence or apoptosis. Therefore, any mutations which affect DDR signalling would 
help cells to evade such cellular responses, enabling proliferating despite the presence of 
damage. If the damage is not repaired, this could result in elevated mutation rate and 
genomic instability, which are major contributors to carcinogenesis. Therefore, it is 
important to define the effects of active Akt on DDR signalling and clarify the role of Akt 
deregulation in tumour cell survival and resistance to cancer therapy. 
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3.2 Results 
3.2.1 PTEN deletion suppresses DDR signalling 
The initial experiments were designed to analyze how deletion of PTEN, one of the most 
common mutations in tumours and a cause of Akt activation, affects the activation and 
execution of DDR signalling following treatment with a DNA damaging agent.  
To address these questions, several analyses were performed using two cell lines derived 
from colon carcinoma DLD1 and HCT116 cells, either “wild type” or harboring a targeted 
genetic deletion of exon II in both PTEN alleles (Figure 3.1A) (Lee et al., 2004). These 
cells were treated with ionizing radiation (IR) (10Gy) to induce DSBs, and an hour later 
the expression and activation of key DDR proteins was analyzed by Western blotting. The 
absence of PTEN in the knockout cells confirms the genetic deletion of the locus. As 
expected, this was found to cause elevated basal levels of activated S473-­‐phosphorylated 
Akt when compared to wild-type controls (Figure 3.1B). 
Interestingly, all three components of the MRN (Mre11, Rad50 and Nbs1) complex 
showed strikingly reduced expression in the PTEN null cells to the parental cell line 
(Figure 3.1B). In particular, Mre11 is the most affected component of the MRN complex, 
dropping to undetectable levels in HCT116 cells. The reduction in Rad50 and Nbs1 levels 
is not as strong as Mre11, suggesting that Mre11 could be the primary target that then 
affects the levels of the other two components. It is indeed well known that Mre11 is 
essential for the stabilization of Rad50 and Nbs1 polypeptides (Takemura et al., 2006). 
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As previously mentioned, the MRN complex is the sensor for DSBs and is necessary for 
the activation of the DDR machinery, the ATM kinase (Horejsi et al., 2004; Lavin, 2007; 
Lukas et al., 2003). The surprising reduction in the expression of MRN complex suggested 
that the loss of PTEN could potentially lead to a defective cellular response to DSBs. 
Indeed, PTEN-null cells didn’t fully activate Chk2 in response to IR, as shown by the low 
levrl of phosphorylation at T68 by ATM, whereas total Chk2 levels remain unchanged 
(Figure 3.1B). Chk2 is responsible for the regulation of the G1, S and G2 checkpoints, and 
is also required for activation of several targets involved in initiating the DNA strand 
resection at DSBs (Xu et al., 2002), a precursor to ATR/Chk1 activation. In agreement 
with this, the downstream activation of the ATR/Chk1 pathway was suppressed, as 
indicated by reduced phosphorylation of the activating residue 345 of Chk1 in PTEN-null 
cells (Figure 3.1B).   
Thus, the deletion of PTEN in two human colon carcinoma cell lines was found to cause 
hyperactivation of Akt and lead to suppression of the DNA damage response to ionizing 
radiation. All further analyses were performed with the HCT116 cells, since they presented 
with the strongest reduction in DDR signalling. 
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Figure 3.1: PTEN deletion affects DDR pathway activation following IR. (A) Schematic of PTEN gene targeting 
strategy. Exon II of PTEN was targeted by a recombination event between the genomic locus and the targeting vector, 
replacing it with a promoterless IRES-neoR, which is flanked by LoxP sites (Lee et al., 2004). (B) Western blots for key 
proteins in the DDR pathway were performed on whole cell extracts from HCT116 and DLD1 cells 1hr post 
irradiation with 10 Gy. Actin provides the loading control.  
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3.2.2. Mre11 is required for the activation of ATM/Chk2 and ATR/Chk1 
pathways downstream of DSBs 
In order to establish whether the reduction in expression of MRN complex components in 
PTEN null cells causes the reduced downstream activation of the ATM/Chk2 and 
ATR/Chk1 pathways, siRNA knockdowns were performed on the HCT116 WT cells. 
Mre11 levels were depleted by transfection with a smart pool of siRNA against Mre11 and 
and a non-targeting siRNA pool provided a negative control. The expression of MRN 
complex and activation of DDR proteins in response to IR was analysed by WB 48 hours 
post transfection. Mre11 expression was reduced by 60% when compared to control 
siRNA and as expected the expression of Rad50 was affected in a similar manner (Figure 
3.2). Moreover, the reduction in expression of the MRN complex affects Chk1 and Chk2 
activation one hour after exposure to IR, as evident by the reduced T68 and S345 
phosphorylation of Chk1 and Chk2 respectively. 
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Figure 3.2: siRNA mediated depletion of Mre11 reduces Chk2 and Chk1 activation. Western blot analysis was 
performed on whole cell extracts from HCT116 WT cells 48hrs post-transfection with 200nM smart pool siRNA against 
Mre11 or non-targeting siRNA pool and 1hr post-irradiation with 10Gy. Actin provides the loading control.  
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In addition to this, the requirement for MRN complex and, in particular, for Mre11 
nuclease activity in DDR signalling activation was also investigated using an Mre11 
inhibitor, Mirin. Mirin is a new molecule produced to bind specifically Mre11, inhibiting 
its interaction with ATM and its exonuclease activity (Dupre et al., 2008; Garner et al., 
2009). HCT116 WT cells were pretreated with two different concentrations of Mirin for 40 
mins, exposed to 10Gy of radiation and Western blots were performed one hour later. As 
expected the level of Mre11 and Nbs1 remained unaltered by Mirin treatment (Figure 3.3). 
It has been previously shown that Mirin does not inhibit MRN complex formation or its 
recruitment to DBSs (Dupre et al., 2008; Lee et al., 2013). The inhibition of Mre11 with 
100µM of Mirin was found to reduce the phosphorylation of Nbs1 on S343 and of Chk2 on 
T68, which confirms that Mre11 is necessary for the full activation of ATM. Chk1 
activation via S345 phosphorylation was found to be reduced in a similar manner, 
indicating that Mre11 nuclease function is crucial for DSBs resection to ssDNA, which is 
required for the activation of ATR/Chk1 pathway.  
Thus, the data so far indicate that the Mre11 expression is necessary for the stability of the 
entire MRN complex and that the presence of fully functional MRN complex is required 
for both full ATM/Chk2 and ATR/Chk1 activation.   
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Figure 3.3: The inhibition of Mre11 activity by Mirin ablates Chk2 and Chk1 activation. Western blot analysis was 
performed on whole cell extracts from HCT116 WT cells, generated one hour after exposure to 10Gy irradiation and pre-
treatment with 50µM and 100µM Mirin for 40 minutes. Actin provides the loading control.  
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3.2.3 Loss of PTEN causes defective HR due to reduced strand resection  
As mentioned previously, DSBs are highly cytotoxic lesions that are mainly repaired in 
cells by two repair mechanisms, HR and NHEJ. It is also well known that the MRN 
complex is directly involved in early steps of DSBs repair. The effects of reduced MRN 
expression and activity in HCT116 cells as a result of PTEN loss or Mirin treatment on 
these two different repair mechanisms was further evaluated.  
An elegantly designed fluorescent reporter system obtained from Gorbunova laboratory 
(Seluanov A., 2010) allowed the sensitive and qualitative measurement of these DNA 
repair processes. Two different constructs contain an engineered GFP gene, which is 
normally not expressed because it contains a disrupting exon or a mutation. In the case of 
the NHEJ reporter cassette, the GFP gene is disrupted by the insertion of the Pem1 intron, 
which contains an adenoviral exon cassette flanked by recognition sites for the I-SceI 
endonuclease (Figure 3.4A). These non-palindromic restriction sites are in an inverted 
orientation so as to generate two incompatible DNA ends upon cleavage, which mimics a 
DSB. Once the construct is digested with the I-SceI and the disrupting adenoviral exon 
removed, only repair with NHEJ can restore the GFP gene. The HR reporter cassette is 
based on the same Pem1 system. In this case, GFP-Pem1 has a 22bp deletion next to three 
restriction sites I-SceI/HindIII/I-SceI. The deletion ensures that repair with NHEJ cannot 
reconstitute an intact GFP ORF (Figure 3.4B). As before, the two I-SceI sites are in an 
inverted orientation so as to generate two incompatible ends. This GFP-Pem1 is followed 
by a second promoter-less/ATG-less first exon and intron of GFP-Pem1. After digestion 
with I-SceI, only HR via an intermolecular and intramolecular gene conversion between 
the two copies of GFP-Pem1 can restore a functional GFP ORF (Figure 3.4B) (Seluanov 
A., 2010). Thus, each construct is made with unique features to allow the successful repair 
of the I-SceI-induced breaks by one specific repair mechanism, HR or NHEJ.  
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The constructs were used in an extrachromosomal assay, where they were first digested in 
vitro by I-SceI and then transfected into HCT116 WT and PTEN knockout cells together 
with the DsRed plasmid expressing RFP, which controls for transfection efficiency. 
HCT116 WT cells were either pretransfected with a siRNA smart pool against Mre11 48 
hours prior or pretreated with 15µ Mirin 40 mins prior to transfection with the linearised 
constructs. Cells well cultured in regular media or with Mirin for 24 hours post-
transfection, following which they were harvested and the number of GFP and RFP 
positive cells was counted by flow cytometry (Figure 3.4C). The number of GFP positive 
cells was divided by the number of RFP positive cells in order to correct for transfection 
efficiency. The number obtained provides a quantitative measure of NHEJ or HR 
efficiency and is plotted in Figure 3.4D. The data suggest that the deletion of PTEN in 
HCT116 significantly affects their ability to repair DSBs with HR, which shows a 50% 
reduction compared to WT cells. On the contrary, NHEJ repair of DSBs shows a 30% 
increase, which possibly compensates for the inability to use HR. A similar decrease in HR 
was also observed for WT cells treated with Mirin or siRNA against Mre11. These data 
suggest that HR, but not NHEJ, is sensitive to the loss of the MRN complex.  
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Figure 3.4: Efficient HR repair is sensitive to the loss of MRN complex. (A) (B) Schematics of the reporter constructs 
used to quantify NHEJ and HR repair [Figure adapted from Seluanov A., 2010]. (C) Representative FACS profiles with 
cells harvested 24 hours post-transfection with the reporter constructs presented in panel A. Cells transfected with empty 
vector provided the negative control. (D) Frequency of NHEJ and HR was analyzed with two independent NHEJ and HR 
constructs in HCT116 WT and PTEN-/- cell lines. The WT cell line was either pre-transfected with control siRNA or 
siRNA pool against MRE11 or pre-treated with 15µM Mirin for 40 mins. The ratio of GFP+/DsRed+ cells was used to 
measure repair efficiency and is presented as a percentage of the untreated WT control. The data represent three 
independent biological replicates. ** denote p<0.01 as calculated by Student’s t-test. 
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Mre11 plays a crucial role in HR repair. Its nuclease activity in conjunction with additional 
factors, such as Ctip, opens DNA to catalyse the reaction 5´!3´ single strand resection. 
This action is required for the formation of 3´ ssDNA for RPA loading and then for strand 
invasion, a step that characterises HR (Limbo et al., 2007; Sartori et al., 2007; Williams et 
al., 2008).  
To investigate if the failure in HR repair in HCT116 PTEN knockout cells is due to a 
defect in this pivotal step of HR, the recruitment of RPA to DNA damage sites was 
analysed. Before performing the immuno-staining, cells were treated with a detergent-
containing buffer to remove the nucleoplasmic and cytoplasmic proteins, leaving behind 
the chromatin bound and matrix-associated proteins. The number of RPA foci per nuclei 
was counted. As shown in figure 3.5A-B, immunofluorescence analysis showed that 
irradiation induced a marked persistence in concentration of RPA at γH2Ax foci in the 
majority of HCT116 WT cells. However, a dramatic reduction in chromatin-associated 
RPA foci was observed in PTEN null cells compared to WT. In addition to this, 
persistence of γH2Ax foci was also observed, especially at longer time points (data not 
shown), verifying a defect in the repair process. The pre-treatment of WT cells with Mre11 
inhibitor Mirin was also found to inhibit RPA foci formation without affecting γH2Ax 
foci, resembling the phenotype observed in PTEN null cells.  
Collectively, these data suggest that PTEN null cells, due to the low amount of MRN 
complex, fail to resect DSBs into ssDNA required for HR repair, thus impairing the 
recruitment of RPA and activation downstream of ATR/Chk1 pathway.  
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Figure 3.5: Loss of PTEN leads to reduced strand resection at DSBs. (A) Immunofluorescence analysis of 
phosphorylated H2Ax and RPA foci in HCT116 WT with or without pre-treatment with Mirin, and in PTEN null cells 4 
hours after exposure to 10Gy IR. (B) Quantification of the number of RPA foci per nuclei. The data represent three 
independent biological replicates. 
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3.2.4 Loss of PTEN ablates effective G2/M checkpoint activation 
The data so far suggest that reduced expression of MRN complex in cells without PTEN 
correlates with the compromised activation of the two checkpoint kinases. This event is 
apparently mediated by two different factors: failure to fully activate ATM due to low 
levels of MRN component proteins, and failure to activate ATR/Chk1 due to compromised 
strand resection. To ask whether failure to activate Chk1/Chk2 is linked to defective 
downstream signalling and G2 arrest, several analyses were performed.  
To analyse the dynamics and timing of the G2/M checkpoint activation, both HCT116 WT 
and PTEN-/- were exposed to 10Gy of IR and the samples were analysed by flow 
cytometry at different time points. The distribution of cells along the cell cycle was 
visualized by PI incorporation. PI is a fluorescent dye that stains the DNA, thus allowing 
the visualisation of the cell cycle profile as two different peaks, the first one constituted by 
cells in G1 phase (2N DNA content) and the second one by cells in G2 phase (4N DNA 
content). In between these two peaks lie the cells in S phase. HCT116 WT displayed a 
proficient G2/M checkpoint, as seen from the progressive accumulation of cells in the G2 
phase, which peaked at 9 hours (marked by an asterisk). This is followed by the release of the 
cells from G2 arrest by 24 hours (Figure 3.6). PTEN null cells also displayed a G2 
accumulation following irradiation, however the G2 peak at 9 hours appeared smaller and the 
G1 peak bigger. At 9 hours, 74% of WT cells had arrested in G2 compared to 55% of PTEN-/- 
cells. This result indicates that the G2/M checkpoint is not fully activated in PTEN null cells, 
thus allowing the damaged cells to progress into mitosis and then renter the cell cycle.  
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Figure 3.6: Loss of PTEN impairs the cell cycle checkpoint response to IR. FACS analysis measuring the 
incorporation of PI into HCT116 WT and PTEN null cells to analyse the cell cycle progression at different time 
points after exposure to 10Gy IR. The asterisk indicates the maximal accumulation of cells in G2 phase. 
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In order to more accurately assess the checkpoint proficiency, cells were subjected to a 
nocodazole trapping experiment. Cells with or without prior exposure to different doses of 
IR were incubated with nocodazole, and the accumulation of mitotic cells was quantified 
after 9 hours by evaluating the phosphorylation of histone H3 (pH3) by FACS (Figure 
3.7A). Nocodazole is able to trap cells in mitosis by disrupting microtubules, thereby 
enabling the measurement of the rate at which cells enter mitosis from G2. This 
measurement can directly document the efficacy of the G2/M checkpoint activation in 
response to damage.  
As shown in the figure 3.7A, HCT116 WT cells increasingly accumulated in G2 phase in 
an IR-dose dependent manner (4N DNA content) and less cells progressed to mitosis, as 
measured by reduced pH3 staining. However, PTEN null cells showed a comparatively 
higher number of pH3 positive mitotic cells. An IR-dose dependent increase in the 
difference between the two cell lines was observed (Figure 3.7B). Thus, the higher is the 
dose of IR, the greater is the difference in ability to activate the G2/M checkpoint between 
the two cell lines. Western blot analysis of lysates from HCT116 WT cells revealed that 
Chk1 activation as measured by S345 phosphorylation is IR dose-dependent  (Figure 
3.7C). This leads to a dose-dependent inhibition of the G2/M progression activator 
CDC25C, as measured by the inhibitory S216 phosphorylation. However, this trend is lost 
in HCT116 lacking PTEN.  
Put together these results suggest that PTEN null cells are unable to activate the G2/M 
checkpoint as efficiently as the control parental cell line. This defect becomes increasingly 
apparent following incremental damage due to higher doses of IR. 
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Figure 3.7: PTEN null cells show an impaired G2/M checkpoint. (A) FACS analysis measuring phopho-histone H3 
levels and PI incorporation in replicate cultures of HCT116 WT and PTEN-/- cells with or without prior exposure to 
different doses of IR and incubation with Nocodazole for 9 hours. (B) FACS data presented as the ratio of cells in G2 
(4N cells) over cells in M phase (positive for phosphorylated H3). The data are normalised to the Nocodazole (noc) 
sample not exposed to IR and average ± S.E.M. of n=3 are plotted. (C) Western blot analysis performed on lysates from 
cells in panel A. Actin provides the loading control. 
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3.2.5 PTEN loss or inhibition of Mre11 radiosensitises HCT116 cells 
In order to test whether an inefficient activation of the G2/M checkpoint and HR 
impairment in PTEN null cells affects their ability to proliferate after exposure to ionising 
radiation, a clonogenic survival assay was performed. As Mirin was used to inhibit Mre11 
in the clonogenic assay, it was necessary to establish the minimum dose that hits the target 
prior to the performing experiment. An initial clonogenic assay with varying doses of 
Mirin was performed in order to establish this optimal dose (Figure 3.8A). In addition to 
this, CellTiter-Glo® Luminescent Cell Viability Assay kit was also used to determine the 
number of viable cells in the plate after treatment with the titration of Mirin (Figure 3.8B). 
The assay measures the relative luminescence emitted by each sample, that is proportional 
to the amount of ATP present in the plate and used by the luciferase present in the reagent 
CellTiter-Glo®. Thus the amount of luminescence is a measure of the metabolic activity of 
cells and reflects the number of viable cells. From the results of both these cell viability 
measures, 15 µM was chosen as the highest least-toxic concentration of Mirin. 
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Figure 3.8: Dose tolerance curve for Mirin in HCT116 WT cells. (A) Clonogenic assay with HCT116 WT cells 
treated with a titration of Mirin for 24 hours and allowed to recover for 12 days. (B) CellTiter-Glo® Luminescent Cell 
Viability Assay performed on HCT116 WT cells treated with a titration of Mirin for 24 hours. The % Luminescence 
reflects the cell viability and the blue arrow points to dose used for further experiments. 
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The clonogenic assay showed that increasing doses of IR progressively impair the survival 
of HCT116 WT cells (Figure 3.9). The highest dose of IR reduced the % survival by a 
third in the WT cells. However, the PTEN null cells showed much greater sensitivity to IR 
than the WT counterparts, showing only 13% survival following treatment with 5Gy IR. 
Moreover, the treatment of WT cells with Mirin also sensitises them to IR, giving an 
intermediate response when compared to PTEN null cells. PTEN null cells were not 
treated with Mirin, however it may interesting to evaluate if additional Mre11 inhibition 
further reduces cell survival.  
These results suggest that the impairment of HR repair due to the lack of a functional 
Mre11 causes the presence of high levels of unrepaired damage that then dramatically 
impairs cell survival. 
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Figure 3.9: PTEN loss or Mirin treatment radiosensitises HCT116 cells. (A) Clonogenic assay performed on 
HCT116 WT cells with or without 40 min pre-treatment with 15μM Mirin or HCT116 PTEN-/- cells exposed to different 
doses of IR (0 to 5Gy). The cells were then cultured with or without Mirin for 24 hours and allowed to recover for 12 
days. The colonies formed were visualized by Crystal violet staining. (B) Survival curves plotted with the number of 
colonies determined by the GelCount™. % Survival was calculated relative to the cells untreated with IR. The data 
represent three independent biological replicates.  
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3.2.6 Cells without PTEN are prone to genomic instability 
Despite the overall reduction in cell survival compared to the wild-type cells, a percentage 
of PTEN null cells do survive and form colonies following irradiation in Figure 3.9. In 
order to assess the long-term effects of irradiation on the cell cycle in the checkpoint and 
HR deficient HCT116 PTEN-/- cells, FACS analysis similar to figure 3.6, at extended times 
after IR.  
The data obtained revealed that a few days (120 hours) after irradiation, the WT cells 
recover perfectly from the damage and reacquire a normal cell cycle profile. On the 
contrary, PTEN null cells are still severely affected showing cell death as observed from the 
sub-G1 peak (Figure 3.10A). Moreover, a substantial proportion of the PTEN-/- cells also 
present with >4N DNA content as indicated by the arrow in figure 3.10A and quantified in 
figure 3.10B. 8% of the surviving PTEN-/- population was detected to be polyploid, whereas 
just 1% of the wild-type cells demonstrated this phenotype.  
DAPI staining of HCT116 PTEN-/- nuclei confirmed the presence of nuclear abnormalities 
consistent with polyploidy (Figure 3.10C). In addition to this, these cells also showed the 
presence of micronucleation 72 hours post-irradiation. These data indicate that the loss of 
PTEN leads to genomic instability following exposure to IR.  
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Figure 3.10: PTEN-/- cells present elevated genomic instability following IR exposure. (A) FACS analysis measuring 
the incorporation of PI into HCT116 WT and PTEN null cells at different time points following exposure to 10Gy IR. (B) 
Quantification of polyploid cells in HCT116 WT and PTEN null cells from the FACS analysis. The data represent three 
independent biological replicates. (C) DAPI staining of HCT116 WT and PTEN null cells at different time points after 
exposure to 10Gy IR.  
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3.3 Discussion 
Cells are constantly exposed to various sources of stress that cause DNA damage and if not 
dealt with, this can threaten genomic integrity. Therefore, cells have evolved powerful 
mechanisms to contend with damaged DNA. The activation of cell cycle checkpoints is 
crucial for preventing the accumulation and inheritance of damage to daughter cells (Tyson 
et al., 1995). Furthermore, checkpoint-mediated arrest is necessary for allowing the cells to 
resolve the damage with the appropriate DNA repair pathway (van den Bosch et al., 2002). 
Loss of function or mutations in any of DDR components that govern these cellular 
mechanisms, result in abnormal genomes with chromosomal rearrangements and 
aneuploidy, thus predisposing cells to cancer (Jackson and Bartek, 2009). 
Akt is often found activated in several human cancers driving neoplastic transformation 
(Calvo et al., 2009). Several publications have shown DDR signalling to be a target of Akt 
signalling, however the mechanism behind this is still unknown. However, other studies 
suggested that also PTEN is correlated with DNA repair. PTEN deletion has been shown to 
affect DNA repair causing elevated levels of unrepaired DSBs (Pappas et al., 2007; Shen et 
al., 2007b). 
Using a PTEN null background, we present evidence suggesting that PTEN deletion 
affects the expression of the components of the MRN complex in two human colon 
carcinoma cell lines. However, more experiments are required to ascertain whether 
activated Akt or PTEN deletion leads to this reduction and the mechanism by which it is 
achieved. This is required in order to fathom the full implications of the findings in this 
chapter and the following chapter will address this issue further.  
Mre11 is among the first proteins to be recruited to DSB sites. Helped by the other two 
components Rad50 and Nbs1, it binds the broken ends of the DNA mediating the 
recruitment of ATM machinery to activate the DDR signalling (Uziel et al., 2003). It has 
been shown that MRN-ATM interaction, mediated mainly by Nbs1, is pivotal for its full 
activation after damage (You et al., 2005). Therefore, the reduction of MRN complex 
affects the phosphorylation and activation of Chk2, the main target of ATM. In agreement 
with this, the reduction in the components of MRN complex in PTEN-/- cells was also 
found to reduce the downstream DDR signalling via the ATM/Chk2 and ATR/Chk1 
pathways in response to irradiation. This reduction in signalling can be replicated by the 
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inhibition of MRE11 with Mirin in wild-type cells, and is therefore likely to be a direct 
result of reduced MRE11 expression in PTEN-/- cells. 
A reduction in MRE11, due to loss of PTEN or treatment with Mirin, was found to cause 
reduced HR efficiency in HCT116 cells. HR is able to mediate a faithful repair of DNA 
damage preventing the accumulation of any illegitimate repair, which may contribute to 
cell transformation (Johnson and Jasin, 2001). DNA strand resection is an essential step in 
HR repair, and is dependent on the nuclease activity of MRE11. Thus, a substantial 
reduction in RPA foci is observed in wild-type cells treated with Mirin or PTEN-/- cells. 
RPA32 is a ssDNA binding protein and RPA foci are widely used as markers for ssDNA. 
However, MRN complex is not necessary for ATM or ATR or DNA-PK-mediated 
phosphorylation of γH2Ax. This explains why no substantial reduction in γH2Ax foci was 
observed. 
The recruitment of ATRIP-ATR is strictly dependent on ssDNA-RPA via PCNA like 9-1-1 
checkpoint clamp (Delacroix et al., 2007). Activated ATR recruits a second mediator, 
Claspin, which binds Chk1 bringing it in proximity of ATR for its phosphorylation and 
activation. All these events are regulated by the formation of single-stranded DNA. 
Therefore, the reduced strand resection would severely impair Chk1 activation. Chk1 and 
Chk2 are checkpoint kinases. These proteins are essential for the regulation of many 
nuclear and cytoplasmic substrates downstream ATM/ATR (Lukas et al., 2003). The 
extent of their activation is directly proportional to the severity of the damage. High level 
of damage requires high amount of Chk1 active to induce a longer cell cycle arrest by 
inhibition of CDC25C phosphatase.  
PTEN-/- cells were found to display a defective G2/M checkpoint and reduced clonogenic 
survival in response to IR exposure. This was consistent with wild-type cells treated with 
Mirin, suggesting a crucial role of MRE11 in the observed phenotypes. The lack of a 
strong activation of ATM/ATR by the MRN complex is likely to have impaired the Chk1-
dependent activation of G2/M checkpoint. This would allow a big part of the population to 
progress to mitosis, despite containing unrepaired damage. Moreover, in the cells that do 
arrest, deficiency in HR would lead inefficient and error-prone repair. Together, this 
contributes to make PTEN null cells extremely sensitive to radiation.  
Damaged DNA compromises the fidelity of Mitosis, promoting aneuploidy. Thus, a 
significant percentage population surviving following IR insult was found to display 
Chapter 3  94 
genomic instability and micronucleation. These data indicate that cells with a PTEN 
deletion or hyperactive Akt are more likely to attain unstable genomes due to reduced 
repair and checkpoint efficiency. Thus, despite a reduction in cell viability following 
irradiation, the surviving population is more mutagenic and possibly more prone to 
tumourigenesis. Therefore, loss of PTEN or Akt hyperactivation could be acquired by 
tumour cells to gain more genomic instability, necessary to promote tumour progression 
and invasion.  
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Chapter 4: Activated Akt impairs the stability of 
MRN complex through S6K activity 
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4.1 Introduction 
The Mre11-Rad50-Nbs1 is an evolutionary conserved complex, and orthologues of Mre11 
and Rad50 can be found in all taxonomic kingdoms (van den Bosch et al., 2003). Mre11 is 
uniformly spread in the nuclei of resting undamaged cells. Following treatment with agents 
that induce DNA DSBs such as IR, Mre11 is dynamically redistributed (Nelms et al., 
1998). Mre11 associates with the DNA at these breakage points forming discrete nuclear 
foci (Maser et al., 1997). Mre11 foci appear in a dose- and time-dependent way in cells 
treated with DSB-inducing agents. However, this is not the case in cells treated with DNA 
damaging agent such as UV that induce other type of DNA lesions (Limoli et al., 2000; 
Maser et al., 1997). Moreover, it has been observed that MRN complex associates to 
chromatin even in unperturbed conditions (Costanzo et al., 2001; Mirzoeva and Petrini, 
2003).  These and other evidences showing the localization of MRN complex at replication 
forks have suggested that MRN complex has also a preventive role against the 
accumulation of DBSs during replication (Mirzoeva and Petrini, 2003; Olson et al., 2007; 
Robison et al., 2004; Tittel-Elmer et al., 2009). 
MRN complex in vivo is constituted by a core complex Mre112Rad502, further stabilized 
by Nbs1 binding giving an overall stoichiometry of Mre112Rad502Nbs12 (Trujillo et al., 
1998). The intra-molecular interactions between the three components are essential for the 
physiological roles of the complex itself. The interaction of Rad50-Mre11 stimulates both 
Mre11 exo- and endo-nuclease activity, which is further stimulated by Nbs1 interaction 
(Paull and Gellert, 1998, 1999). The knockdown of one component of MRN decreases the 
levels of the other two members. Thus, mutations in Mre11 cause reduction levels of 
Rad50 and Nbs1 resulting in a strongly destabilized complex (Paull and Gellert, 1999; 
Stewart et al., 1999; Zhong et al., 2005). The addition of wild type Mre11 in these cells 
restores the normal level of Rad50 and Nbs1 (Stewart et al., 1999; Uziel et al., 2003).  
Emerging data also suggest an important role for post-translational modifications in the 
regulation of the MRN complex. Upon its recruitment by the MRN complex to the DNA 
damage sites, ATM along with ATR phosphorylates all three components of the MRN 
complex (Matsuoka et al., 2007; Mu et al., 2007). This suggests that MRN complex 
activity is regulated by a feedback loop mechanism that involves phosphorylation. Mre11 
in particular contains eight putative phosphorylation sites for PIKK kinases. Its 
phosphorylation is crucial for regulating the entire dynamic of DDR, whereby the 
phosphorylation facilitates its dissociation from the chromatin and is necessary for its 
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inactivation after completion of repair. This allows the downregulation of the DNA 
damage signalling and the recovery from checkpoint arrest.  However, the inhibition of 
ATM and ATR with caffeine or wormannin only partially inhibits Mre11 phosphorylation, 
suggesting that other kinases might be involved in Mre11 phosphorylation (Di Virgilio et 
al., 2009).   
Moreover, Mre11 ATM-mediated phosphorylation is mediated by Nbs1-ATM interaction. 
Thus Nbs1 deficient cells lose Mre11 phosphorylation, which also impairs Mre11 foci 
formation (Dong et al., 1999). Several ATM-dependent phosphorylation sites have also 
been mapped on Nbs1 by mass spec analysis, and these are found to be evolutionary 
conserved in vertebrates (Tauchi et al., 2001; Tauchi et al., 2002). These sites seem to be 
important for the regulation of different cellular processes such as intra-S checkpoint 
activation and p53-independent apoptosis (Iijima et al., 2008a; Iijima et al., 2008b). Nbs1 
can be also acetylated by PCAT and p300 histone acetyl transferases (HATs), whereas 
SIRT1 regulates its deacetylation when it is bound to Mre11-Rad50. Interestingly, 
hyperacetylation of Nbs1 impairs DNA damage-induced activation mediated by ATM 
phosphorylation, suggesting that phosphorylation and acetylation work antagonistically in 
regulating Nbs1 activity (Yuan et al., 2007).  
However, other post-translational modifications, such as methylation, have been shown to 
impact Mre11 activity. At least nine methylated arginines were identified in the C-terminus 
of Mre11 protein, which are important for the function of this region (Boisvert et al., 
2005b). PRMT-mediated methylation of Mre11 occurs before Mre11 associates with 
Rad50 and Nbs1 to form the complex. However, the impairment of Mre11 methylation 
doesn’t affect the formation of the complex, but it affects the binding to DNA and its 
nuclease activity (Boisvert et al., 2005b; Dery et al., 2008). Thus, Mre11 methylation 
seems to be crucial for its recruitment to the damage sites, regulating DSB processing and 
intra-S checkpoint activation.  
As mentioned previously, Akt signalling has previously been shown to influence DNA 
repair and checkpoint response. In particular, Akt-mediated phosphorylation can affect the 
expression or subcellular localisation of its targets. In some cases of human cancer, 
activated Akt phosphorylates Brca1 inducing its cytoplasmic retention inhibiting HR repair 
(Plo et al., 2008; Tonic et al., 2010). Akt also mediates Chk1 phosphorylation at S280, 
inducing its translocation to the cytosol and then inhibiting its checkpoint function (King et 
al., 2004; Puc et al., 2005; Shtivelman et al., 2002). This phosphorylation also affects its 
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interaction with Claspin and its full ATR-mediated activation (Pedram et al., 2009). 
Therefore, it has been observed in many cancers that high level of active Akt correlates 
with resistance to treatment as chemotherapy and/or radiotherapy (Bellacosa et al., 2005). 
However, Akt exerts its full oncogenic potential through the activation of other protein 
kinases such as mTORC1 and S6K. Therefore, the inhibition of mTOR by rapamycin has 
been shown to induce cell cycle arrest and/or apoptosis in tumours with activated Akt 
(Alam et al., 2004; Altomare et al., 2004; deGraffenried et al., 2004). mTOR, often called 
the master regulator of cell growth, is also found to regulate the abundance of several 
proteins involved in maintenance of chromosomal integrity and DDR activation (Li et al., 
2006). The knockdown of mTOR or its inhibition by rapamycin induces ATM activation 
by upregulating the steady-state level of unidentified proteins in the DDR pathway, which 
are responsible for ATM activation (Bandhakavi et al., 2010). However, this can be 
achieved via indirect regulation through other direct targets and more studies are necessary 
to clarify the link between mTOR and DDR signalling.  
mTOR controls growth, proliferation and translation efficiency through two downstream 
signalling molecules, S6K1 and S6K2. Recently evidences have linked S6K to 
tomourigenesis. It has been shown that activated Akt induces the tumour formation in 
mouse pancreas through S6K1 protein activation (Alliouachene et al., 2008). Other studies 
have shown how mTOR-S6K pathway controls p53-mediated DNA damage response in 
presence of genotoxic stresses. S6K1 adapts the damage response to the growth condition 
and energy levels of the cells, regulating cell death by MDM2 inhibition (Lai et al., 2010). 
Therefore, mTOR-S6K pathway can be another pathway involved in tumourigenesis, 
through the regulation of DDR.  
This chapter investigates the potential mechanisms by which PTEN loss or activated Akt 
signalling ablates MRN complex expression and activity.  
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4.2 Results 
4.2.1 S6K1 but not Akt impairs MRN complex stability  
The data so far indicate that in HCT116 cells the deletion of PTEN causes a reduction in 
MRN complex which compromises both the G2/M checkpoint and the DNA repair 
response, associated with a higher basal level of active Akt. To investigate whether 
activated Akt or the lack of PTEN is most directly responsible, HCT116 WT cells were 
transiently transfected with a constitutively active form of Akt (GAG-Akt), and its effect 
on levels of MRN complex components was analyzed by Western blot at different time 
points post-transfection. GAG is a viral sequence, which anchors Akt to the plasma 
membrane where it is fully activated by PDK1 and mTORC2. High levels of active GAG-
Akt (reflected by its phosphorylation on S473) were expressed in WT cells for 72 hours, 
identified as the upper band above the endogenous Akt (Figure 4.1). Kinase activity was 
determined by the phosphorylation of p70-S6K, and showed a substantial increase 
following expression of GAG-Akt. The expression of active GAG-Akt in WT cells 
correlated with the gradual reduction of both Mre11 and Rad50 levels, dropping to lowest 
levels at 72 hours. These data are consistent with the idea that activated Akt mediates the 
downregulation of MRN complex in HCT116 PTEN-/- cells.  
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Figure 4.1: Expression of hyperactive Akt in HCT116 WT cells reduces expression of MRN complex. Western blot 
analysis of HCT116 WT cells transiently transfected with GAG-Akt and lysed at the indicated time-points post-
transfection. Actin provides the loading control.  
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Constitutive activation of Akt induces the activation of other protein kinases downstream 
in the signalling pathway. To further investigate if the downregulation of MRN complex is 
directly mediated by Akt or one of its downstream effectors, PTEN null cells were treated 
with several inhibitors targeting various kinases at different levels in the 
Akt/mTORC1/S6K pathway.  
Cells were treated with inhibitors for 72 hours, following which the levels of MRN 
complex and DDR pathway activation upon IR exposure were analysed by Western 
blotting. A pleckstrin homology (PH) domain inhibitor at the concentration of 1µM was 
used to inhibit the activation of both Akt1 and Akt2, which resulted in a strong reduction 
of its phosphorylation on S473 (Figure 4.2). Surprisingly, the inhibition of Akt did not 
affect the activation of mTORC1/S6K pathway. 500nM Everolimus, a Rapamycin 
analogue, was used to selectively inhibit mTORC1 activity. This was found to efficiently 
inhibit mTORC1-mediated activation of S6K, as observed from the lack of its activating 
phosphorylation and from the decreased phosphorylation of its substrate, the ribosomal S6 
protein. Furthermore, PF4708671 at 20µM was used to inhibit S6K1 activity, confirmed by 
the strongly reduced phosphorylation of S6 protein. The inhibition of mTORC1 not only 
restored Mre11 and Rad50 levels, but also Chk1 and Chk2 activation after exposure to IR. 
Interestingly, inhibition of S6K1 also had the same effect on the DDR pathway, despite not 
affecting mTORC1 activity. This suggests that downregulation of DDR following 
depletion of PTEN depends on the Akt-mediated activation of its effector S6K1.  
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Figure 4.2: The inhibition of S6K1 activity in PTEN-/- cells restores MRN complex levels and DDR signalling 
following IR. Western blot analysis of HCT116 PTEN-/- cells treated for 72 hours with different inhibitors targeting 
various kinases within the Akt/mTOR/S6K pathway. Cells with or without IR exposure were analyzed. Actin provides 
the loading control. 
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Since S6K1 inhibition restores the expression of MRN complex in PTEN null cells, a 
likely rescue of its strand resection activity was investigated. The inhibition of S6K1 was 
found to rescue RPA foci formation following the exposure to IR (Figure 4.3A-B). These 
data indicate that in absence of S6K1 activity, not only is DDR signalling restored as 
judged by Chk1/2 phosphorylation, but also the processing of DSBs into ssDNA is 
rescued. I conclude that S6K1 contributes to the downregulation of MRN complex stability 
and function, and decreased activity of the ATM/Chk2 and ATR/Chk1 pathways, in PTEN-
/- cells. 
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Figure 4.3: S6K1 inhibition restores the resection of DSBs into ssDNA in PTEN-/- HCT116 cells. (A) 
Immunofluorescence analysis of phosphorylated H2Ax and RPA foci in HCT116 WT and PTEN null cells minus or plus 
72 hours pre-treatment with S6K1 inhibitor, 4 hours after exposure to IR. (B) Quantification of the number of RPA foci 
per nuclei. The data represent three independent biological replicates. 
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4.2.2 S6K1 affects MRN protein stability 
Several analyses were performed in order to clarify the mechanism by which S6K1 altered 
MRN levels in HCT116 PTEN-/- cells. Firstly, a quantitative PCR analysis was used to 
analyse any significant alterations in the level of Mre11, Rad50 and Nbs1 transcripts between 
the WT and PTEN-/- cell lines. The expression levels were normalized to Actin mRNA levels. 
The clear absence of PTEN transcripts in the null cells validates the assay and the gene 
deletion. Surprisingly, the levels of Mre11, Rad50 and Nbs1 consensus transcripts were found 
to be comparatively similar in both WT and PTEN-/- cells (Figure 4.4). These data indicate that 
the reduction in protein levels of MRN complex components observed in PTEN-/- cells is not 
due to alteration in transcription or mRNA stability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4  106 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Transcript levels for components of MRN complex are unaltered upon PTEN deletion. RT-qPCR 
analysis of Mre11, Rad50 and Nbs1 mRNAs in HCT116 WT and PTEN-/- cells. Data was normalized to Actin mRNA 
and is presented relative to the WT signal. The error bars represent the standard deviation of three independent biological 
replicates.  
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To examine whether the reduction of MRN complex is due to reduced protein stability, the 
HCT116 cells were cultured in presence of Cycloheximide for 24 hours, and stability of 
the complex was analyzed by Western blot at 7 and 24 hours post-treatment. 
Cycloheximide is an inhibitor of protein synthesis, which inhibits the polypeptide 
elongation step during translation. The levels of p53 were drastically reduced in both cell 
lines following Cycloheximide treatment, expected for this highly unstable protein. 24hr 
treatment did not alter the levels of MRN components in WT cells, whereas MRN complex 
levels were drastically reduced following 7 hours of treatment of PTEN-/- cells (Figure 
4.5A). As quantified in Figure 4.5B, 80% reduction in MRE11 signal was observed in 
PTEN-/- cells. This result suggests that active S6K1 reduces MRN complex in PTEN null 
cells by severely impairing its protein stability. 
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Figure 4.5: MRN complex is unstable in PTEN null cells. (A) Western blot analysis of HCT116 WT and PTEN-/- cells 
following treatment with Cycloheximide for 7 and 24 hours. p53 provides the positive control and Actin provides the 
loading control. (B) Quantification of the Mre11 Western blot analysis using ImageJ. 
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To further test the stability of the MRN complex, PTEN WT and null cells were 
transfected with a vector to ectopically express Mre11A. The expression of ectopic Mre11-
Myc-flag was identified by Western blot using an anti-Myc antibody. As seen in figure 
4.6A, the ectopic Mre11-Myc was already well expressed at 24 hours post-transfection in 
WT cells, reaching its maximal peak at 32 hours. Conversely, PTEN null cells showed a 
significantly lower expression of ectopic Mre11-Myc, and by 48 hours post-transfection it 
returned to basal levels. Moreover, the transient expression of Mre11 transiently increases 
Rad50 levels in both cell types, confirming that the ectopically expressed protein is 
functional. This further validates the idea that Mre11 protein regulates the levels of the 
other two components of MRN complex.  
However, the low level of Mre11A-Myc in PTEN-null cells could be due to reduced 
expression of the ectopic gene or could be caused by the rapid degradation of the protein 
itself. In order to address this, HCT116 cells expressing the maximal level of Mre11A-Myc 
(32 hours time point) were treated with Cycloheximide for up to 24 hours. Similar to the 
endogenous protein, the treatment was found to cause rapid reduction in the ectopically 
expressed protein (Figure 4.6B). The quantification of the Western blot clearly shows that 
Mre11A-Myc is strongly unstable in PTEN-/- cells compared to the parental cell line 
(Figure 4.6C). Thus, Mre11 protein stability is severely impaired in PTEN null cells as a 
result of high level of active S6K1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4  110 
 
 
 
Figure 4.6: Ectopically expressed Mre11A is unstable in PTEN null cells. (A) Western blot analysis of HCT116 and 
PTEN-null cells harvested at different times following transfection with ectopic Mre11A-Myc-Flag. (B) Western blot of 
HCT116 WT and PTEN null cells expressing ectopic Mre11A with or without Cycloheximide treatment for 8 and 
24hours. (C) Quantification of the Mre11A-Myc-Flag Western blot signal by Image J. 
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4.2.3 Cause of MRN complex instability 
Considering that p70-S6K is a kinase, in order to clarify the possible mechanism by which 
active S6K1 may regulate MRN complex stability, a bioinformatics analysis was 
performed to investigate if Mre11 could be a direct target. The preferred S6K1 
phosphorylation motif RXRXXS/T (where X is any amino acid) was found in the sequence 
of Mre11 isoform1 (Figure 4.7A). The analysis identified a Threonine in position 597 as a 
possible target of S6K1 phosphorylation, suggesting the possibility of another regulatory 
site for Mre11 DNA-binding and stability. Interestingly, this potential residue is located 
within the glycine-arginine rich (GAR) motif of Mre11 (Figure 4.7B). Several studies have 
shown that the methylation of 9 arginines between 565-600 in this region is crucial for 
Mre11-mediated DSB repair and checkpoint activation (Boisvert et al., 2005a; Dery et al., 
2008; Yu et al., 2012). The resulting positive charge of this domain controls Mre11 DNA 
binding and then its nuclease activity. Therefore, the phosphorylation of this site could 
alter the net positive charge of this domain, thus compromising the ability of Mre11 to 
bind DNA and hence its stability and function.  
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Figure 4.7: Mre11 isoform 1 has a possible phosphorylation site for S6K1.  (A) Sequence analysis of Mre11A reveals 
the presence of S6K1 consensus sequence. The analysis identified a site on T597. (B) Schematic of domains arrangement 
in human Mre11 [Figure adapted from Park et al., 2011].   
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An in vitro kinase assay was performed to confirm if Mre11 is a direct substrate for S6K1 
activity. Briefly, various amounts of recombinant S6K1 were incubated with 480ng of 
Mre11A recombinant protein for 30  min at 30°C. Following this, the proteins were 
resolved on an SDS-PAGE gel and 32P incorporation into Mre11 was visualised by 
autoradiography (Figure 4.8A). The levels of recombinant Mre11A and S6K1 were 
visualised by Coomassie staining. The Mre11 band from each lane was cut out carefully 
avoiding the S6K1 band. The incorporation of 32P for each sample was then quantified by 
the scintillation counting, and the values were plotted in the graph shown in Figure 4.8B. 
As seen in figure 4.8A, increasing concentration of the kinase resulted in increasing 
incorporation of the 32P into the kinase itself due to auto-phosphorylation. This verifies that 
kinase is functional. However, no substantial increase was observed for 32P incorporation 
into Mre11A protein by autoradiography. Scintillation counting did reveal incremental 32P 
incorporation into Mre11A, however this could be due to cross contamination from the 
S6K1 band. 
Therefore, increased Akt activity leads to a reduced Mre11 protein stability in PTEN-/- 
cells. Mre11 contains a S6K1 target consensus site, however, it is still unclear if S6K1 
directly or indirectly regulates its stability. 
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Figure 4.8: S6 Kinase assay for Mre11A. (A) SDS-PAGE performed on recombinant Myc-Mre11A incubated with 
ϒ32P-ATP and varying amounts of recombinant S6K1. The lower panel shows coomassie staining. (B) Scintillation 
counts of Mre11 bands cut from the SDS-PAGE gel quantifying 32P incorporation into Mre11. 
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4.3 Discussion  
PTEN is a well-known tumour suppressor that controls cell growth and apoptosis by 
inhibiting PI3K/Akt signalling. Several lines of evidence have shown that both PTEN and 
Akt are involved in regulating DNA repair and DNA damage response, however the 
mechanism for this still remains unclear (Kandel et al., 2002; King et al., 2004; Pappas et 
al., 2007; Plo et al., 2008; Puc et al., 2005; Puc and Parsons, 2005; Shen et al., 2007b). The 
previous chapter showed that a reduction in the components of MRN complex correlates 
with the reduced ability of PTEN-/- cells to achieve checkpoint arrest and efficiently 
perform DNA repair. Therefore, it seemed necessary to clarify if the reduction in MRN 
complex was most directly caused by PTEN deletion or Akt activation. The transient 
expression of constitutively active form of Akt in WT cells confirmed that oncogenic Akt 
specifically ablates MRN complex levels, suggesting that the effects of PTEN deletion are 
exerted via Akt.  
The activation of Akt induces the indirect activation of other major kinases downstream in 
the PI3K pathway, such as mTORC1 and S6K. Akt regulates important cellular functions 
such as proliferation, growth, survival and metabolism through these kinases. The use of 
chemical inhibitors to target the PI3K pathway in PTEN-/- cells revealed that the inhibition 
of S6K1 was able to restore MRN complex levels, and subsequently the activation of DDR 
pathway in response to radiation. The inhibition of mTORC1 by Everolimus was also 
found to reduce S6K1 activity and thus rescues the expression of MRN complex and DDR 
response. However, the direct inhibition of Akt was surprisingly unable to rescue MRN 
expression. It has been previously demonstrated that Pdk1 is able to compensate for the 
lack of Akt activity, directly phosphorylating and activating the p70-S6K (Pullen et al., 
1998). In agreement with this, the levels of active p70-S6K were not reduced upon 
inhibition of Akt1/2 in PTEN-/- cells, consistent with the idea that S6K activity is 
responsible for reduction in MRN expression. This new finding suggests that the 
deregulation of Akt activation could affect DDR response through elevated S6K1 activity. 
Therefore, inhibition of S6K1 could provide a potential new therapeutic avenue for 
tumours with PTEN loss or activated Akt.  
Not much is known about the role of S6K1 in tumourigenesis. It was just recently that Lai 
and colleagues showed that in presence of genotoxic stress, S6K1 modulates DDR 
response according to cellular energy conditions (Lai et al.). The regulation of MRN 
complex could be the mechanism through which S6K1 fine-tunes DDR according to 
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cellular environment. This hypothesis motivated us to investigate the details of the 
mechanism by which S6K1 may regulate MRN complex stability.  
The observed reduction in MRN complex level could be caused by a reduced transcription, 
translation or protein stability. In ATLD cells, the observed reduction in MRN complex is 
caused by a mutation in Mre11 gene, which alters the stability of its transcript, and 
consequently of the other two components Rad50 and Nbs1 (Bartkova et al., 2008). 
However, cycloheximide treatment and ectopic expression experiments revealed that the 
reduced levels of MRN complex in PTEN null cells are due to impaired Mre11 protein 
stability. 
It is well known that protein phosphorylation can mark proteins for ubiquitylation and 
proteasomal degradation (Swaney et al., 2013). For example, the phosphorylation of 
Cyclin D1 induces its nuclear export and ubiquitination–mediated degradation (Alt et al., 
2000). Mre11 contains several serine and threonine residues within its carboxyl-terminus, 
which are phosphorylated by the PIKK family members in presence of DNA damage, thus 
regulating its association with chromatin and its function (Di Virgilio et al., 2009). Several 
studies have shown that inhibition of PIKK proteins doesn’t abolish Mre11 
phosphorylation, indicating that other proteins are involved in phosphorylating Mre11 (Di 
Virgilio et al., 2009). Bioinformatic analysis revealed the presence of a phosphorylation 
consensus site for S6 kinase in the carboxyl-terminus of Mre11. However, an in vitro 
kinase assay with recombinant S6K1 failed to show significant phosphorylation of Mre11. 
Despite this, due to doubts regarding substrate purity one cannot rule out Mre11 as a S6K1 
substrate. Thus, further definitive analysis is required to investigate this possibility. In 
addition to this, mass spectrometric analyses are in progress to investigate other possible 
sites and/or post-translational modifications of that may impact Mre11 stability in the 
PTEN-/- HCT116 cells.  
Although, phosphorylation has been demonstrated to cause ubiquitination-mediated 
proteolysis of certain proteins, MG132 mediated inhibition of the proteasome does not 
rescue the levels of MRN complex in PTEN-/- cells (data not shown).  This suggests that 
degradation of MRN components is not proteasome-mediated, but must occur through 
alternative pathways. Thus, further work is required to define the mechanism by which 
S6K affects MRN complex stability. 
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5.1 Introduction 
As previously mentioned, the abrogation of DDR pathway by the alteration of its 
components results in genomic instability, which significantly contributes in driving 
tumourigenesis. The activation of an oncogene has been established to be a powerful 
trigger of DDR signalling. The expression of the oncogenic HRAS leads to an initial burst 
of proliferation causing high level of DNA replication stress, after which cells slow down 
and eventually undergo senescence (Di Micco et al., 2007). DNA replication stress is 
caused by several factors: an increased number of simultaneously active origins of 
replication, DNA re-replication events, accumulation of single stranded DNA, impaired 
progression of replication forks and subsequent formation of DSBs (Bartkova et al., 2006; 
Di Micco et al., 2006). These events, together with aberrant activation of cell cycle 
regulators and associated transduction pathways, lead to the activation of DDR, formation 
of senescence-associated DNA damage foci (SDFs) and accumulation of DNA damage. 
DDR activation is indeed crucial for the establishment and maintenance of senescence. 
Early stage preneoplastic lesions show high levels of DDR activation, which coincides 
with the expression of senescence markers. For example, skin papillomas harbouring RAS 
mutations or precancerous colon adenomas demonstrate a positive correlation between 
DDR activation and markers of senescence (Bartkova et al., 2006; Di Micco et al., 2006). 
However, inactivation of DDR bypasses senescence, thus significantly contributing to 
cancer progression. In agreement with this, it has been observed that DDR activation peaks 
at early dysplastic stages of tumourigenesis in lung, bladder and colon, but its activation is 
lost during the progression to advanced stages of the cancer (Bartkova et al., 2005; 
Gorgoulis et al., 2005; Nuciforo et al., 2007; Tort et al., 2006).  
Therefore, senescence poses a fundamental barrier to cell (Braig et al., 2005; Chen et al., 
2005b; Collado et al., 2005; Michaloglou et al., 2005). The expression of an oncogene is 
called a driver mutation because it provides the bases for tumour initiation and 
progression. However, additional mutations are required in order to switch this driver 
mutation from a senescence trigger to a driver of cellular transformation. For example, 
90% of invasive pancreatic ductal adenocarcinoma (PDAC) present activating KRAS 
mutation, in conjunction with inactivation of various tumour suppressor genes such as 
BRCA1, TIP53, SMAD4 and CDKN2A (Hruban et al., 2000).  
The most important effectors of RAS are PI3K and its downstream effector Akt. These 
function as mediators of RAS-induced cell survival and proliferation (Castellano and 
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Downward, 2010). Activating mutations of PI3K, deletion of PTEN or Akt overexpression 
are observed in several cancers. Moreover, an increasing level of Akt activity was also 
found to correlate with melanoma progression (Dai et al., 2005). Interestingly, the 
combinations of activating RAS mutations and PI3K/PTEN/Akt signalling mutations are 
commonly found within the same tumours (Repasky et al., 2004). Endometrial cancer, 
thyroid cancer and acute lymphoblastic leukemia have all been shown to harbor the 
simultaneous mutation of RAS and genes encoding proteins for the PI3K signalling 
(Yeang et al., 2008). Published data suggest that 25% of human colon cancers contain 
mutations in both KRAS and PI3K-associated genes (Parsons et al., 2005). Moreover, 60% 
of human PDAC show PTEN loss, due to deletions, mutations or epigenetic silencing 
(Biankin et al., 2012). 
Since PI3K/Akt is an effector of RAS, the molecular advantage of these co-occuring 
mutations within the same pathway is still not fully understood. Several studies have 
suggested that inactivation of PTEN or activation of Akt promotes escape from senescence 
and confers a selective advantage for tumour growth (Dankort et al., 2009; Kennedy et al., 
2011; Vredeveld et al., 2012). In primary human fibroblasts, Akt overexpression leads to a 
reduction in percentage of cells with SAHF and suppression of p16 expression. In addition 
to this, RASG12D/Ptenfl/+ mice show a reduction in p21 and β-gal expression, along with 
increased proliferation in pancreatic intraepithelial neoplasia (PanIN) (Kennedy et al., 
2011). Acute shRNA-mediated depletion of PTEN was shown to reduce β-gal expression 
and rescue proliferation defect in BRAF expressing human melanocytes. PTEN depletion 
was also found to drive tumour formation from BRAF expressing nevi (Vredeveld et al., 
2012). Thus in these models, an activation of PI3K signalling leads to senescence 
suppression and confers a growth advantage. 
Considering my findings regarding the involvement of Akt in suppressing DNA damage 
sensing and processing, it is necessary to establish if Akt induces or bypasses senescence 
and if this is achieved via the inhibition of DDR.  
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5.2 Results 
5.2.1 Activated Akt suppresses DDR in RAS-expressing cells 
In order to investigate the effects of activated Akt on oncogene-induced senescence (OIS), 
a specific cell type was used as a model. IMR90’s are primary human diploid fibroblasts 
(HDFs) isolated from foetal lung. This cell line has been utilized for nearly 30 years in the 
study of replicative lifespan and senescence (Nichols et al., 1977). The expression of 
constitutively active mutant H-RAS allele (HRASG12V) has been shown to induce 
senescence in HDFs (Serrano et al., 1997). Early passage IMR90 cells were infected with 
either control retroviruses or retroviruses encoding HRASG12V or activated myristoylated 
Akt (Myr-Akt) or both (hereon in referred to as Control, RAS, Akt or RAS/Akt cells). 
After infection, cells were subjected to antibiotic selection, and harvested after 12 days 
when a majority of the RAS cells demonstrate a flat enlarged and vacuolated morphology 
that is typical of senescent cells. 
As expected, infection with HRASG12V retrovirus causes high RAS expression and 
infection with Myr-Akt retrovirus causes elevated total Akt as detected by Western 
blotting (Figure5.1). Myristoylation causes Akt to localize to the plasma membrane where 
it is activated by PDK1 and mTORC2. Thus, Myr-Akt expression also leads to an increase 
in the phosphorylation of Akt on S473, confirming that it is fully active. Elevated Akt 
activity leads to increased phosphorylation of its direct target GSK3α/β and the activation 
of the mTORC1-S6K pathway, as observed by an increase in S6 protein phosphorylation. 
RAS expression was found to cause activation of DDR signalling, as observed from the 
phosphorylation of Chk2 on T68 and of Chk1 on S345. This is in agreement with several 
studies published by d’adda di Fagagna and colleagues showing that activating mutations 
of RAS induce hyperproliferation-mediated replication stress, which leads to the formation 
of DBSs causing the activation of DNA damage response (Evan and d'Adda di Fagagna, 
2009; Suram et al., 2012). As observed in HCT116 cells, the expression of active Akt in 
IMR90’s was found to cause a reduction in all three components of the MRN complex. 
Moreover, in the presence of DNA damage caused by RAS, active Akt also inhibited the 
activation of Chk2 and Chk1.  
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Figure 5.1: Activated Akt suppresses DDR in RAS-expressing IMR90’s via a reduction in MRN complex.  Western 
blot analysis on IMR90 cells twelve days post-infection with retroviruses expressing CTR, HRASG12V, Myr-Akt or 
HRASG12V/Myr-Akt. Actin provides a loading control. 
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Since Akt expression in RAS cells demonstrates a dramatic inhibition of DDR signalling, 
it is highly likely that the genomic integrity of these cells would be compromised. Alkaline 
comet assay was used to assess the integrity of the DNA in these cells (Figure 5.2A), 
where intact DNA forms the head of the comet and damaged DNA forms the tail due to its 
increased electrophoretic mobility. Thus, total DNA damage can be measured and 
expressed as a percentage of DNA migrating in the tail of the comet (Figure 5.2B). Cells 
expressing Myr-Akt similarly to CTR cells present low amount of damage DNA. The 
majority of RAS comets present a small tail, suggesting the presence of small amount of 
broken DNA compared to the CTR cells. However, the presence of much higher levels of 
DNA breaks was evident from the long tail of RAS/Akt comets compared to RAS cells. 
This difference was found to be statistically significant (p<0.001) and suggests that the 
reduced expression of MRN complex leads to inefficient repair in these cells.  
Interestingly, this assay also revealed a marked difference in nuclei size and shape among 
the three different cell types (Figure 5.2A). The control cells presented relatively small 
nuclei and with fairly round morphology. RAS cells showed an increase in nuclei size, 
whereas the RAS/Akt cells showed a large proportion of comets with irregular and larger 
nuclei. Therefore, in presence of DNA damage caused by the expression of oncogenic 
RAS, activated Akt inhibits DDR activation and repair via the reduction in MRN 
expression, thus causing an accumulation of unrepaired DNA.  
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Figure 5.2: Activated Akt leads to high levels of DNA breaks in RAS-expressing IMR90’s. (A) Immunofluorescence 
images obtained following an alkaline comet assay with IMR90 cells 12 days post-infection with CTR, HRAS G12V, 
Myr-Akt or HRAS G12V and Myr-Akt retroviruses. (B) Total DNA damage (sum of single and double DNA breaks) was 
measured as percentage of DNA migrated in the tail of the comet over the total signal from the head and tail. *** denotes 
p<0.001 as calculated by Student’s t-test. Data was quantified by using ImageJ OpenComet, and it was derived from 
three independent biological replicates. 
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5.2.2 Activated Akt reinforces RAS-induced senescence 
Previous work from our lab showed that activated Akt in vitro suppresses some features of 
RAS-induced senescence. Oncogenic Akt suppresses the upregulation of p16 and the 
formation of SAHF, but it didn’t suppress the RAS-induced proliferation arrest as 
measured by cyclin A expression (Kennedy et al., 2011). So far, my results have suggested 
that overactivation of Akt signalling inhibits DDR and DNA repair via suppression of 
MRN complex. Since DDR plays a crucial role in triggering RAS-mediated proliferation 
arrest, we set out to investigate the impact of activated Akt on the establishment of OIS. 
To do this, the expression of several markers of cell proliferation and senescence were 
analyzed. RAS cells showed a flattened and bigger cell morphology, which is 
characteristic of senescence induced by the expression of this oncogene (Figure 5.3A). Akt 
cells appeared larger and flatter compared to control cells, but smaller compared to the 
RAS cells. This is consistent with the idea that the expression of active Akt can induce 
some feature of senescence, but it is much less potent in this regard than activated RAS 
(Kennedy et al., 2011). Interestingly, the combined expression of activated RAS and Akt in 
IMR90 cells caused a peculiar phenotype. These cells were much bigger than the RAS 
cells with various protrusions emerging from the cellular body. This morphological 
difference suggests that the expression of active Akt in RAS-expressing cells may have an 
important qualitative impact of RAS-induced senescence.  
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High levels of cyclin A and phosphorylated pRb, along with low levels of cell cycle 
inhibitors p21WAF1 and p16INK4a as seen by Western blot in control IMR90 cells 
indicate normal cell cycle progression (Figure 5.3B). Contrary to this, the expression of 
oncogenic RAS was found to induce a robust expression of p16INK4a and p21WAF1. An 
increase in ATM-dependent S15 phosphorylation of p53 was also detected. In addition to 
this, cyclin A and phosphorylated pRb were reduced, suggesting that the cells had 
undergone cell cycle arrest and were senescent. Akt cells depicted a similar reduction of 
proliferation markers, however they were found to have reduced induction of p21 and p16 
compared to RAS cells. This supports the idea that Akt is a less potent inducer of 
senescence when compared to RAS, as reported in Kennedy’s paper (Kennedy et al., 
2011). On the other hand, extremely low levels cycln A and phosphorylated pRb, along 
with higher levels of p16 and p21 were detected in RAS/Akt cells. This finding suggests 
that the activation of Akt in the presence of oncogenic RAS leads to a stronger senescent 
phenotype. It must be noted that no increase in S15 phosphorylation of p53 was observed 
in cell line expressing Akt, possibly due to the lower ATM activity in the absence of 
Mre11. 
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Figure 5.3: RAS/Akt cells show a stronger senescent phenotype. (A) Light microscopy images of IMR90 fibroblasts 
12 days post-transduction with CTR, HRASG12V, Myr-Akt or both HRASG12V and Myr-Akt retroviruses. (B) Western 
blot analysis of lysates from cells shown in (A). Actin provides a loading control. 
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In order to establish if the senescence program in RAS cells is altered by Akt expression, a 
further marker crucial for defining the senescence status was analyzed. High level of β-
galactosidase activity is normally used as diagnostic tool to distinguish senescent cells 
from other cellular states. Its activity can be visualized as perinuclear blue precipitate in 
cells incubated with a reaction mix containing the substrate X-gal. The number of β-
galactosidase positive cells at 6 and 13 days post-infection were quantified and expressed 
as a percentage of the total number of cells. As expected, control cells were found to have 
few cells (<5%) positive for β-galactosidase activity 13 days post-infection (Figure 5.4). 
However, Akt expression lead to nearly 40% of the cell population to be positive for the 
staining 12 days post-infection, suggesting that Akt by itself is weak inducer of 
senescence.  
RAS cells were found to enrich with positive cells at 6 days post-transfection, and by day 
13 the majority of them (70%) were found to demonstrate a robust staining for β-
galactosidase activity. However, the co-expression of activated Akt lead to an earlier and 
increased enrichment of β-galactosidase positive cells. The RAS/Akt cells demonstrated a 
lower cell density compared to the RAS or Akt only cells, however 40% of cells at day 6 
and 90% of cells at day 12 were found to stain positive. This provides further evidence to 
suggest that co-expression of Akt compounds oncogenic RAS-induced senescence.  
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Figure 5.4: Majority of activated RAS/Akt cells are β-galactosidase positive. (A) Bright field of microscopy images 
of CTR, HRAS G12V, Myr-Akt or HRAS G12V/Myr-Akt cells stained for β-galactosidase activity. (B) Quantification 
of SA β-galactosidase positive cells plotted as a percentage of total cells. The quantification was performed on the 
average of 100 cells per sample.  
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The effects of these retrovirally expressed proteins on cell proliferation were investigated 
using a cell proliferation assay. The cells were pulsed for 24 hours with BrdU 12 days post 
infection, following which BrdU and PI incorporation was measured by flow cytometry 
(Figure 5.5A). The percentage of cells in each phase of the cell cycle was then calculated 
for each condition (Figure 5.5B). Control cells showed a cell profile typical of actively 
proliferating cells, with nearly 70% of cells in S phase. Consistent with the previous data, 
RAS cells demonstrated a severe reduction in cell proliferation, with just 20% of the cell 
population in S phase. This is caused by the majority of the cells arresting in G1 and G2 
phases of the cell cycle. Activated Akt had a similar impact on cells, however they were 
found to be slightly more proliferative (30% S phase cells) with a higher G1 accumulation, 
consistent with the result obtained in Chapter 4 that activated Akt partly inhibits G2/M 
checkpoint activation. The simultaneous expression of both oncogenic RAS and Akt had a 
catastrophic effect on the proliferative potential of IMR90 cells with only 5% in S-phase, 
inducing a stronger G1 cell cycle arrest. Despite the inhibition of Chk1 and Chk2 
activation, a small part of RAS/Akt cells still arrest in G2. This could be sustained by the 
higher level of p21, which is known to be one of the effector of the cell cycle arrest in both 
G1 and G2/M phases (Cayrol et al., 1998; Wu et al., 1996). Interestingly, the FACS 
analysis showed the presence of a sub-G1 peak in Akt cells, which is severely amplified (5 
fold) by the simultaneous presence of activated RAS. This generally indicates the presence 
of cell debris and is in agreement with the lower cellular density observed in the β-
galactosidase staining of these cells (Figure 5.4A). This could suggest that the inhibition of 
DDR by Akt produces such high levels of damaged DNA in some cells, that it is 
incompatible with cell viability. 
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Figure 5.5: Simultaneous expression of RAS/Akt in IMR90 cells induces a drastic cell cycle arrest and cell death. 
(A) FACS analysis measuring the incorporation of BrdU after 24 hours of incubation, and Propidium Iodide (PI) into 
CTR, HRASG12V, Myr-Akt or HRASG12V/Myr-Akt cells 12 days post infection. (B) Quantification of BrdU and PI 
incorporation from the FACS analysis .  
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Considering the presence of the substantial sub-G1 peak, a cell death assay was used to 
determine whether RAS/Akt co-expression could kill cells due to unrepaired DNA lesions. 
Cells were incubated with Sytox green, a dye that stains nucleic acid in dead cells, and 
imaging by an IncuCyte imager was used to quantify the number of stained cells 10 to 12 
days post-infection. This value was then divided by the confluence factor to correct for cell 
density, and the resulting values were plotted in figure 5.6. Control cells showed minimal 
cell death, and cells expressing activated Akt or activated RAS do not show a substantial 
increase in cell death either. However, when both these activated protein are expressed 
simultaneously a substantially larger proportion cells incorporate Sytox green indicating a 
dramatic elevation in cell death. However, this cell death is unlikely to be caused by p53-
mediated apoptosis, since RAS/Akt cells did not show an increase in p53 levels (Figure 5.3B).  
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Figure 5.6: Simultaneous expression activated Akt and RAS induces cell death. Time lapse quantification of Sytox 
Green uptake by IMR90 cells 10-days post-infection with CTR, HRASG12V, Myr-Akt or HRASG12V/Myr-Akt 
retroviruses using an IncuCyte imager. Data were normalised to the confluence factor.  
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In order to assess the proliferative potential of the RAS/Akt cells, a clonogenic survival 
assay was performed with the surviving cells 14-days post infection. As expected, in the 
absence of senescence, the proliferation proficient control cells formed a large number of 
colonies as observed from the crystal violet staining (Figure 5.7A). Akt cells formed 70% 
of colonies compared to control cells, confirming that these cells are actively proliferative 
(Figure 5.7B). RAS cells instead formed 60% less colonies relative to control cells, 
however this confirms that a component of this population is still proliferative. On the 
other hand, the surviving senescent RAS/Akt cells appeared to form very few colonies. 
Importantly, the RAS/Akt cells did not lose viability, but persisted as viable cells with a 
classic senescent morphology in culture. Altogether, these data suggest that the 
combination of Akt and RAS in IMR90 cells results in a more robust senescence program 
compared to activated RAS alone. 
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Figure 5.7: RAS/Akt cells have a markedly reduced proliferative potential. (A) Clonogenic survival analysis of CTR, 
HRASG12V, Myr-Akt and HRASG12V/Myr-Akt senescent cells 2 weeks post-infection. Cells were reseeded in equal 
numbers and were then cultured for 2 weeks. The colonies formed were visualized by Crystal violet staining. (B) 
Quantification of the number of colonies relative to the CTR cells. The data represent three independent biological 
replicates.  
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5.2.3 Mre11 inhibition in ER-RAS-induced cells reproduces RAS/Akt 
phenotype  
The data so far have suggested that the expression of activated Akt in presence of a 
genotoxic stress of RAS activation suppresses DDR activation by reduction of MRN 
complex, causing accumulation of damaged DNA. This correlates with a strong cellular 
senescence in response. To confirm this phenotype in RAS/Akt cells is achieved via the 
reduction in MRN complex expression and activity, RAS expressing cells were treated 
with Mre11 inhibitor Mirin.  
For these studies, a model system dependent on the chemical induction of a form of 
activated RAS fused to ER-α (Estrogen Receptor Alpha) was used Littlewood (Littlewood 
et al., 1995). This fusion protein ER-RAS is formed by the in-frame fusion of the mouse 
ER Hormone Binding Domain (HBD) and the full-length HRASG12V encoded by the 
retrovirus pLNC-RAS:ER. The ER part has a mutation at the codon 525 (G525R) that 
makes it insensitive to 17β‐estradiol, but responsive to its synthetic ligand 4‐
hydroxytamoxifen (4OHT) (Reuter and Khavari, 2006). In absence of 4OHT, ER-RAS is 
kept inactive by HSP90 in the cytoplasm, whereas 4OHT biding to the receptor ER 
releases it from this repression.  
ER-RAS cells were treated with 100nM of 4OHT for 8 days to allow for the induction of 
senescence by activated RAS, in the absence or presence of 20µM of Mirin. The dose of 
Mirin was chosen in preliminary experiments as the minimum dose that hits the target. The 
inhibition of MRN activity by Mirin treatment was monitored by immunofluorescence 
analysis of DNA damage markers such as S139 phosphorylated γH2Ax, and T68 
phosphorylated Chk2. Control cells with or without Mirin treatment did not show any 
visible signs of DDR activation (Figure 5.8). Contrastingly, RAS-induced cells presented 
strong activation of DDR response, as seen from the presence of several γH2Ax foci of 
different sizes dispersed in the nucleus. Chk2 phosphorylation was observed in smaller and 
less sparse foci, which in some places were focused in large spots. It has been reported that 
the formation of these big foci in OIS is the result of unrepaired DSBs, which are usually 
localized within telomeric regions and are crucial for the maintenance of senescent 
phenotype (Suram et al., 2012). The co-treatment with Mirin leaded to a substantial 
reduction in γH2Ax and phospho-Chk2 foci. However, a prevalence of cells with larger 
and comparatively fainter phospho-Chk2 foci was noticed. The inhibition of DDR by 
reduction in Mre11 activity may lead to an increased amount of permanently damaged 
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DNA in ER-RAS-induced Mirin treated cells, potentially causing the formation of these 
bigger foci. The presence of these larger foci is likely to also contribute to a qualitative 
difference in the senescence phenotype of these cells. 
In the control proliferating cells, the DAPI signal was found to be relatively uniform across 
the nucleus. However, ER-RAS-induced cells treated with Mirin had much bigger nuclei 
compared to control cells, which contained large foci of intense DAPI staining 
demarcating the presence of SAHF. Interestingly, in ER-RAS-induced Mirin treated cells 
the DAPI staining revealed a different nuclear conformation with a prevalence of large 
DAPI unstained areas that are apparently depleted of DNA content. 
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Figure 5.8: Mirin treatment of ER-RAS-induced cells leads to a reduction in DDR activation. Immunofluorescence 
analysis of phosphorylated γH2Ax and phosphorylated Chk2 in ER-RAS cells with or without induction with 100nM 
4OHT in the absence or presence of 20µM Mirin for 8 days. DAPI was used for nuclear staining. 
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ER-RAS-induced cells were found to present the typical large flattened morphology of 
senescent cells (Figure 5.9A). The treatment with 20µM Mirin drastically reduced the 
number of cells, and the surviving cells appeared even longer and flattened. Control cells 
retained normal spindly morphology of fibroblast, both in the absence or presence of 
Mirin.  
Western blot analysis demonstrated that the use of 4OHT in ER-RAS cells efficiently 
induced the activation of RAS (Figure 5.9B). As expected, this was associated with high 
levels of p16 and p21, and low levels of cyclin A along with activated pRb, indicating that 
these cells were senescent. Control cells with or without Mirin treatment presented high 
levels of proliferation markers and undetectable level of p16 and p21, indicating a normal 
cell proliferation status. ER-RAS-induced Mirin treated cells showed a strong reduction of 
proliferation markers. As previously seen for the RAS/Akt IMR90 cells (Figure 5.3B), 
Mirin treatment lead to higher levels of p16 and p21 when compared to ER-RAS-induced 
only. The increase in p21 is unlikely to be due to DDR signalling. It is still unclear how 
p21 levels are unregulated despite the inhibition of DDR by Mirin, but a stress-dependent 
induction model is a distinct possibility. It has been shown that various stress signals by 
TGF-β1 activation increase p21 levels by p38α and JNK1 mediated phosphorylation (Kim 
et al., 2002). 
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Figure 5.9: 4OHT treatment of ER-RAS cells in the absence or presence of Mirin induces senescence. (A) Bright 
field images of ER-RAS cells 8 days post-treatment with or without 100nM 4OHT in the absence or presence of  20µM 
Mirin. (B) Western blot analysis of lysates from cells shown in A. Actin provides a loading control. 
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Since the induction of ER-RAS caused a strong reduction in cell proliferation markers 
(Figure 5.9), it is likely to alter the cell cycle profile of these cells. Moreover, higher levels 
of p16 and p21 in Mirin treated cells could suggest a stronger cell cycle arrest compared to 
the untreated cells. Thus, to evaluate the cell cycle profiles, cells were incubated with 
BrdU for 24 hours and then BrdU/PI was analysed by flow cytometry (Figure 5.10A). The 
majority of control cells were found to have undergone DNA replication, demonstrating 
that these cells were actively proliferating (Figure 5.10B). Control cells treated with Mirin 
showed a similar trend to untreated cells, indicating that Mirin alone did not have any 
significant effect on cell proliferation. Contrary to this, the expression of activated ER-
RAS for 8 days was found to drastically reduce the proliferating population to 25%, 
arresting most of the cells in G1 and fewer in G2 phases of the cell cycle. The inhibition of 
Mre11 by Mirin treatment in ER-RAS cells lead to an even greater number of cells to 
arrest in G1, with just 10% of the cell population detected to have undergone S phase. 
These data clearly demonstrate that Mirin contributes to a stronger cell cycle arrest caused 
by oncogenic RAS. 
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Figure 5.10: Mirin treatment enhances ER-RAS-induced cell cycle arrest. (A) FACS analysis measuring the 
incorporation of BrdU after 24 hours of incubation, and Propidium Iodide (PI) into ER-RAS cells with or without 
treatment with 100nM 4OHT in the absence or presence of 20µM Mirin for 8 days. (B) Quantification of BrdU and PI 
incorporation from the FACS analysis.  
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Considering that ER-RAS induction caused a strong cell cycle arrest, SA β-galactosidase 
activity was analyzed to establish the senescent status of these cells. Less than 10% of the 
control cells with or without Mirin treatment were found to be positive for lysosomal β-
galactosidase activity (Figure 5.11). The ER-RAS-induced cells instead showed high 
number (70%) of blue cells positive for β-galactosidase activity, demonstrating that ER-
RAS expression caused cellular senescence. Moreover, Mirin treatment of ER-RAS-
induced cells was found to cause a 15% increase in β-galactosidase positive cells compared 
to untreated cells, and as shown previously they are also sparser (Figure 5.9A).  
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Figure 5.11: Mirin treatment reinforces cellular senescence in ER-RAS-induced cells. (A) Bright field of 
microscopy images of ER-RAS cells with or without induction with 100nM 4OHT in the absence or presence of 20µM 
Mirin for 8 days. (B) Quantification of β-galactosidase positive cells plotted as a percentage of total cells. The 
quantification was performed on the average of 100 cells per sample.  
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In addition to this, the presence of numerous floating dead cells was observed when ER-
RAS-induced Mirin treated cells were inspected under the microscope. In order to confirm 
this observation, cells were incubated with Sytox green and the number of positive cells 
was measured by IncuCyte. The treatment of control cells with Mirin does not affect cell 
viability, however ER-RAS induced cells presented a subtle cell death phenomenon, which 
is significantly enhanced by Mirin treatment (Figure 5.12). This is in agreement with the 
observed reduction of cells ER-RAS/Mirin cells (Figure 5.9A), and previous observations 
in the RAS/Akt cells (Figure 5.6). 
Collectively, these results suggest that inhibition of Mre11 activity by Mirin inhibits DDR 
activation and damage processing that results in high cell death in response to genotoxic 
stress and accumulation of DNA damage caused by oncogenic RAS. However, the 
majority of the surviving cellular population is strongly arrested in G1 phase of the cell 
cycle, resulting in a strong cellular senescence response. Thus, the robust induction of cell 
senescence in RAS/Akt cells is likely to be due to the reduction in MRN levels caused by 
Akt-induced S6K activity. 
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Figure 5.12: Mre11 inhibition induces cell death in presence of ER-RAS. Time-lapse quantification of Sytox Green 
uptake by ER-RAS cells 8-days post-treatment with or without 100nM 4OHT in the absence or presence of 20µM Mirin 
using an IncuCyte imager. Data were normalised to the confluence factor. 
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5.3 Discussion 
The previous chapters have shown that the hyperactivation of the Akt pathway severely 
impairs the stability of the MRN complex in human colon carcinoma cell lines. The same 
phenomenon was found to occur in primary human IMR90 fibroblasts expressing activated 
Akt. It is well known that the expression of constitutively active oncogenes such as 
HRASG12V induces the DNA damage response by engaging both the ATM and ATR 
pathways (Bartkova et al., 2006; Di Micco et al., 2006). The expression of HRASG12V in 
IMR90 cells was found to induce the activation of both checkpoint kinases Chk1 and 
Chk2, however this was abrogated by co-expression of activated Akt.  
As it was demonstrated in previous chapters, the full activation of these checkpoint kinases 
relies on optimal MRN complex activity, which directly regulates the recruitment and 
activation of ATM machinery, and causes the activation of ATR by resecting DSBs into 
ssDNA. Chk1 and Chk2 are essential for stopping damaged cells from completing DNA 
replication (intra-S checkpoint) and progressing into mitosis (G2/M checkpoint), thus 
preserving genome stability. Comet assay analysis revealed the presence of severely 
damaged DNA in cells co-expressing activated RAS and Akt compared to cells only 
expressing RAS, suggesting that reduced checkpoint activation and lack of MRN-complex 
mediated HR repair severely affects genomic integrity. However, a substantial part of 
RAS/Akt cells were also found to undergo cell death. This could be due to unbearable 
levels of damaged DNA accumulate in the cells due to reduced Mre11 function, thus 
leading to cell death. An increase in damage-mediated ROS formation could also be a 
secondary cause of cell death.  
Despite the lack of checkpoint activation, the majority of RAS/Akt cells were found to 
arrest dramatically in G1 phase of the cell cycle and present a marked senescence 
phenotype. It has been previously shown that activated RAS can cause p21 activation via 
DNA damage-mediated increase in p53 activity (Di Micco et al., 2006; Fikaris et al., 
2006). This is reflected in increased S15 phosphorylation of p53, which is known to be 
dependent on ATM activity (Saito et al., 2002). Also, Akt activity can contribute to 
upregulation of p21 by direct phosphorylation of p21 (Li et al., 2002). Furthermore, 
increased damage causes a rise in ROS levels that leads to elevated p16 activation 
(Takahashi et al., 2006). In the absence of Mre11 activity, the increased amount of 
unrepaired damage thus provides an essential trigger for p16-mediated senescence in 
response to oncogene activation. This likely causes the majority of the RAS/Akt cells to 
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arrest in G1, even in the absence of Chk1/2 activation. The additive effects of p21 
activation by RAS and Akt, along with elevated p16 activation due to damage-induced 
ROS could be responsible for the even stronger proliferation arrest in RAS/Akt cells. 
Activating RAS and PI3K pathway mutations often correlate with more aggressive 
tumours (Biankin et al., 2012; Dai et al., 2005). Previous studies have shown that 
activation of Akt or PTEN deletion facilitates to bypass RAS or RAF-induced senescence. 
Contrary to these studies, the data in this chapter propose that oncogenic Akt and RAS 
cooperate to induce a qualitatively stronger senescence. 
Vredeveld and colleagues found that the depletion of PTEN in human fibroblasts led to 
reduced BrdU incorporation, however this does not seem to cause a reduction BRAF-
induced p16 expression (Vredeveld et al., 2012). Activating PI3K mutations were also 
found to confer a proliferative advantage. It must be noted that the BrdU incorporation data 
in this study was obtained 3 days post-infection, whereas the Western blot and β-gal 
incorporation analyses were performed 8-days post-infection. Thus it is unclear if these 
cells were fully engaged in the senescence program when the PI3K/PTEN loss-mediated 
increase in BrdU incorporation was measured. Thus, it cannot be concluded that 
PI3K/PTEN loss enables cells to fully evade the senescence program. The data in this 
chapter use BrdU incorporation in conjunction with PI staining and FACS analysis to 
quantitate cells in various stages of the cell cycle 13 days following RAS expression, and 
therefore is likely to reflect the effect of Akt expression on the long term establishment of 
senescence. 
In agreement with this, Kennedy et al found that co-expression of RAS and Akt for 7 days 
did not lead to a rescue in the expression of cyclin A as measured by immunofluorescence. 
Moreover, Akt expression on its own was also found to reduce proliferation of IMR90 
fibroblasts. A reduction in SAHF formation in RAS/Akt cells was also observed, however 
this might not confer a growth advantage since SAHFs have been reported to not correlate 
with growth arrest (Di Micco et al., 2011). Thus, previously published data have 
demonstrated that loss of PTEN or Akt activation can lead to partial reprieve from the 
senescence phenotype in vitro, however, a full escape from the senescence program is not 
evident. 
Both the above studies use PTEN deletion in vivo, however PTEN loss may not be 
functionally equivalent to Akt activation. PTEN loss loads leads to genomic instability via 
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multiple mechanisms and may therefore provide a more potent mechanism by which cells 
can escape senescence (Yin and Shen, 2008). DDR and the checkpoint machinery provide 
a powerful barrier against tumourigenesis. Tumour cells in clinical specimens from 
different tissues present the constitutive activation of DNA damage signalling, as seen 
from the presence of γH2Ax foci and the activation of ATM/ATR machinery. Several 
studies have shown that any breach of this defence barrier due to mutations and/or loss of 
expression of DDR components facilitate early cancer progression (Bartkova et al., 2005; 
Gorgoulis et al., 2005). Therefore, it seems reasonable that the inhibition of DDR by Akt-
mediated suppression of MRN complex may provide a growth advantage to RAS 
expressing cells.   
However, it seems that senescence provides a secondary barrier that must be overcome. 
Genomic instability following PTEN loss or Akt activation is likely to provide the 
mechanism by which these cell eventually evade senescence. For example, cells with 
genomic instability would have an increased probability of loss of function mutations 
within the p16 or p53 pathways, therefore not only enabling the escape from senescence 
but also providing these cells with a substantial growth advantage.  
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During the past decade, an increasing number of studies have highlighted the significance 
of the DNA damage response pathway in the evolution and treatment of cancer. Genomic 
instability is the common feature of cancer cells, which fuels high mutation rates that lead 
to an accumulation of oncogenic and tumour suppressor mutations. The DDR is regulated 
by two kinase-signalling cascades, i.e. ATM/Chk2 and ATR/Chk1, which are primarily 
activated by DSBs and ssDNA respectively (Matsuoka et al., 2007). From the data 
presented, it is clear that the functions of the MRN complex are essential for coordinating 
the activation dynamic of these two pathways in HCT116 cells following exposure to 
irradiation. Full activation of ATM at DSBs completely relies on MRN complex and 
therefore a reduction in MRN complex levels results in reduced phosphorylation of its 
downstream target Chk2. Activated ATM is not only crucial for assembling and activating 
the DDR machinery, but also for the phosphorylation of many well-known repair factors, 
including Mre11 and Nbs1 (Di Virgilio et al., 2009; Horejsi et al., 2004; Lavin, 2007). 
Thus, a reciprocal activation loop exists between ATM and MRN complex, whereby the 
lack of one of the two factors severely impairs the activity of the other.  
Moreover, activated MRN complex is also required for enzymatic processing of the 
damaged DNA (Paull and Gellert, 1998). Mre11 nuclease activity is indispensible for 
nucleolytic resection of DSBs in ssDNA, which is crucial for the initial steps of HR repair. 
Therefore, its reduced availability or the inhibition by the drug Mirin results in reduced HR 
repair efficiency, and consequently reduction of chromatin RPA-associated foci formation. 
RPA foci are essential for marking the sites of DNA damage to which HR factors are 
recruited. They also signal the activation of the cell cycle checkpoint through ATRIP/ATR 
recruitment and Chk1 activation. Thus, a reduction in RPA foci impairs activation of the 
Chk1 protein in presence of IR-induced damage. Thus it is clear that MRN complex is 
central to DDR response, and its suppression impairs genome stability.  
Multiple studies have shown that the overactivation of Akt can promote genome instability 
by its inhibitory effect on the DDR pathway (Henry et al., 2001; Hirose et al., 2005; 
Kandel et al., 2002; King et al., 2004; Plo et al., 2008; Tonic et al., 2010), however no 
specific mechanism has been proposed. The data obtained here demonstrates that this may 
be achieved via reduction in the expression and activity of the MRN complex.  
PTEN has a crucial role in the maintenance of various cellular processes. It targets a vast 
range of proteins, from membrane-bound receptor tyrosine kinases and cytoplasmic 
signalling molecules to transcriptional factors within the nucleus. However, the PI3K/Akt 
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pathway is considered the primary physiological target of PTEN, where it counteracts Akt 
activation by PI3K (Leslie and Downes, 2004; Sulis and Parsons, 2003). In normal growth 
conditions, Akt kinase promotes growth, proliferation and survival by regulating the 
activity of kinases such mTORC1 and S6K (Figure 6.1). Moreover, in response to damage 
it is activated in PIKK family members-dependent manner (Caporali et al., 2008; Toulany 
et al., 2008; Viniegra et al., 2005). In this case, it provides the pro-survival signal required 
to allow the reengagement of the cell cycle post repair. The observed inhibition of MRN 
expression by Akt is likely to help fine-tune the amplitude of the DNA damage response. 
This would act as a feedback mechanism to avoid hyperactive DDR signalling. Contrary to 
this, when Akt is hyperactivated due to oncogenic stimulus (activating PI3K mutations) or 
loss of tumour suppression (PTEN loss), the dramatic downregulation of the MRN activity 
makes this prosurvival mechanism to become detrimental due to accumulation of 
unrepaired DNA damage. In agreement with this, a study in breast cancer lines has shown 
that Akt hyperactivation suppressed RAD51 and BRCA1 foci formation, thus inhibiting 
homologous recombination. This correlates with supernumerary centrosomes and 
aneuploidy in hamster ovary cells (Plo et al., 2008). Thus it can be hypothesised that this 
interplay between active Akt signal and MRE11 activity provides a crucial two-way link 
between the PI3K pathway and DDR, i.e. growth control and growth arrest. 
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Figure 6.1: Model for the interplay between the DDR and PI3K pathways. 
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Activating RAS and PI3K pathway mutations often correlate with more aggressive 
tumours (Biankin et al., 2012; Dai et al., 2005). These findings suggest a new mechanism 
by which activated Akt pathway can contributes to tumourigenesis. Downregulation of 
DDR and DNA repair could be a mechanism to allow the cells to keep proliferating despite 
the presence of damaged DNA. However, it is still unclear how Akt or S6K activity 
regulates stability of the MRN components. Further work is required to investigate 
potential alterations in the post-translational modifications of MRE11 in response to Akt 
activation. This will provide mechanistic insights into how this finely tuned network 
functions. 
Senescence poses a fundamental barrier against cellular transformation (Mathon and 
Lloyd, 2001). In the primary human fibroblast IMR90 cell line, the expression of activated 
oncogene HRASG12V induced formation of DSBs due to its hyper-proliferative effects 
(Di Micco et al., 2006). However, as expected in this non-transformed cells line, persistent 
DDR activation caused a p16 and p21-mediated cell cycle arrest. On the contrary and as 
has been shown by previous studies, activated Akt was found to be a weak inducer of 
senescence (Alimonti et al., 2010; Kennedy et al., 2011). However, these cells did not 
show an increase in DNA damage, which is consistent with the idea that Akt activation due 
to PTEN deletion induces a different form of senescence that is not associated to DDR and 
hyper-replication (Alimonti et al., 2010; Miyauchi et al., 2004). Moreover, as observed in 
the human colorectal carcinoma cell lines, IMR90 cells expressing activated Akt were also 
found to demonstrate a loss of MRN expression and activity, which impaired their ability 
to induce a DDR. 
In contrast to previous studies (Kennedy et al., 2011; Vredeveld et al., 2012), the activation 
of Akt in RAS-expressing cells was found to reinforce the RAS-induced senescence. In 
presence of DNA damage due to expression of activated RAS, the reduction of MRN 
activity was associated with the accumulation of unrepaired DNA lesions. This, in-turn, 
was linked to stronger G1 arrest likely due to an increased p21 upregulation, which is 
unlikely to be p53-mediated. This arrest was further reinforced by a ROS-induced increase 
in p16. Contrary to this, activated Akt partly abrogated RAS-mediated G2 arrest, which 
relies on the activity of MRN complex. The use of Mirin to inhibit MRN complex activity 
in presence of RAS-induced damage supports the idea that the activated Akt reinforced 
RAS-induced senescence by inhibiting MRN complex-mediated repair. However, a rescue 
experiment will be required to verify if the reintroduction of Mre11 in RAS/Akt cells 
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reverts to the RAS-only senescence phenotype. This will be necessary to ascribe the 
suppression of MRN complex to Akt-mediated effects in RAS cells.  
Senescence triggered by RAS or by RAS/Akt presented diverse severity of damaged DNA, 
suggesting that these senescent cells are not the same. In particular, the RAS/Akt cells 
showed a large amount of broken DNA, which could affect the genome integrity of these 
cells. In addition to this, the observation that the expression of several DDR genes is 
suppressed during cancer progression strengthens the idea that this genomic instability 
caused by activated Akt will eventually contribute to bypass senescence, thus stimulating 
tumour formation and progression (Bartkova et al., 2006; Di Micco et al., 2006).  
Therefore, it can be said that all oncogenes are not equal in their ability to cause cellular 
transformation or senescence. In vitro, oncogenic RAS induces senescence due to 
accumulation of unresolved DNA damage (Figure 6.2); however, in vivo this creates the 
genetic environment required for benign precursor lesions. Comparatively, hyperactive Akt 
is a weak inducer of senescence on its own (Kennedy et al., 2011). But by affecting the 
DNA repair and checkpoint activation, Akt enhances RAS-induced damage, which still 
causes senescence. However, this equips the cells with higher mutation rates by inhibiting 
DDR and perhaps allows the eventual bypass of this senescence. Typical examples for this 
are pancreatic ductal adenocarcinomas (PDACs), which have the poorest prognosis of the 
solid tumours. The progression of PDAC from preneoplastic lesions (PanINs) is associated 
with accumulation of genetic alterations. The activating mutation of H-RAS in the 
pancreas of mice induces the development of PanINs. However, in 90% of cases the 
progression of these PanINs into PDAC is associated with additional loss of crucial tumour 
suppressors such as PTEN (Altomare et al., 2002; Asano et al., 2004; Biankin et al., 2012; 
Tuveson and Hingorani, 2005). Furthermore, activation or amplification of Akt2 and Akt1 
is been reported in 60% of these pancreatic cancers (Altomare et al., 2002; Ruggeri et al., 
1998; Schlieman et al., 2003). A large proportion of PDAC (8%) have also presented 
somatic mutations in ATM, suggesting the importance of DNA damage response 
mechanisms in driving this disease. Interestingly, abnormalities in homologous 
recombination mechanism have been associated with pancreatic cancer too (Biankin et al., 
2012; Goggins et al., 1996; Klein, 2012; Roberts et al., 2012).  In line with this, neoplastic 
tissue from pancreas of mice with HRASG12V and loss of PTEN were found to contain 
significant levels of aberrant mitosis (Kennedy et al., 2011).  
  155 
The data obtained in this study suggest that activated Akt may contribute to the high 
genomic instability that drives RAS-mediated tumourigenesis upon PTEN loss. It is known 
that genome instability can cause the loss of tumour suppression, which can lead to bypass 
of senescence, thus driving uncontrolled proliferation. However, it is unclear if this can be 
achieved just via MRE11 inhibition. Therefore, it could be interesting to test if the 
treatment of mice with Mirin could accelerate the progression of RAS PanINs to PDAC.  
In conclusion, this study could explain the molecular basis of the cooperation between 
oncogenic mutations of the RAS and PI3K pathways in human tumours. 
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Figure 6.2: Model for the contribution of Akt to RAS-induced senescence.  
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